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ABSTRACT OF DISSERTATION 
OXIDATIVE DAMAGE TO DNA IN ALZHEIMERS DISEASE 
 
Previous studies from our laboratory and others show a significant increase in 
levels of both nuclear and mitochondrial DNA and RNA oxidation in vulnerable brain 
regions in the progression of Alzheimer’s disease (AD).  Although total DNA oxidation 
is increased in AD it remains unclear whether oxidative damage is widespread throughout 
the genome or is concentrated to specific genes. To test the hypothesis that specific genes 
are more highly oxidized in the progression of AD, we propose to quantify the percent 
oxidative damage in genes coding for proteins shown to be altered in the progression of 
AD using quantitative/real-time polymerase chain reaction (qPCR/ RT-PCR).  To further 
test the hypothesis that diminished DNA repair capacity in the progression of AD 
contributes  to increased DNA oxidation we will use custom PCR arrays and qPCR, 
Western blot analysis and activity assays to quantify changes in enzymes involved in 
base excision repair (BER).  
In order to carry out these studies tissue specimens from superior and middle 
temporal gyri (SMTG) and inferior parietal lobe (IP), as well as, a non-vulnerable region, 
the cerebellum (CER) will be analyzed from normal control (NC) subjects and subjects 
throughout the progression of AD including those with preclinical AD (PCAD), mild 
cognitive impairment (MCI), and late stage AD (LAD). We will also analyze specimens 
from diseased control subjects (DC; Frontotemporal dementia (FTD) and dementia with 
Lewy bodies (DLB)) to determine if the changes we observe in AD are specific.   
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CHAPTER 1: INTRODUCTION AND BACKGROUND 
1.1. Alzheimer’s Disease (AD)  
1.1.1. Discovery and Incidence  
  Alzheimer’ disease (AD) is a progressive neurodegenerative disorder, first described 
by Alois Alzheimer in 1906 at the 37th meeting of South-West German Psychiatrists in 
Tubingen. Alzheimer’s lecture at Tubingen described the symptomatology, progression 
and course of disease over a period of about five years as well as the histological and 
morphological features of the brain after the death of a patient, Auguste Deter. The 
clinical characteristics of Auguste D. included sleep disorders, memory loss, 
aggressiveness, aphasia and progressive confusion. Histopathologically, Alzheimer 
reported the presence of intracellular and extracellular aggregates in the brain of Auguste 
D after autopsy. Intracellular aggregates composed of hyperphosphorylated microtubule 
associated tau protein (neurofibrillary tangles) and extracellular aggregates of  β-amyloid 
peptide (senile plaques) are now recognized as two of the main pathological markers of 
AD (Hippius and Neundorfer, 2003). Despite discovery a century ago, it is only during 
the last few decades that research into the symptoms, causes and treatment of AD has 
gained momentum as the number of people affected by this disease increased 
dramatically. 
 At present, AD affects 5.2 million Americans with an estimated cost of ~200 billion 
dollars annually. One in 8 Americans age 65 and over suffers from AD, and at present 
there is no way to prevent, cure or even slow the progression of the disease (Burns and 
Iliffe, 2009; Hebert et al., 2013).  Death of patients with AD increased by 68% between 
2000 and 2010 whereas death by other major diseases including breast cancer, prostate 
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cancer, heart disease, stroke and HIV decreased (Thies and Bleiler, 2013). After 
diagnosis, most people with AD survive 4-8 years, on average, with some surviving as 
long as 20 years. On average, 40% of this time is spent in the most severe stage of the 
disease when a patient is completely incapable of taking care of themselves. Although 
AD is the sixth leading cause of mortality in the United States, death is generally due to 
secondary illness/infection Unless medical breakthroughs identify ways to prevent or 
more effectively treat the disease, the number of AD patients in the US is expected to 
triple by the year 2050, with annual costs that may singlehandedly create a massive 
health care crisis (Burns and Iliffe, 2009; Thies and Bleiler, 2011, 2013).  
1.1.2.  Clinical Characteristics 
 The major difficulty in the diagnosis of AD is the lack of laboratory tests to confirm 
AD in a patient antemortem. Clinical diagnosis of AD is based on medical history and 
clinical examination, coupled with laboratory tests and brain imaging (computed 
tomography or magnetic resonance imaging) to exclude other forms of dementia. The 
criteria set by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV), and the National Institute of Neurological and Communicative Disorders and 
Stroke and the Alzheimer’s disease and Related Disorders Association (NINCDS-
ADRDA) are the two most common clinical criteria used for the diagnosis of AD. These 
criteria state that the leading diagnostic element for AD is the steady onset and 
progression of dementia in a patient with no other known cause of dementia. Eventually, 
this steady decline across multiple cognitive domains leads to late stage dementia where 
the patient is almost totally dependent on caregivers for even the most basic functions 
(Brookmeyer et al., 2002; Burns and Iliffe, 2009; Yaari and Corey-Bloom, 2007). 
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 The DSM-IV criteria require an insidious onset along with cognitive function 
decline, memory impairment and a second cognitive deficit such as aphasia, apraxia, 
agnosia or impairment of executive functioning. DSM-IV criteria require that other 
psychiatric, neurological, metabolic or systemic diseases be excluded as a reason for 
impairments in social or occupational functioning before the confirmation of a diagnosis 
for AD. In comparison, the NINCDS-ADRDA guidelines are more comprehensive and 
provide a disease progression sequence for AD classified as probable, possible and 
definite AD. Probable and possible AD diagnosis can be made antemoretem whereas 
definite AD can only be identified postmortem.  Probable AD is characterized by deficits 
in two or more cognitive domains, progressive memory deterioration, preserved 
consciousness and onset between ages 40-90 in the absence of alternative reasons for the 
symptoms. “Possible AD” patients display atypical onset of dementia along with the 
presence of additional signs of dementia. Definite AD can only be diagnosed postmortem 
by a combination of clinical diagnosis and neuropathological evaluation of the brain after 
autopsy. The average time from onset of AD to death varies from 4 to 10 years depending 
on the age of the patient at onset (Dubois et al., 2007; Khachaturian and Radebaugh, 
1996; McKhann et al., 1984; Yaari and Corey-Bloom, 2007).   
1.1.3. Pathological Features  
 Pathologically, a gross visual inspection of an AD brain displays the presence of 
marked cerebral cortical atrophy epitomized by widening of the sulci and shrinkage of 
the gyri (Figure 1.1). Several microscopic changes distinctive of AD include loss of 
neuronal and synaptic densities in the hippocampus, amygdala, entorhinal cortex, 
neocortex, and nucleus basalis of Meynert. Neuropathologically, the AD brain is 
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characterized principally by the presence of two distinctive hallmarks: senile plaques 
(SP) and neurofibrillary tangles (NFT) (Khachaturian and Radebaugh, 1996; Yaari and 
Corey-Bloom, 2007).  Neither of the neuropathological hallmarks is unique to AD and 
are also seen in cognitively normal individuals although AD subjects show considerably 
higher densities. NFTs are also observed in patients with other neurodegenerative 
diseases including frontotemporal dementia (Braak and Braak, 1991; Graff-Radford and 
Woodruff, 2007; Grossman, 2002).   
 Two different types of senile plaques can be observed in the AD brain: neuritic and 
diffuse. Neuritic plaques contain tendrils or dense cores of fibrillar amyloid surrounded 
by dystrophic neurites, reactive astrocytes and activated microglia. Diffuse plaques on the 
other hand are amorphous in appearance, have no abnormal neurites and contain little or 
no fibrillar amyloid. Senile plaques (SP) are principally composed of insoluble amyloid 
beta (Aβ) peptides specifically a mixture of Aβ1-42/43 (> 95%) and small amounts of Aβ1-
40 (reviewed in (Markesbery and Lovell, 2006)). Amyloid β is a ~4 kDa peptide 
containing 11-15 amino acids from the transmembrane domain and 28 amino acids from 
the extracellular domain of the amyloid precursor protein (APP). On average, 90% of the 
larger APP protein is cleaved by α-secretase generating a large secreted derivative sAPPα 
and an 83 amino acid fragment CTFα. CTFα subsequently gets cleaved by γ-secretase 
producing the benign p3 fragment and a cytosolic element, APP intracellular domain 
(AICD).  The remaining 10% of APP is cleaved first by β-secretase to produce a large 
secreted derivative sAPPβ  and a membrane bound 99 amino acid fragment CTFβ. γ-
secretase cleaves the CTFβ fragment further to generate AICD and Aβ40 (~80-90%) or 
Aβ42 (~5-10%). Rapid nucleation of Aβ1-42/43 into amyloid fibrils is considered to be the 
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seed for aggregation and consequent deposition of Aβ in SPs. Although studies have 
shown evidence of Aβ’s involvement in synaptic dysfunction, disruption of neural 
connectivity and neuronal death, only weak correlations have been observed between the 
extent and distribution of Aβ deposition and the clinical manifestation of AD 
(Khachaturian and Radebaugh, 1996; reviewed in Murphy and LeVine, 2010; Selkoe, 
2001).  
 NFTs are composed of paired helical filaments (PHFs) and 15 nm straight filaments. 
PHFs which can also be present in neutrophil threads and dystrophic neurites principally 
contain abnormally hyperphosphorylated isoforms of tau, a protein associated with 
microtubules. Customarily, tau binds to microtubules supporting their formation and 
stabilization. Hyperphosphorylated tau is unable to bind microtubules making them 
unstable leading to their disintegration. Unbound tau then bundles together to form 
neurofibrillary tangles. Tau pathology has also been observed in patients with 
Parkinson’s disease (PD), progressive supranuclear palsy and frontotemporal dementia 
(Khachaturian and Radebaugh, 1996). Unlike SPs, there is a strong correlation between 
number of NFTs and cognitive deficits and neuronal loss in an AD patient’s brain. NFTs 
exhibit a characteristic distribution in the brain allowing differentiation into six stages 
described by the Braak staging scheme  (Braak and Braak, 1991).  The presence of NFT’s 
primarily in the transentorhinal region of the brain indicates Braak stages I and II 
(cognitively normal subjects) whereas stages III and IV indicate progression of tangles 
into  limbic regions such as the hippocampus, and V and VI when there's extensive tangle 
formation in neocortical regions (late AD patients) (Braak and Braak, 1991; Grundke-
Iqbal et al., 1986; Khachaturian and Radebaugh, 1996).  
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 It has been suggested that progressive inflammation and oxidative stress may be 
major factors leading to synaptic dysfunction and the loss of neuronal integrity which 
usually pave the way for the appearance of amyloid plaques and neurofibrillary tangles in 
the brains of AD patients (Jicha and Markesbery, 2010; Khachaturian and Radebaugh, 
1996). The neuropathological hallmarks of AD can be evaluated by several diagnostic 
criteria including the National Institute of Neurological and Communicative Disorders 
and Stroke and the Alzheimer’s disease and Related Disorders Association (NINCDS-
ADRDA) criteria (McKhann et al., 1984), the Consortium to Establish a Registry for 
Alzheimer’s disease (CERAD) criteria (Mirra, 1997) and the National Institute of Aging-
Reagan Institute (NIA-RI) consensus criteria (NIA-Reagan-Institute, 1997). The 
NINCDS-ADRDA criteria require a certain number of SP in an age-dependent manner in 
the neocortex. In this criteria, the type of SP is not identified, changes in the entorhinal 
cortex, hippocampus or amygdala are not considered and presence of NFTs is only 
considered for patients under the age of 50 (Markesbery, 1997a; McKhann et al., 1984).  
The CERAD criteria  is based on the semiquantification of neuritic plaques (NPs) as 
sparse, moderate or frequent in three brain regions: middle frontal gyrus, superior and 
middle temporal gyri and inferior parietal lobule in individuals in three different age 
categories: less than 50, 50 to 75 and over 75. The criteria also require correlation of the 
pathological characteristics with a clinical diagnosis of dementia. The CERAD criteria 
fail to consider the presence of NFTs and the changes in the hippocampus, entorhinal 
cortex and amygdala for AD diagnosis(Markesbery, 1997a; Mirra, 1997). The NIA-RI 
consensus criteria consider the correlation of both SPs and NFTs with AD. This criteria is 
based on the semiquantification of NPs (CERAD criteria), determination of extent of 
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NFTs in hippocampus and neocortex (Braak score) and clinical diagnosis of dementia 
(Geddes et al., 1997; NIA-Reagan-Institute, 1997). 
  
 
Figure 1.1. Macroscopic and microscopic changes in the human brain associated with 
Alzheimers disease including  (A) widened sulci and shrunken gyri in the coronal 
sectioned AD brain (right) compared to the age matched normal control 
(B) staining of senile plaques (SPs) and  (C) staining of neurofibrillary tangles (NFTs) 
(Adapted from (Lovell et al., 1993
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subject (
; Lovell et al., 1998)). 
 
left),  
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1.1.4.  Risk Factors 
  Several factors contribute to the probability of a person developing AD including 
age, genetic predisposition and head trauma. Aging is considered the primary risk factor 
for AD (Evans et al., 1989) and the risk of developing the disease dramatically increases 
with age. After age 65 the possibility of developing AD doubles every five years and 
reaches 50% in people aged 85 and over (Kawas et al., 2000).  Family history is the next 
important risk factor in the incidence of AD (Henderson, 1986). There is a ~ 10-14% 
higher risk of AD in people who have close relatives (parent, brother, sister or child) 
suffering from the disease compared to unrelated individuals (Burns and Iliffe, 2009). 
The expression of Apolipoprotein E (ApoE), a protein involved in cholesterol transport in 
the bloodstream, has also been linked with the incidence of late-onset AD. There are 
three isoforms of ApoE: ε2, ε3 (most common) and ε4. Expression of the ε4 isoform of 
ApoE is associated with increased risk of AD. Studies show the existence of one or two 
copies of the ApoE- ε4 gene in 40-65% of people diagnosed with AD (Farrer et al., 1997; 
Hollingworth et al., 2011; Saunders et al., 1993). On the other hand, factors such as high 
educational and occupational attainment, high levels of social and cognitive engagement, 
postmenopausal estrogen replacement therapy, and long-term use of anti- inflammatory 
drugs have been implicated in decreasing the risk of AD  (Khachaturian and Radebaugh, 
1996; Mortimer et al., 2003; Prasad et al., 2002; reviewed in Murphy and LeVine, 2010; 
Zhang et al., 1990). Additionally, traumatic brain injury, smoking and obesity have been 
implicated in increasing the risk of AD (Gustafson et al., 2003; Merchant et al., 1999; 
Mortimer et al., 1985; Mortimer et al., 1991; Ott et al., 1998). Less than 1% of AD 
patients are affected by Familial Alzheimer's disease (FAD) or early-onset Alzheimer's, 
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an inherited, rare form of the disease which can occur as early as age 35. Mutations in 
APP (located on chromosome 21) or presenelin-1 (PS-1) (located on chromosome 14) or 
presenelin-2 (PS-2) (located on chromosome 1) have been shown to be the cause of FAD 
(Hollingworth et al., 2011; Xie and Tanzi, 2006). Individuals with Down’s syndrome 
have an extra copy of the APP gene which could be a factor in the development of AD-
associated pathology in them as early as age 40 (Mann et al., 1990; Thies and Bleiler, 
2013).  
1.1.5.  Early Stages 
 Increasing evidence suggests that in an Alzheimer’s patient, pathological changes in 
the brain may begin decades before the appearance of clinical symptoms (Fagan et al., 
2005; Lange et al., 2002). In a neuropathological study conducted in 1997, Braak and 
Braak reported the presence of NFTs in subjects as young as 40 years old (Braak and 
Braak, 1997). Thus there has been considerable interest in the diagnosis and 
characterization of the preliminary phases of AD. Identification of the early phases of AD 
may help in the identification of the pathogenesis of AD thus expediting 
enhancement/discovery of early pharmacological intervention and possible reversal of the 
disease. Based on both pathological and/or clinical diagnosis, AD can be broadly 
classified into the following stages: 
Amnestic Mild Cognitive Impairment (MCI):  
 MCI is the phase between normal aging and early dementia characterized as the 
earliest detectable clinical phase of AD. Petersen et al. define amnestic MCI patients as 
individuals with symptoms which include: (a) memory impairment observed over time 
corrected for age and education (b) normal general cognitive function (c) intact activities 
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of daily living and (d) the subject not meeting criteria for dementia (DeCarli, 2003; 
Maynard et al., 2010).  Thus, patients with MCI exhibit characteristics of both clinically 
normal individuals as well as AD patients. MCI subjects go on to develop AD with a 
conversion rate of ~ 15% per year. Histopathologically, MCI subjects show a significant 
increase in neuritic plaques in neocortical regions and a significant increase in 
neurofibrillary tangles in the hippocampus, entorhinal cortex and amygdala, compared to 
NC subjects. Braak staging scores for MCI subjects are usually in the range of III-IV 
(DeCarli, 2003; Petersen et al., 2009; Wang et al., 2005).  
Preclinical AD (PCAD):  
 The criteria for identifying PCAD subjects are not well-defined. Schmitt et al. define 
subjects with PCAD as individuals who show normal antemortem psychometric test 
scores adjusted for age and education, but at autopsy demonstrate distinct AD pathology 
that meets NIA-RI intermediate or high-likelihood criteria for the histopathological 
diagnosis of AD. PCAD subjects demonstrate Braak staging scores of III or higher, 
moderate or frequent neuritic plaque scores, neuronal hypertrophy, increased synaptic 
plasticity and alterations in zinc transporters (Bradley et al., 2010; Schmitt et al., 2000). 
Preclinical AD (PCAD) subjects are diagnosed based on the tentative criteria set by the 
UK-ADC which includes (a) pronounced AD pathology with Braak scores of III-V and 
(b) antemortem psychometric tests in the normal range when corrected for age and 
education (Schmitt et al., 2000).  
1.1.6.  Etiology  
 The etiology and pathogenesis of AD are unknown at present. In order to explain the 
pathology of the disease, several hypotheses have been advanced, including genetic 
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abnormalities, slow or latent virus disorder, deficits in energy metabolism, glutamate 
excitotoxicity, defects in mitochondria, the amyloid cascade, tau abnormality, 
acetylcholine deficiency, trace element neurotoxicity or oxidative stress. Currently, none 
of these hypotheses alone can adequately explain the clinical and pathological aspects of 
AD. It is probable that AD is a multifactorial disease and a combination of multiple 
hypotheses may more adequately explain the pathogenesis of the disease. Multiple 
studies have shown presence of oxidative stress in AD patients, even though the exact 
role of oxidative stress in the pathogenesis of AD is not known (Khachaturian and 
Radebaugh, 1996; Markesbery, 1997b; Thies and Bleiler, 2011). The oxidative stress 
hypothesis is described below as the work in this thesis examines the oxidative damage 
caused to biomolecules when they undergo oxidative stress. 
1.2. Oxidative Stress and AD 
1.2.1   Reactive Oxygen Species (ROS) 
  A free radical is an atom or molecule containing one or more unpaired electrons in 
its outer shell. Free radicals are produced both exogenously and endogenously in the 
human body. Oxygen free radicals (the most common free radicals present in the human 
body) including superoxide (O2• –), hydroxyl (•OH), peroxyl (RO2• –) and alkoxyl (•OR) 
radicals along with non-radicals such as hypochlorous acid (HOCl), ozone (O3), 
peroxynitrite (ONOO-), singlet oxygen (1O2) and H2O2 that can be easily converted to 
radicals, are collectively labeled as “reactive oxygen species” (ROS) (Apel and Hirt, 
2004; Murphy, 2009). Reactive oxygen species (ROS) such as •OH, and O2• – are 
predominantly produced during normal cellular metabolism like oxidative 
phosphorylation during normal cellular respiration.  In a normally functioning cell, 
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approximately 2% of oxygen consumed during oxidative phosphorylation is converted to 
ROS (reviewed in (Murphy, 2009)).  In a normal biological system, excess ROS are 
scavenged by enzymes such as superoxide dismutase, glutathione peroxidase and catalase 
among others, making them less detrimental. Superoxide radicals are converted to 
hydrogen peroxide by antioxidant enzymes, superoxide dismutases. Hydrogen peroxide 
thus produced can be rendered harmless either by conversion to water and molecular 
oxygen by glutathione peroxidase/ catalase or can diffuse into the cytoplasm and react 
with Fe (Fenton’s reaction) or Cu (Haber-Weiss reaction) present to generate hydroxyl 
radicals which cause oxidative damage (Figure 1.2) (Markesbery, 1997b; Wiseman and 
Halliwell, 1996). ROS can also be produced by ionizing or ultraviolet radiation, smoking, 
air pollution and other biological processes such as inflammation (Cooke et al., 2003; 
Markesbery, 1997b; Markesbery and Lovell, 2006; Wiseman and Halliwell, 1996). As a 
result of its high oxygen consumption (1/5 of consumed oxygen) , substantial lipid 
content, relatively high levels of redox active metals, and the comparative inadequacy of 
antioxidant enzymes, the brain is especially susceptible to damage by free radicals 
(Markesbery, 1997b). 
1.2.2.  Oxidative Stress 
  A discrepancy between the production of ROS and the biological system’s ability to 
eliminate these reactive intermediates results in oxidative stress and subsequently 
mitochondrial dysfunction and neuronal damage. Oxidative stress has been linked to 
aging and various age-associated neurodegenerative diseases including AD, Parkinson’s 
disease and amyotrophic lateral sclerosis (Bowling et al., 1993; Harman, 1956; Jenner, 
2003; Markesbery, 1997b). Studies have suggested that the late life onset and slow 
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progression of these conditions could thus be accounted for by cumulative and 
irreversible oxidative damage over time. Oxidative stress can cause damage to most 
biomolecules in the body. Some biomarkers of oxidative damage are 8-hydroxyguanosine 
(oxidative damage of nucleic acids), protein carbonyls, 3-nitrotyrosine (oxidative damage 
of proteins) and 4-hydroxynonenal and malondialdehyde (oxidative damage of lipids). 
Several of the above markers have been detected in multiple vulnerable regions of the 
brains of LAD and MCI patients, leading to the theory that oxidative stress has a 
prominent role in the early pathogenesis of AD (Cooke et al., 2003; Markesbery, 1997b; 
Markesbery and Lovell, 2006).  
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Figure 1.2.  Formation of free radicals in human body (adapted from (Wu et al., 2009) 
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1.2.3.  Lipid Peroxidation and Protein Oxidation  
  Biological membranes are composed of 30-80% lipids by mass and are vitally 
important for the preservation of cellular homeostasis. Elevated levels of both lipid and 
protein oxidation have been reported in several neurodegenerative diseases such as AD 
and Parkinson’s disease (Bradley et al., 2010; Jenner, 2003; Markesbery, 1997b; 
Markesbery and Carney, 1999; Williams et al., 2006; Zhou et al., 2008). Measurements 
of thiobarbituric acid reactive substances (TBARS), changes in polyunsaturated fatty 
acids (PUFA) and breakdown products of PUFA (aldehydes and isoprostanes) are 
indicators of lipid peroxidation in a biological system. Peroxidation of lipids produces 
multiple aldehydic by-products including malonialdehyde, C3-C10 straight chain 
aldehydes and α,β-unsaturated aldehydes such as 4-hydroxynonenal (HNE) and acrolein. 
HNE and acrolein are neurotoxic, can form adducts with DNA/protein thus affecting their 
function and are frequently used as markers of lipid oxidation. Levels of HNE and 
acrolein have been shown to be elevated in AD brain and CSF (Bradley et al., 2010; 
Bruce-Keller et al., 1998a; Bruce-Keller et al., 1998b; Montine et al., 1998; Williams et 
al., 2006). Previous studies show that isoprostanes, produced by free-radical peroxidation 
of arachidonic acid are also elevated in the CSF of AD subjects as compared to control 
subjects (Milne et al., 2005; Montine et al., 1998). 
 Oxidative damage to proteins causes a decrease in protein activity; probably due to 
elevation in protein carbonylation levels, side chain oxidation and protein crosslinking 
(Poon et al., 2004; Soskic et al., 2008). Protein oxidative damage is principally analyzed 
by the hydrazide reactive protein carbonyl analysis (Smith et al., 1991).  Previous studies 
show the presence of nitrotyrosine in NFT’s and an elevation in protein carbonyl levels in 
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the hippocampus and the frontal and parietal lobes in the brain of AD patients compared 
to control subjects (Hensley et al., 1995; Smith et al., 1991; Smith et al., 1997). 
1.2.4.  Nucleic Acid Oxidation  
 The attack of ROS on DNA can generate more than 20 kinds of oxidized base 
adducts including 8-hydroxyguanine (8-OHG), 2,6-diamino-4-hydroxy-5-
formamidopyrimidine (fapy guanine), 8-hydroxyadenine (8-OHA), 4,6-diamino-5-
formamidopyrimidine (fapy adenine) 5-hydroxycytosine (5-OHC) and 5-hydroxyuracil 
(5-OHU) (Figure 1.3A) (Cooke et al., 2003; Gabbita et al., 1998; Markesbery and 
Carney, 1999). ROS such as hydroxyl radical reacts with the double bonds in both 
purines and pyrimidines leading to the formation of purine-OH (at positions C4, C5 or 
C8) or pyrimidine-OH (at position C5 or C6) adducts. 8-hydroxyguanine (-OHG) /8-
hydroxyadenine (8-OHA) are produced by oxidation of the C8-hydroxyl radical formed 
by the reaction of •OH radical with the C8-N9 double bond of purines. In the absence of 
oxygen however, 2,6-diamino-4-hydroxy-5-formamidopyrimidine  (fapyguanine; fapyG) 
and 4,6-diamino-5-foramidopyrimidine (fapyadenine; fapyA) are formed due to 
imidazole ring opening  at the C8-N9 site (Figure 1.3B and 1.3C). 5-hydroxycytosine (5-
OHC) is formed by dehydration of cytosine glycol and 5-hydroxyuracil (5-OHU) is 
produced by deamination of cytosine glycol. Cytosine glycol is in turn produced by 
reduction of the pyrimidine-OH adduct with water (Figure 1.3D) (Cooke et al., 2003; 
Steenken, 1989a, b). Bulky exocyclic adducts are formed when DNA base modifications 
are caused by lipid peroxidation products including 4-hydroxynonenal and acrolein. 
These modifications in DNA bases could cause mispairing during DNA replication 
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eventually leading to altered protein synthesis (Markesbery and Carney, 1999; Wang et 
al., 2005).  
 As a result of its high electron density and low oxidation potential, guanine (G) is the 
most vulnerable to oxidation among the five DNA bases (Bhattacharya and Barton, 2001; 
Candeias and Steenken, 1989; Steenken and Jovanovic, 1997). Oxidation of guanine 
leads to the formation of 8-OHG under elevated oxygen levels and fapyguanine under 
hypoxic conditions (Steenken and Jovanovic, 1997). The predominant biomarker for 
oxidative damage of DNA is the major oxidation product of guanine, 8-OHG. 8-
hydroxyguanine production can lead to its mispairing with adenine and even misreading 
of adjacent bases during replication (Cheng et al., 1992). Previous studies have shown an 
increase in levels of 8-OHG and 8-OHA in nDNA from various regions of the brain 
including the temporal, parietal and frontal lobes of AD patients even in the earlier stages 
of the disease as compared to normal control subjects (Gabbita et al., 1998; Wang et al., 
2008).  
 Increased oxidation of nuclear and mitochondrial DNA, and RNA by ROS especially 
the hydroxyl radical (•OH), have been implicated in multiple neurodegenerative diseases 
including AD, PD and DLB (Bowling et al., 1993; Gabbita et al., 1998; Lyras et al., 
1998; Wang et al., 2005; Zhang et al., 1999; Zhou et al., 2008). Although oxidation in 
both nuclear and mitochondrial DNA in AD subjects has been extensively studied, there 
are few studies that focus on RNA oxidation in AD. Shan et al. showed an elevation of 8-
OHG in mRNA and a corresponding decrease in protein expression in LAD subjects 
compared to NC subjects (Shan et al., 2007; Shan and Lin, 2006). Messenger RNA 
oxidation may result in premature translation termination and reduction in activity of 
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translated mRNAs (Shan et al., 2007; Shan et al., 2003). Due to the lack of protective 
histones, lack of rich antioxidant system, diminished DNA repair capability and the 
proximity to the site of generation of ROS, mitochondrial DNA (mtDNA) appears to be 
more vulnerable to oxidative damage compared to nuclear DNA. Previous studies have 
found ~ 2-10 fold higher levels of oxidized bases in mtDNA compared to nDNA 
(Mecocci et al., 1993; Wang et al., 2005). Oxidative damage to DNA by ROS can result 
in base alterations, single and double strand breaks, DNA-DNA/DNA-protein crosslinks, 
sister-chromatid exchange and translocation. These changes in the DNA can lead to 
altered protein expression which in turn may cause apoptosis. 
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Figure 1.3A. Structure of some representative oxidized DNA bases 
 
21 
 
N
H
NH
O
O
Thymine glycol
(cis- and trans-)
H3C
HO
H
HO
N
H
NH
O
O
5,6-Dihydrothymine
H3C
H
H
H
N
H
NH
O
O
5-Hydroxymethyluracil
HOH2C
H
HN
N
H
O
O
H
OH
5-Hydroxyhydatoin
HN
N
H
O
O
CH3
OH
5-Hydroxy-5-methylhydantoin
N
H
NH
O
O
5-Hydroxy-6-
hydrouracil
H
H
H
HO
N
H
N
NH2
O
Cytosine glycol
H
HO
H
HO
N
H
N
NH2
O
5-Hydroxycytosine
HO
H
N
H
NH
O
O
5-Hydroxyuracil
HO
H
N
H
NH
O
O
5,6-Dihydroxyuracil
HO
HO
 
 
Figure 1.3A Contd. Structure of some representative oxidized DNA bases 
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Figure 1.3C. Reaction scheme for oxidation of adenine 
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Figure 1.3D. Reaction scheme for oxidation of cytosine 
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1.3. DNA Repair Pathways  
 In healthy individuals, damaged DNA is repaired via multiple DNA repair pathways 
including base excision repair (BER), nucleotide excision repair (NER), double strand 
break repair (DSB) and mismatch repair (MMR). A brief description of these repair 
pathways is given below. 
1.3.1.  Base Excision Repair (BER) Pathway  
 The primary pathway for DNA repair of small base modifications such as alkylation, 
deamination and oxidation is the BER pathway. The BER pathway proceeds via removal 
of damaged DNA bases by substrate specific glycosylases including oxoguanine DNA 
glycosylase (OGG1) and uracil DNA glycosylase (UNG), incision of the 
apurinic/apyrimidinic site by endonucleases such as AP endonuclease (APE1), followed 
by incorporation of the correct nucleotide(s) by DNA polymerase and strand ligation by 
DNA ligase (Figure 1.4).  The BER pathway is further divided into two sub-pathways: 
short-patch BER (single nucleotide excision) and long-patch BER (repair patch size of 2-
8 nucleotides). It is postulated that in age-related neurodegenerative diseases like AD, the 
DNA repair system loses its capacity leading to accumulated oxidative DNA damage 
(Lovell et al., 2000; Markesbery and Lovell, 2006; Moreira et al., 2008; Weissman et al., 
2007).  
 Proteins implicated in aging/AD from the base excision repair (BER)  pathways 
including 8-oxoguanine DNA glycosylase (OGG1), Uracil-DNA glycosylase (UNG), 
APE nuclease1 (APE1), Polymerase (DNA directed), beta (POLB), Flap structure-
specific endonuclease 1 (FEN1), Poly (ADP-ribose) polymerase 1 (PARP1) and X-ray 
repair complementing defective repair in Chinese hamster cells 1 (XRCC1) were 
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investigated in this study. Previous studies have shown that 8-hydroxyguanine or its 
isomeric form 7,8-dihydro-8-oxoguanine is the major DNA lesion resulting from 
nuclear/mitochondrial DNA oxidation (Cooke et al., 2003; Loft et al., 2008; Moreira et 
al., 2008). Unrepaired 8-hydroxyguanine induces G:C → A:T transversion mutations 
during replication or in the case of postmitotic cells like neurons, it may lead to 
diminished cellular activity and death. 8-oxoguanine DNA glycosylase (OGG1) is the 
principal enzyme for excision of 8-oxoguanine in the initiation step of the BER pathway 
for both nuclear and mitochondrial DNA lesions. Previous studies show a decrease in 
gene expression, protein levels and incision activity of nuclear OGG1 in vulnerable brain 
regions of patients suffering from AD (Dorjsuren et al., 2011; Lovell and Markesbery, 
2007b; Weissman et al., 2007). Mao et al. showed that there was complete loss of 8-oxo-
guanine glycosylase activity in vitro with a single base deletion (C796) observed in a 
subset of AD subjects whereas, two different single base substitutions resulted in reduced 
glycosylase activity in vitro (Mao et al., 2007). Another common lesion observed in DNA 
is the introduction of uracil into genomic DNA by deamination of cytosine. Unrepaired 
uracil in DNA leads to a C→T transition mutations during replication. Uracil-DNA 
glycosylase (UNG) initiates the BER pathway in cases of misincorporation of uracil into 
DNA and is the primary enzyme for removal of uracil from DNA. UNG protein levels 
and protein activity are lower in AD subjects compared to clinically normal subjects 
(Hegde et al., 2008; Kruman et al., 2004; Weissman et al., 2007).  Both OGG1 and UNG 
lead to the creation of an apurinic/apyrimidinic (AP) site after excision of the damaged 
base. APE nuclease1 (APE1), a multifunctional DNA repair enzyme, primarily functions 
as a nuclease in the second and rate limiting step in the BER pathway. APE1 removes the 
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AP site by cleaving the DNA strand 5´ to the AP site leaving a gap in the DNA strand 
with a 3´ OH and a 5´ deoxyribose phosphate terminus (Hegde et al., 2008; Weissman 
et al., 2007). Studies have shown an increase in the expression of APE1 but no significant 
changes in AP-site incision activity or APE1 protein levels in the brain of AD patients 
compared to normal control subjects (Burns and Iliffe, 2009; Davydov et al., 2003; 
Weissman et al., 2007).   
 Polymerase (DNA directed), beta (POLB) is implicated occasionally in de novo 
DNA synthesis. Recent studies indicate POLB may be involved early in the pathogenesis 
of AD. An increase in expression of POLB was observed in neurons with minor AD-
related neuropathology but the protein expression reduced with severity of pathology 
(Copani et al., 2006; Weissman et al., 2007). X-ray repair complementing defective 
repair in Chinese hamster cells 1 (XRCC1) facilitates the repair and rejoining of DNA 
strand breaks and repairs gaps left during BER. Doğru-Abbasoğlu et al. found that the 
Trp allele of the functional XRCC1 Arg194Trp genetic polymorphism occurs more 
frequently in AD patients than in clinically normal individuals (Dogru-Abbasoglu et al., 
2007; Woodhouse and Dianov, 2008). Poly (ADP-ribose) polymerase 1 (PARP1) is 
activated when oxidative damage leads to single strand or double strand breaks of DNA. 
PARP1 acts as a catalyst in two processes: (a) cleavage of NAD+ into adenosine 5'-
diphosphoribose (ADP-ribose) and nicotinamide and (b) the covalent attachment of ADP-
ribose polymers to nuclear proteins such as histones. An increase in gene expression of 
PARP1 in AD patients, leading to massive NAD+ depletion and subsequent cell death, 
has been reported (Reddy P.V., 2006). Flap endonuclease 1 (FEN1) acts as an 5’-
exonuclease and gap endonuclease in DNA replication and long patch BER respectively. 
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FEN1 helps remove the flap segment formed during long-patch BER by addition of 
nucleotides around the damaged base by POLB. DNA ligase then seals the gap that 
remains after repair (Podlutsky et al., 2001a; Zheng et al., 2011).  
 
   
Figure 1.4. Base Excision Repair (BER) Pathway
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1.3.2 Nucleotide Excision Repair (NER) Pathway  
  The NER pathway is the principal repair mechanism for removal of bulky helix 
distortions such as lesions made by UV-induced pyrimidine dimers, intra-strand 
crosslinks, protein DNA crosslinks, and bulky chemical adducts. Multiple enzymes 
including xeroderma pigmentosum, EF-hand protein, replication protein A (RPA) and the 
UV-damaged DNA-binding protein (UV-DDB) are functional in the NER pathway. In 
humans, multiple inherited disorders caused by mutations in NER enzymes have been 
diagnosed. Studies show that in non-replicating cells such as neurons, NER is highly 
diminished. (von Kobbe et al., 2003). Xeroderma pigmentosum complementation group 
A (XPA), an enzyme in the nucleotide excision repair (NER) pathway, has also been 
implicated in aging. Subjects with XP, a rare autosomal recessive disease characterized 
by hypersensitivity of skin to sunlight and an increased risk of skin cancer of sun-exposed 
parts of the body, show a defect in the early step of nucleotide-excision repair. 
Xeroderma pigmentosum consists of eight different complementation groups (groups A–
G, and a variant). Of all the complementation groups, Group A (XPA) is the most severe 
clinical form (Bennett et al., 1997).  
1.3.3.  Double Strand Break (DSB) Repair  Pathway 
   The DSB repair pathway is involved in the repair of potentially lethal DNA double-
strand break lesions formed by broken strands of the DNA duplex. DSBs can be caused 
by both exogenous agents such as ionizing radiation and cellular processes such as DNA 
replication (Chapman et al., 2012). Flap structure-specific endonuclease 1 (FEN1), 
Meiotic recombination 11 homolog A (MRE11A) and RAD50 homolog (RAD50) are 
enzymes that function in the DSB repair pathway. FEN1 is a nuclease protein in the BER 
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pathway and helps in the Polγ-catalyzed DNA synthesis process. Polymerase γ is 
necessary for replication and repair as it is the only currently identified mitochondrial 
DNA polymerase (Podlutsky et al., 2001a). MRE11A is a part of the Mre11 protein 
complex which also includes Rad50 and Nbs1 proteins. The Mre11 protein complex has 
multiple functions including initiation of cell cycle checkpoints and recognition and 
repair of damaged DNA. Studies have shown a reduction in the expression of the Mre11 
complex proteins in neurons of AD cortex compared to age-matched controls (Jacobsen 
et al., 2004).  
1.3.4.  Mismatch Repair (MMR) Pathway  
 The MMR pathway repairs base-base and insertion/deletion mismatches that escape 
proof-reading by DNA polymerase during replication and recombination. If left 
unrepaired these mismatches can lead to mutations in DNA in subsequent replication 
cycles which in turn can lead to phenotype changes and consequent dysfunction and 
disease (Henneke et al., 2003; Hsieh and Yamane, 2008; Yamaguchi et al., 1989). EXO1 
is an essential enzyme in the mismatch repair pathway and is involved in 5’-3’ 
exonuclease activity on dsDNA, 5’ flap endonuclease activity and weak RNaseH activity 
(Balusu et al., 2007). 
1.3.5.  Other Genes Involved in DNA Repair 
     Other genes related to DNA repair studied in this project include Ataxia 
telangiectasia mutated (ATM). ATM helps in regulation of the activity of molecules that 
manage cell-cycle arrest and repair by initiating signal transduction pathways. ATM 
deficiency may lead to radiation sensitivity, germ cell degeneration, mild 
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immunodeficiency, and an extreme sensitivity to developing T cell lymphomas (Strom et 
al., 2011).   
1.4. Additional Neurodegenerative Diseases 
       Besides AD, several other types of dementia leading to neurodegeneration exist 
including vascular dementia, dementia with lewy bodies, frontotemporal dementia, 
Creutzfeldt-Jakob disease, Parkinson’s disease, normal pressure hydrocephalus, 
Huntington's disease and Wernicke-Korsakoff syndrome. In order to determine if the 
changes seen in this study were AD-specific or were a common phenomenon of 
dementia, tissue specimens were studied from diseased control subjects suffering from 
dementia with lewy bodies (DLB) and frontotemporal dementia (FTD).  
1.4.1. Dementia with Lewy Bodies 
 Dementia with Lewy bodies accounts for 10-25% of dementia cases making it the 
second most common form of dementia in elderly populations after AD (Zaccai et al., 
2005). Clinically, DLB is difficult to diagnose as it shares clinical, neuropsychological 
and pathological hallmarks with AD, vascular dementia and Parkinson’s disease. DLB 
patients suffer from visual hallucinations, delusions, significant memory loss, impairment 
in thinking and reasoning, REM sleep disorder and Parkisonian symptoms such as 
hunched posture, rigid muscles and shuffled gait. The neuropathological hallmark for 
DLB is the presence of spherical intracellular microscopic inclusions called Lewy bodies 
in the midbrain and cerebral cortex. The primary structural component of Lewy bodies is 
a protein called α-synuclein (Henchcliffe et al., 2011; Zaccai et al., 2005). Currently, the 
clinical diagnosis for DLB are based on criteria described by the Consortium on DLB 
criteria and includes the semi-quantitative evaluation of lesion density in the brainstem, 
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basal forebrain/limbic regions and neocortical regions, alpha-synuclein 
immunohistochemistry, REM sleep behavior disorder, severe neuroleptic sensitivity, and 
decreased activity of striatal dopamine transporter (McKeith et al., 2005).  
1.4.2.  Frontotemporal Dementia (FTD) 
        Frontotemporal dementia is defined as a group of multiple neurodegenerative 
diseases caused by progressive neurodegeneration in the frontal and temporal lobes.  FTD 
accounts for approximately 4-20% of all dementia cases with average age of onset being 
in the 50’s or early 60’s.  Patients with FTD can survive from 2-20 years with most 
subjects surviving an average of 6-8 years. Occurrence of FTD is more common in men 
than women at a ratio of 14:3 (Grossman, 2002; Ratnavalli et al., 2002). Symptoms of 
FTD can be categorized into three different groups: 
1.4.2.1.  Behavioral Variant Frontotemporal Dementia (bvFTD) 
       Patients with bvFTD primarily show changes in personality and behavior. Clinically, 
bvFTD patients suffer from disinhibition, apathy, loss of sympathy, compulsive 
behaviors, hyperorality and a dysexecutive neuropsychological profile (Rascovsky et al., 
2011). 
1.4.2.2.  Primary Progressive Aphasia (PPA) 
  In PPA, language is impaired in the early stage of the disease followed by changes in 
behavior in advanced stages. The two primary forms of PPA are semantic dementia and 
progressive nonfluent aphasia (PNFA). Semantic dementia patients are characterized by 
increasing decline of naming and word comprehension but retention of fluency in syntax 
and phonology. People with PNFA suffer from impairments in speech articulation and 
34 
 
reading and writing ability but preserve speech comprehension abilities (2010; Lambon 
Ralph et al., 1999; Sobol et al., 1996). 
1.4.2.3.  FTD Movement Disorders (FTDMD) 
 Impairments in language, behavior and involuntary, automatic muscle functions are 
characteristic of FTD movement disorders. Most prevalent forms of FTDMD include 
corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP). CBD is 
characterized by shakiness, lack of coordination, muscle rigidity and spasms whereas 
PSP patients show eye movement, walking and balance problems; neck and upper body 
muscle stiffness and frequent falls (Keith-Rokosh and Ang, 2008; Mahapatra et al., 2004; 
Scaravilli et al., 2005). 
 Clinical diagnosis of FTD is based on observation of behavioral changes, brain 
imaging and neuropsychological tests. MRI images can help detect frontal/temporal 
atrophy characteristic of FTD in the later stages. The similarity of symptoms between AD 
and FTD makes the clinical diagnosis of FTD difficult. Pathologically FTD diagnosis is 
based on immunohistochemical evaluation for Tau epitopes, PHF1 (PHD finger protein 
1) and AT8 (paired helical filament tau), ubiquitin and α-synuclein in the middle frontal 
gyrus (MFG), superior temporal gyri (SMG), parietal lobe (PL), 
hippocampus/parahippocampal gyri (HPG), and the cingulated gyrus (CG) (Hutton et al., 
1998; Neumann et al., 2007; Rosen et al., 2002; Talbot et al., 1998). 
1.5. Statements of Research Projects   
1.5.1.   Oxidative DNA Damage in Genes of Proteins Modified During AD 
    Although multiple studies demonstrate increased oxidative DNA damage in the 
progression of AD (Gabbita et al., 1998; Lovell et al., 1999; Lovell and Markesbery, 
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2007b; Markesbery and Lovell, 2006), the exact site of the oxidation in the human 
genome remains unclear. We hypothesized that DNA oxidative damage is not an 
arbitrary process but may be distinctively localized to specific genes. We further 
hypothesize that the most highly oxidized genes are those coding for proteins whose 
expression has shown to be altered in the brain of AD subjects. In order to test this 
hypothesis, nDNA from NC, MCI, PCAD and LAD specimens were treated with 
formamidopyrimidine glycosylase (fpg), a DNA repair enzyme that recognizes and 
removes damaged bases including 8-oxoguanine, 8-oxoadenine, fapy-guanine, methy-
fapy-guanine, fapy-adenine, aflatoxin B1-fapy-guanine, 5-hydroxy-cytosine and 5-
hydroxy-uracil. Formamidopyrimidine glycosylase has both N-glycosylase (release of 
damaged purines from dsDNA creating an apurinic (AP) site) and AP-lyase (cleavage of 
AP site) activities leading to a single-nucleotide gap flanked by phosphate termini in 
damaged DNA (Du et al., 2009). The percent oxidative damage in different amplicons of 
genes coding for proteins shown to be altered in the progression of AD were then 
quantified using quantitative/real-time polymerase chain reaction (qPCR/ RT-PCR). To 
understand the utilization of qPCR in this study, both traditional PCR and qPCR are 
discussed in the following section. Table 1.1 lists several genes for which alterations in 
proteins are observed in AD. This study focused on the three isoforms of the voltage 
dependent anion channel proteins, VDAC1, 2 and 3. VDACs were the ideal candidate for 
this study as the three forms differ in abundance, size and activity, and are altered 
differentially in the AD brain. Lovell et al. found a significant elevation of VDAC1 
levels, no significant change in VDAC2 levels and a trend towards significant increase of 
VDAC3 levels in Aβ-treated primary rat cortical neuron cultures (Lovell et al., 2005). To 
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test the assumption oxidation of the coding sequence of a protein leads to differential 
protein levels and activity, we designed an experiment using the protein IGF2 (insulin 
like growth factor-II). IGF2 was selected for this experiment because it has one of the 
smallest coding sequences (only 202 bp in length) and well characterized activity assays. 
Progressively increasing amounts of 8-oxoguanine were incorporated into the IGF2 
coding sequence and the DNA thus obtained subjected to in vitro transcription and 
translation using a cell  free system to produce the IGF2 protein. The protein levels and 
activity in these samples was quantified and compared to a positive control sample 
containing no oxo-guanine.  
1.5.1.1.  Polymerase Chain Reaction  
 Polymerase chain reaction (PCR) is a biochemical technique conceived by Kary 
Mullis and colleagues in 1985 for exponentially amplifying short DNA segments (100-
600 bases). Automation of PCR following the discovery and isolation of thermo-stable 
DNA polymerase (Taq polymerase) from the bacterium Thermus aquaticus has led to its 
application in multiple facets of biology and chemistry.  The reaction components of a 
traditional PCR reaction include target DNA, forward and reverse primers, DNA 
polymerase, deoxynucleotide triphosphates (dNTPs), MgCl2, PCR reaction buffer and 
water. The PCR reaction buffer provides an optimal pH and monovalent salt environment 
and water acts as an interaction medium for the other reaction components of the PCR 
reaction. Magnesium cations required as cofactors for the DNA polymerase enzymes are 
provided by MgCl2. Individual DNA bases are supplied by the dNTPs to DNA 
polymerases for formation of new DNA strands during a PCR reaction. The β and γ 
phosphates of the dNTPs also fulfill the energy requirements of the PCR reaction. Target 
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DNA provides the template for amplification by DNA polymerases. Ideally, template 
DNA should be uncontaminated by any other DNA/RNA source. Specific thermostable 
DNA polymerases including Taq polymerase (source: Thermus aquaticus) , Tth 
polymerase (source: Thermus thermophilus), Tfl polymerase (source: Thermus flavus),  
Pfu polymerase (source: Pyrococcus furiosus) Tli polymerase (source: Thermus litoralis) 
and Pyrococcus species GB-D may be used in PCR reactions dependent on specific 
application. The DNA polymerase enzyme for a PCR reaction is selected based on three 
factors, (1) processivity (rate at which the polymerase produces a complementary copy of 
the template), fidelity (accuracy of complementary copy formation) and persistence 
(stability of enzyme at high temperature).  Taq polymerase, the most commonly used 
enzyme in PCR, has a procesivity of 50-60 nucleotides per second at 72 C, an error rate 
of 285 x 10-6 errors per template nucleotide and a half-life of 1.5 hours at 95 C. Taq 
polymerases have 5’→3’ nuclease activity but lack 3’→5’ proof reading ability leading 
to the incorporation of a single 3’ adenosine nucleotide on both strands of every 
amplicon. Primers are short oligonucleotide sequences designed to be complementary to 
the target DNA necessary for new DNA strand synthesis and are usually added in excess 
amounts in a PCR reaction. For maximum efficiency of a PCR reaction, primers should 
be at least 20 nucleotides in length with PCR reaction compatible melting temperatures 
and the forward and reverse primers should not form primer-dimer bands. In 
conventional PCR, PCR products are visualized using ethidium bromide on an agarose 
gel and analyzed using radio-imaging or other densitometric methods.  
 Typically a PCR reaction is characterized by three steps shown in Figure 1.5: 
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a) Denaturation in which the double stranded target DNA is denatured by heating to 94-
95 oC to produce single stranded DNA strands that act as templates for new DNA strand 
synthesis. 
b) Annealing in which DNA primers anneal to the complementary single stranded DNA 
in preparation for DNA synthesis by DNA polymerases. This annealing process requires 
cooling to the primer annealing temperature which is determined by the melting 
temperatures of the primers. The temperature at which 50% of a DNA duplex dissociates 
to become single stranded DNA is called its melting temperature (Tm). Tm’s are 
dependent on pH, ionic strength and base composition of DNA. Primer annealing 
temperatures are typically 2 oC lower than the lowest primer Tm.  
c) Elongation in which new DNA is synthesized by addition of dNTPs onto the primers 
by DNA polymerase in the 5’→ 3’ direction from the primer. The release of 
pyrophosphate on addition of dNTPs to the growing DNA strand provides the energy 
needed for the polymerase to appropriate and add the next complementary base. 
Polymerization usually occurs at a temperature of 72 oC, the optimal temperature for Taq 
polymerase but the polymerization temperature used can vary based on length of product, 
number of cycles and usage of other DNA polymerases for polymerization.  
 These three steps are repeated for a defined number of cycles depending on the output 
required. A PCR reaction with 25-40 cycles is the usual norm. 
  A PCR reaction theoretically doubles the amount of target DNA after each reaction 
cycle. For example, a PCR reaction with 25 cycles should produce 225 or more than 33 
million copies of the amplicon for each double stranded target DNA molecule present. 
This can be represented by the exponential curve shown in Figure 1.6a.  Experimentallly 
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PCR amplification typically resembles Figure 1.6b and is composed of three separate 
sequential phases: 
a) Exponential phase: In the initial exponential phase DNA polymerase works at near 
optimum capacity leading to almost exact doubling in the amount of product after each 
cycle. This phase closely resembles the theoretical expectation of PCR amplicon 
production and has high specificity and precision.  
b) Linear phase: After a time, reaction components are consumed at different rates, the 
amplicon production slows down and the PCR reaction enters a quasi-linear phase. 
Amplification of the target is highly variable in this phase. 
c) Plateau phase: This is the final phase of the PCR reaction which is traditionally 
detected by gels (end-point detection). In this phase, amplicon production is negligible. 
Consumption of reaction components, reduction in DNA polymerase activity due to heat, 
limited concentrations and increasing pyrophosphate concentration, reannealing of 
products at higher concentrations and risk of degradation of products over time due to 
Taq polymerase 5’-3’ exonuclease activity are some of the factors contributing to the 
plateau phase in later PCR cycles (Garrett and Grisham, 2010; Kainz, 2000; Lehninger et 
al., 2005; Peake, 1989; Rose, 1991; Saiki et al., 1985) 
 Figure 1.7 shows the PCR amplification of three replicate samples with the same 
amount of DNA at the start of the reaction. After PCR, these samples show different 
quantities instead of identical quantities at the plateau phase. On the other hand, the 
replicate samples have identical graphs in the exponential phase. Figure 1.8 shows the 
PCR amplification curve for a 7-fold dilution series. Although the exponential phase 
distinctively shows a difference between the samples, the difference in DNA quantities is 
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not very perceptible in the plateau phase. Hence, it seems more accurate to measure the 
amount of DNA in the exponential phase rather in the plateau phase as has been done 
traditionally. 
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Figure 1.6: PCR amplification (A) theoretical and (B) experimental 
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1.5.1.2.  Real Time Quantitative PCR (qPCR) 
  Due to the limitations of end-point detection in traditional PCR, the amount of 
product obtained is not always fully comparable to the amount of input DNA. Thus this 
method can at best be characterized as semi-quantitative/qualitative. Traditional PCR also 
has the disadvantages of low sensitivity and resolution, non-quantitative staining by 
ethidium bromide, additional post PCR processing steps and a narrow dynamic range (< 
2 logs). In contrast, real time quantitative PCR quantifies amplification in the exponential 
phase of the PCR reaction thus eliminating the inconsistency associated with end-point 
detection in traditional PCR and therefore providing the accurate amount of starting 
target sample. Real time quantitative PCR (qPCR) can detect upto a two-fold change in 
concentration compared to agarose gel analysis which can only detect a 10-fold change in 
concentration. qPCR also uses highly sensitive fluorescent dyes such as SYBR green for 
detection instead of  a low fluorescence dye like ethidium bromide. qPCR also has the 
advantages of wide dynamic range (> 107 fold) and an absence of post PCR processing. 
 Since the first reported qPCR procedure by Higuchi et al in 1993 (Higuchi et al., 
1993), qPCR has found  use in multiple biochemical applications including gene 
expression studies, quantification of DNA copy number in genomic or viral DNA, 
quantitation of cytokine levels, microarrays and allelic discrimination assays. 5’ nuclease 
assays using Taqman probes, molecular beacons and SYBR Green fluorescent dyes are 
the most common chemistries used in qPCR  (Bustin et al., 2005; Espy et al., 2006; 
Mackay et al., 2002; VanGuilder et al., 2008) .  
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1.5.1.3. qPCR Data Analysis  
 The increase in fluorescence during a PCR reaction is detected in real time using any 
of the different probe chemistries used in qPCR. Some of the important terms used in 
data analysis are briefly described below (Figure 1.9) (Arya et al., 2005): 
a) Baseline: The baseline for a qPCR reaction is usually between cycles 1 and 15 and is 
defined as the number of qPCR cycles that lead to a fluorescence signal below the limits 
of detection of the qPCR instrument. 
b) ΔRn: ΔRn is the difference between the fluorescence signal of the product at each time 
point and the fluorescence signal of the baseline. Amplification curves in a qPCR 
reaction are produced by plotting ΔRn vs cycle number.   
c) Threshold: An arbitrary threshold, measured as approximately ten times the standard 
deviation of the average fluorescent signal of the baseline is usually chosen by the qPCR 
software. The threshold is in the region of exponential amplification and provides a 
minimal detection level for the qPCR reaction. It can be changed manually to include the 
amplification curves of multiple reactions.  
d) Ct (Threshold  cycle):  Ct  is the PCR cycle number at which a detectable, statistically 
significant fluorescence signal is observed. The higher the initial concentration of 
template DNA in the qPCR reaction, the lower the Ct value. The Ct value is always 
observed in the exponential phase of DNA amplification and is the basis for data analysis 
methods in qPCR. 
The two different methods used for quantification and analysis of data obtained in qPCR: 
absolute quantification/ standard Curve method and the relative quantification/ 
comparative Ct method which are briefly described below. 
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Figure 1.9. Description of terms used in qPCR data analysis 
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1.5.1.3.1.  Absolute Quantification/ Standard Curve Method 
 In this method, a standard curve is obtained by plotting the log of initial DNA 
concentration for a set of known standards (five or ten fold dilution series) versus Ct and 
should be a straight line for an efficient qPCR reaction (Higuchi et al., 1993). The amount 
of DNA in unknown samples is then determined by measuring their Ct values and 
comparing these Ct values with the standard curve. Purified plasmid DNA, synthetic 
ssDNA or any cDNA/DNA sample expressing the target gene can be used to generate the 
standard curve. This method is used in experiments requiring the absolute quantitation of 
sample (Arya et al., 2005; Schmittgen and Livak, 2008).   
1.5.1.3.2.  Relative Quantification/ Comparative Ct/ 2-ΔΔCt Method 
 In the comparative Ct method, quantification is carried out by comparing the Ct 
value of the sample of interest to the Ct value of an internal control or some calibrator 
such as a non-treated sample. Appropriate housekeeping genes (HKGs) are used to 
normalize the Ct values of both the sample of interest and the internal control. 
Housekeeping genes commonly used for qPCR include glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), β-actin, 28S or 18S ribosomal RNA, β2-microglobulin, 
hypoxanthine-guanine, cyclophilin or phophoribosyl transferase (HPRT) (Arya et al., 
2005; Derveaux et al., 2010). In order to use the comparative method, it is assumed that 
PCR reaction efficiency is 1 and that both the sample of interest and internal control have 
similar PCR efficiency. The amount of target is calculated by the formula 2-ΔΔCt (Livak 
and Schmittgen, 2001; Schmittgen and Livak, 2008) where 
                             ΔΔCt = ΔCt,sample − ΔCt,control 
                             ΔCt,sample = Ct,sample − Ct,HKG 
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                             ΔCt,control = Ct,control − Ct,HKG 
1.5.1.4.  Voltage Dependent Anion Channels (VDACs)  
       Pore-forming VDACs, also known as mitochondrial porins, are found in the 
mitochondrial outer membrane and brain postsynaptic membranes and are ion channels 
that facilitate transport of small hydrophilic solutes including ATP, ADP, Pi, Ca2+, K+ 
and Na+ from the cytosol to mitochondrial sites of utilization or vice versa. In addition, 
VDAC along with adenine nucleotide translocase and cyclophilin-D form the 
mitochondrial permeability transition pore (PTP). Three different isoforms of the VDAC 
protein: VDAC1, VDAC2 and VDAC3 have been observed in humans. Although the 
three isoforms are sequentially homologous and are expressed in most tissues, they differ 
in function and abundance in the human body. For example, VDAC3 has diminished 
pore-forming ability compared to VDAC1 and VDAC2. VDACs form ion channels 
between the mitochondrial outer and inner membranes and have been implicated in the 
regulation of apoptosis and membrane potential, and ATP production. Mitochondrial 
function is considered to be regulated by the voltage dependent closure/opening of 
VDACs. Studies show that VDAC forms a single 2.5-3 nm wide pore which shows a 
slight anion-selectivity in its open state and slight cation- selectivity in its partially closed 
state. VDACs are open at low voltages (≈ ±10 mV) and closed at higher voltages (over 
±30 mV). In addition, VDACs act as coordination sites for multiple ATP using cytosolic 
enzymes including hexokinase, glucokinase, glycerol kinase and mitochondrial creatine 
kinase. Multiple studies (Cuadrado-Tejedor et al., 2011; Lovell et al., 2005; Yoo et al., 
2001) have shown changes in VDAC proteins in the brain of patients with Alzheimer’s 
disease. Lovell et al. found a significant elevation of VDAC1 levels, no significant 
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change in VDAC2 levels and a trend towards significant increase of VDAC3 levels in 
Aβ-treated primary rat cortical neuron cultures (Lovell et al., 2005). Yoo et al. reported a 
significant decrease in VDAC1 levels in thalamus and frontal and temporal cortex and 
significant elevation of VDAC2 levels in temporal cortex of AD subjects (Yoo et al., 
2001). A recent study by Cuadrado-Tejedor et al. showed an overexpression of VDAC1 
in the brain of AD patients (Cuadrado-Tejedor et al., 2011).  
1.5.2.  Changes in DNA Repair Enzymes of BER Pathway in AD Subjects 
 Increased oxidative DNA damage seen during the progression of AD could be due to 
either an increase in formation of oxidized DNA lesions or due to impairments in DNA 
repair mechanisms or both. Previous studies suggest DNA repair pathways may be 
diminished in the progression of AD and may contribute to increased accumulation of 
markers of DNA oxidation (Bohr, 2002; Dianov et al., 2001; Weissman et al., 2007). In 
this study, we hypothesized that the BER pathway has diminished repair capacity 
throughout the progression of AD leading to increased oxidative DNA damage seen 
during AD. To test this hypothesis, custom PCR arrays containing genes for 12 DNA 
repair enzymes, 2 housekeeping genes (Beta actin (ACTB) and Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH)), and negative and positive PCR controls, and qPCR 
were used to quantify expression levels for DNA repair enzymes relative to the 
pathogenesis of AD. To confirm PCR results, enzyme activities were assessed using gel 
shift assays and radiolabeled/fluorescent oligonucleotides and protein levels were 
quantified using Western blot analysis and antibodies specific for each protein. 
 For both projects, tissue specimens were analyzed from normal control (NC) 
subjects and subjects throughout the progression of AD including those with preclinical 
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AD (PCAD), mild cognitive impairment (MCI), late-onset AD (LAD), and diseased 
control (DC) including frontotemporal dementia (FTD) and dementia with Lewy bodies 
(DLB) subjects. Both projects analyzed specimens from a vulnerable brain region 
(superior and middle temporal gyri (SMTG) and a non-vulnerable region (cerebellum 
(CER)).   
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  Table 1.1. List of potential genes studied in Project 1 
 
  # Name used 
in 
experiment 
Gene 
1 VDAC1 Voltage dependent anion-selective channel protein 1 
2 VDAC2 Voltage dependent anion-selective channel protein 2 
3 VDAC3 Voltage dependent anion-selective channel protein 3 
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CHAPTER TWO: MATERIALS AND METHODS 
2.1. Materials  
2.1.1. Brain Specimen Sampling  
 Brain tissue specimens of superior and middle temporal gyri (SMTG) and 
cerebellum (CER) of NC, MCI, PCAD, LAD and DC subjects were collected from short 
postmortem interval (PMI) autopsies and stored at -80 ◦C until used for analysis. All 
subjects were followed longitudinally at the University of Kentucky Alzheimer’s Disease 
Center Clinic (UK-ADC) and had annual neuropsychological testing and physical and 
neurological exams. Results of neuropsychological testing for NC subjects were in the 
normal range. MCI subjects were normal upon enrollment into the study cohort but 
developed MCI during follow up. MCI subjects were diagnosed based on clinical criteria 
described by Petersen et al. which include: (a) memory complaints (b) objective memory 
impairment for age and education (c) normal general cognitive function (d) intact 
activities of daily living and (e) the subject not meeting criteria for dementia (DeCarli, 
2003; Maynard et al., 2010; Petersen et al., 2009; Petersen et al., 1999).  
Histopathologically, MCI subjects showed a significant increase in neuritic plaques in 
neocortical regions and a significant increase in neurofibrillary tangles in the 
hippocampus, entorhinal cortex and amygdala, compared to NC subjects (Markesbery et 
al., 2006). Braak staging scores for MCI subjects were in the range of III-IV. Preclinical 
AD (PCAD) subjects were diagnosed based on the tentative criteria set by the UK-ADC 
which includes (a) pronounced AD pathology with Braak scores of III-V and (b) 
antemortem psychometric tests in the normal range when corrected for age and education 
(Schmitt et al., 2000). Subjects with Braak scores of VI who met both standard clinical 
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and histopathological criteria for probable AD were diagnosed with LAD (Bradley et al., 
2010; Schmitt et al., 2000).  
 Samples from subjects with dementia with Lewy bodies (DLB) and frontotemporal 
dementia (FTD) were analyzed as diseased control specimens.  DLB patients showed 
antemortem diagnostic features including visuospatial problems worse than memory 
problems, executive dysfunction, sleep disturbance, visual hallucinations, facial masking 
and decreased dopamine transporter in the absence of systemic or neurologic disorders. 
Pathologically, DLB was characterized by the presence of ubiquitin and α-synuclein 
positive Lewy bodies (LB) and α-synuclein positive Lewy neurites (LN) in the limbic and 
temporal regions of the brain.  In addition, some DLB brain specimens may have AD-
type pathology including neurofibrillary tangles and diffuse/ neuritic plaques (Ferman 
and Boeve, 2007; Geldmacher, 2004) 
 Frontotemporal dementia describes a group of progressive neurodegenerative 
diseases with diagnostic features including changes in personal and social behavior, 
akinesia, progressive aphasia, labile blood pressure and a variety of other exclusionary 
features. Pathological changes include degeneration of frontal and/or anterior temporal 
lobe and basal ganglia, microvacuolation,  swollen cortical neurons,  neuron loss and loss 
of pigmentation in the substantria nigra (Graff-Radford and Woodruff, 2007; Grossman, 
2002).  
  All subjects had neuropathological assessment of multiple sections of neocortex, 
hippocampus, entorhinal cortex, amygdala, basal ganglia, nucleus basalis of Meynert, 
midbrain, pons, medulla and cerebellum by the modified Bielschowsky stain, 
hemotoxylin-eosin stain and Aβ, and α-synuclein immunostains. Braak staging scores 
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were determined using the Gallyas stain on sections of the hippocampus, entorhinal 
cortex and amygdala and the Bielschowsky stain on neocortex.  
      The subject demographics are shown in Table 2.1. Age, and post-mortem intervals 
are reported as mean ± SEM (Table 2.1) and were compared using ANOVA. Braak 
staging scores are listed as median [range] values and were compared using the Mann 
Whitney U test. 
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Table 2.1. Subject Demographics 
 
Age 
(Mean ± SEM) 
Braak Score 
(Median) 
PMI 
(Mean ± 
SEM) 
Sex 
NC (N = 15) 86.3 ± 1.4 I 2.8 ± 0.2 4M : 11W 
MCI (N = 7) 91.0 ± 1.9* III* 2.6 ± 0.2 2M : 5W 
PCAD (N = 13) 85.7 ± 1.8 IV* 2.8 ± 0.2 3M : 10W 
LAD (N = 14) 81.4 ± 1.4 VI* 3.6 ± 0.4 6M : 8W 
DC (N = 12) 68.9 ± 4.8* II* 3.5 ± 0.4 7M : 5W 
                                                                                                                  * P < 0.05 
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2.1.2.  Antibodies  
        Polyclonal rabbit anti-OGG1 was obtained from Novus Biologicals (Littleton, CO, 
USA). Polyclonal rabbit anti-Ref1, polyclonal rabbit anti-XRCC1, polyclonal rabbit anti-
POLB, polyclonal rabbit anti-PARP1, polyclonal rabbit anti-UDG and polyclonal rabbit 
anti-FEN1 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).     
2.2.  Methods  
2.2.1   Isolation of Nuclear DNA 
   For Project 1 (Oxidative DNA damage in genes of proteins modified during AD), 
two separate methods of DNA isolation were tested to obtain the method with least 
amount of artifactual oxidation of DNA during isolation. The subject demographics for 
the study are shown in Table 2.1. 
a) Genomic DNA was isolated from brain tissues using a DNeasy Tissue Kit per 
manufacturer’s instructions (Qiagen, Valencia, CA). Briefly, ~ 25 mg brain tissue was 
lysed by incubating overnight at 56 oC with proteinase K and lysis buffer. After lysis, AL 
buffer (proprietary mix containing guanidine hydrochloride) and ethanol were added to 
the sample mixture and the mixture was pipetted into a DNeasy Mini spin column and 
centrifuged. The flow-through was discarded. The sample in the DNeasy Mini spin 
column was washed with wash buffers (proprietary mix containing guanidine 
hydrochloride and ethanol) and genomic DNA eluted using ddH2O.  Subsequent to 
elution with ddH2O, purified DNA was stored at −80 °C. 
b) Phenol Extraction Method: Total genomic DNA was isolated from brain tissues using 
a previously published procedure (Mecocci et al., 1993; Sims and Anderson, 2008; Wang 
et al., 2005). A glass Dounce homogenizer was used to homogenize brain tissue 
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specimens in cold isolation buffer (0.3 M sucrose, 10 mM Tris-HCl, 1 mM K2EDTA, pH 
7.4) (10% tissue wet wt/vol).  The homogenate was centrifuged at 1,300 x g at 4°C for 3 
minutes. The pellet obtained was resuspended in isolation buffer and centrifuged again at 
1,300 x g at 4 °C for 3 minutes. The resulting pellet was used for nuclear DNA (nDNA) 
isolation by the phenol extraction method. The pellet was resuspended in digestion buffer 
(0.5% sodium dodecyl sulfate, 0.05 M Tris-HCl, 0.1 M Na2EDTA) with proteinase K 
(0.5 mg/ml) and incubated overnight in a water bath at 56°C. After overnight incubation, 
160 µL of 5 M NaCl per 10 mL solution was added to the mixture. This was followed by 
extraction with buffer-saturated phenol containing 5.5 mM 8-hydroxyquinoline (to limit 
artifactual DNA oxidation) three times and three times with chloroform/isoamyl alcohol 
(24:1).  800 µL of 5 M NaCl per 10 mL was added to the resulting clear extract along 
with an equal volume of chilled absolute ethanol and left overnight at -20°C to precipitate 
nDNA. Subsequently, the DNA pellet was centrifuged, washed three times with 60% 
ethanol and air-dried. The pellet was then dissolved in nuclease-free water. The 
concentration and purity of DNA samples at 260 and 280 nm was measured using a 
ND1000 Nanodrop Spectrophotometer (Thermoscientific, Wilmington, DE). 
2.2.2.  Polymerase Chain Reaction (PCR) 
 PCR reactions were performed with genomic DNA initially to verify oxidative 
damage in specific genes with a range of primers designed for each gene (listed in Table 
2.2). PCR reactions were also used to validate the primers obtained for RT-PCR (listed in 
Table 4). A PCR reaction mixture contained 250 ng genomic DNA, 1× Thermoscientific 
PCR Master Mix and 1 μM primer mix (forward and reverse) in a total volume of 25 µL. 
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A 1.2% low-melt agarose gel containing ethidium bromide was used to separate the PCR 
products (Wang et al., 2005).  
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Table 2.2. Primers for PCR 
Gene 
DNA bp 
location 
Bp 
length 
Primer sequence 
Tm 
(oC) 
 
VDAC1 134-913 780 5’-AATCTGCCAGGGATGTCTTCACCA-3’ 60.3 Forward 
5’-CACCAGCATTGACGTTCTTGCCAT-3’ 60.3 Reverse 
VDAC1 134-505 372 5’-AATCTGCCAGGGATGTCTTCACCA-3’ 60.3 Forward 
5’-GCCCAGCAATGTCGAAATCCATGT-3’ 60.2 Reverse 
VDAC1 438-913 476 
5’-AATCAAGACAGGGTACAAGCGGGA-3’ 60.2 Forward 
5’-CACCAGCATTGACGTTCTTGCCAT-3’ 60.3 Reverse 
VDAC2 193-546 354 
5’-CAAAGTCTTGCAGTGGCGTGGAAT-3’ 60.2 Forward 
5’-CAAGCCAGCCCTCATAACCAAAGA-3’ 59.4 Reverse 
VDAC2 545-749 205 
5’-TGCTGGCTACCAGATGACCTTTGA-3’ 60.2 Forward 
5’-ACGAGTGCAGTTGGTACCTGATGT-3’ 60.2 Reverse 
VDAC2 726-1024 299 
5’-ACATCAGGTACCAACTGCACTCGT-3’ 60.2 Forward 
5’-CCTGCTGCTGGTCACAATGGAAAT-3’ 60.0 Reverse 
VDAC2 
1024-
1404 
381 5’-GCTTTTTTCCCCCAAGAAGATGAT-3’ 55.9 Forward 
 5’-TTGTCATGTTCTGGGATACCAAAA-3’ 54.7 Reverse 
VDAC2 193-738 546 
5’-CAAAGTCTTGCAGTGGCGTGGAAT-3’ 60.2 Forward 
5’-TGGTACCTGATGTCCAAGCAAGGT-3’ 60.2 Reverse 
VDAC2 193-749 557 
5’-CAAAGTCTTGCAGTGGCGTGGAAT-3’ 60.2 Forward 
5’-ACGAGTGCAGTTGGTACCTGATGT-3’ 60.2 Reverse 
VDAC2 193-1021 829 
5’-CAAAGTCTTGCAGTGGCGTGGAAT-3’ 60.2 Forward 
5’-CCTGCTGCTGGTCACAATGGAAAT-3’ 60 Reverse 
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2.2.3. Oxidative DNA Damage 
 Real time PCR/ quantitative PCR was used to determine the level of oxidative 
damage in the DNA sequences of various genes. The range of primers designed for each 
gene, are listed in Table 2.3. Briefly, 250 ng of total genomic DNA was incubated with 8 
units of formamidopyrimidine glycosylase (fpg) and 100 μg/ml of BSA at 37°C for 12 h. 
The fpg enzyme was inactivated after 12 h by incubation at 60°C for 10 min. Real time/ 
quantitative PCR was carried out with an aliquot of the reaction mixture on an ABI 7000 
Sequence Detection System using TaqMan 2x  PCR Master Mix (Applied Biosystems, 
Carlsbad, CA) and SYBR Green for detection. The RT-PCR reaction mixture contained 
1× TaqMan PCR Master Mix, 4 μM primer mix (forward and reverse), SYBR Green, 
ROX reference dye and template genomic DNA. The absolute concentrations of intact 
DNA in the template were calculated using a standard curve derived from 5-fold serial 
dilutions of genomic DNA from NC subjects. The data presented show the average of 
triplicates from RT-PCR. Oxidative damage was calculated as 
 
 % Oxidative damage =                                    
 
RT-PCR reaction mixtures without template DNA served as negative controls in order to 
monitor nonspecific amplification. PCR products were verified by melting curves (Du et 
al., 2009).  
 
 
 
aliquot nontreatedin DNA intact 
aliquot)  treatedfpgin DNA                   
intact -aliquot nontreatedin DNA (intact 
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Table 2.3. Primers for RT-PCR  
Table 2.3.1. VDAC1 primers 
Gene DNA bp 
location 
bp 
length 
Primer sequence Tm 
(oC) 
 
VDAC1A 438-613 176 
5’-AATCAAGACAGGGTACAAGCGGGA-3’ 60.2 Forward 
5’-CAACTGCAAAGTTGCTCTGGGTCA-3’ 60.0 Reverse 
VDAC1B 482-689 208 
5’-ACATGGATTTCGACATTGCTGGGC-3’ 60.2 Forward 
5’-TTCTGGTAAATGGAGCCGCCAAAC-3’ 59.9 Reverse 
VDAC1C 666-913 248 
5’-GTTTGGCGGCTCCATTTACCAGAA-3’ 59.9 Forward 
5’-CACCAGCATTGACGTTCTTGCCAT-3’ 60.3 Reverse 
VDAC1D 695-896 202 
5’-ACAAGAAGTTGGAGACCGCTGTCA-3’ 60.4 Forward 
5’-TTGCCATCCAGAAGAGCTGACAGT-3’ 60.4 Reverse 
VDAC1E 722-913 192 
5’-TTGCCTGGACAGCAGGAAACAGTA-3’ 60.5 Forward 
5’-CACCAGCATTGACGTTCTTGCCAT-3’ 60.3 Reverse 
VDAC1G 914-1173 260 
5’-GCCACAAGCTTGGTCTAGGACTGG-3’ 61.6 Forward 
5’-AAGTTCTCCCCGAGTCTACCACTG-3’ 59.8 Reverse 
VDAC1H 
1174-
1411 
238 
5’-GAGAACTTGGTGGCCCCTTTGAGA-3’ 61.0 Forward 
5’-GGGGTGGGAACAGGTCATGAAGAT-3’ 60.8 Reverse 
VDAC1I 
1398-
1594 
196 
5’-CCTGTTCCCACCCCAGTTCATCAT-3’ 61.0 Forward 
5’-GCTGGAGCTCCTGGAAGCTATTTC-3’ 59.6 Reverse 
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Table 2.3.2. VDAC2 primers 
Gene DNA bp 
location 
bp 
length 
Primer sequence Tm 
(oC) 
 
VDAC2A 24-213 190 5’-GCGAAGTGAAGGAGACACCGTTCC -3’ 61.7 Forward 
5’-CCACGCCACTGCAAGACTTTGTTT -3’ 60.6 Reverse 
VDAC2B 167-354 188 5’-TGGGTTGGTGAAACTGGATGTGAA -3’ 58.9 Forward 
5’-TTGCGATTTCTGTTCCCAGAGTGT -3’ 58.8 Reverse 
VDAC2C 331-538 208 5’-ACACTCTGGGAACAGAAATCGCAA -3’ 58.8 Forward 
5’-CCCTCATAACCAAAGACAGCTGAACC 59.4 Reverse 
VDAC2D 522-738 217 5’-GTCTTTGGTTATGAGGGCTGGCTT -3’ 59.4 Forward 
5’-TGGTACCTGATGTCCAAGCAAGGT -3’ 60.2 Reverse 
VDAC2E 726-956 231 5’-ACATCAGGTACCAACTGCACTCGT -3’ 60.2 Forward 
5’-TCAGCTGGATTAAGCCTCCAACTC -3’ 58.7 Reverse 
VDAC2G 948-1152 205 5’-TCCAGCTGAAAGAAACCTTTGGGA -3’ 58.7 Forward 
5’-GCAGGACTGCAGCATTGGTAACTA -3’ 59.3 Reverse 
VDAC2H 1126-
1310 
185 5’-ATCTAGTTACCAATGCTGCAGTCC -3’ 56.8 Forward 
5’-CCACTGATCCATCTCATTCAATGGT -3’ 56.9 Reverse 
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Table 2.3.3: VDAC3 primers 
Gene DNA bp 
location 
bp 
length 
Primer sequence Tm 
(oC) 
 
VDAC3A 248-447 200 5’-AGGGAAAGCATCAGGCAACCTAGA-3’ 60.1 Forward 
5’-AGGAGGCCTTCAATTTCCCACTCT-3’ 60.2 Reverse 
VDAC3B 367-651 285 
 
5’-TGGCTGAAGGGTTGAAACTGACTC-3’ 59.2 Forward 
5’-GTTCTCATGTGTGTGCAGATGGAA-3’ 57.5 Reverse 
VDAC3C 540-735 196 5’-TGGCTTGCTGGCTATCAGATGAGT-3’ 60.3 Forward 
5’-TCCCAGCTGTCCAAGCAAGGTTTA-3’ 60.6 Reverse 
VDAC3D 627-865 239 5’-TTCCAGCTGCACACACATGTGAAC-3’ 60.2 Forward 
5’-ATTTGACTCCTGGTCGAAGGGTCT-3’ 59.7 Reverse 
VDAC3E 718-932 215 5’-TTGCTTGGACAGCTGGGAGTAACA-3’ 60.5 Forward 
5’-AAATCCCAAGCCAACCTTGTGACC-3’ 60.1 Reverse 
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2.2.4. Oxoguanine Incorporation into IGF2 Gene Sequence 
 PCR reactions were performed with genomic DNA with primers designed 
specifically for IGF2. PCR reaction mixtures contained 100 ng genomic DNA, 10mM 
dATP, 10mM dCTP, 10mM dTTP, 10mM (deoxyguanine/8-oxoguanine in varying 
ratios), 10X PCR reaction buffer, Taq polymerase, 25 mM MgCl2 and 10 μM primer mix 
(forward and reverse) in a total volume of 25 µL. A 1.2% low-melt agarose gel 
containing ethidium bromide was used to separate the PCR products (Wang et al., 2005). 
The PCR product band was excised from the agarose gel and purified DNA was obtained 
using a gel extraction kit and a DNA clean-up and concentration kit per manufacturer’s 
instructions (Zymo Research, Irvine, CA). 
2.2.5. In vitro Transcription 
 IGF2 DNA with 8-OHG was transcribed to RNA in vitro using a Megascript kit per 
manufacturer’s instructions (Life Technologies, Grand Island, NY). Briefly, 100-500 ng 
of template DNA was incubated with dNTPs (2 μl each of ATP, CTP, GTP and UTP), 2 
μl enzyme mix, 2 μl of 10X reaction buffer and water at 37 °C for 16 hours. The reaction 
mixture was then incubated at 37 °C for 15 minutes with 1 μl DNase to remove template 
DNA. The RNA transcript was purified using the phenol:chloroform extraction and 
isopropanol precipitation. RNA transcript was diluted by addition of 115 μl of water and 
15 μl ammonium acetate solution and extracted with an equal volume of phenol and then 
with an equal volume of chloroform. RNA was then precipitated with an equal volume of 
isopropanol overnight. The pellet removed after centrifugation was resuspended in 
nuclease-free water and sample was stored at −20°C. 
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2.2.6. In vitro Translation 
 IGF2 protein was synthesized in vitro using a Retic Lysate IVT kit per 
manufacturer’s instructions (Life Technologies, Grand Island, NY). Briefly, 100-750 ng 
in vitro transcribed RNA was incubated in a reaction mixture containing 20X translation 
mix (-Met), 50 μl L-Met, 17 μl retic lysate and nuclease-free water at 30 °C for 90 
minutes. The mixture was then incubated with 2.5 μl of 1 mg/ml RNase at 30 °C for 10 
minutes. Subsequently, the reaction mixture was placed on ice for 5 minutes to quench all 
reactions and stored at −20 °C. 
2.2.7. IGF2  Activity Assay 
 IGF2 activity assays were as previously described (Gicquel et al., 2004; Spicer et al., 
1994). Briefly, IGF2 was radioiodinated in a 20 μl reaction mixture containing 0.3M 
PBS, 1mCi Na-125I and 1.6 μg chloramine-T at 25 °C for 30 s. 6 μg of sodium 
metabisulfite was added to quench the reaction. Iodinated IGF2 specimens were 
incubated with 150 μl plasma samples in a reaction mixture containing 25 mM Hepes (ph 
7.4), 0.1% BSA and 0.1% Triton X-100 overnight at 4 °C. IGF2 binding complex pellets 
were separated by precipitation with 4% gammaglobulin and 18% w/v PEG 6K, and 
subsequent centrifugation. The pellet was counted in a scintillation counter. Blanks 
containing only iodinated IGF2 and no plasma were run for each sample set.  
2.2.8. RNA Isolation and cDNA Synthesis 
a) RNA isolation: Total RNA was isolated from tissue specimens using an RNeasy 
Tissue Kit per manufacturer’s instructions (Qiagen, Valencia, CA). Briefly, ~ 20 mg of 
brain tissue was homogenized in RLT buffer (proprietary mix containing guanidine 
thiocyanate and β-mercaptoethanol). Ethanol (one volume) was added to the 
67 
 
homogenized sample and the reaction mixture was transferred to an RNeasy Mini spin 
column. The spin column was subsequently washed with multiple washing buffers and 
total RNA eluted using RNAse-free H2O.  Following elution with RNAse free H2O, 
purified RNA was stored at −80 °C or used directly for cDNA synthesis.  
b) cDNA synthesis: RNA samples were converted into cDNA using the RT2 First Strand 
Kit per manufacturer’s instructions (SABiosciences, Frederick, MD). Briefly, 75-100 ng 
of RNA were incubated with genomic DNA elimination buffer at 42°C for 5 minutes in 
order to eliminate genomic DNA contamination. The reaction mixture was then mixed 
with a reverse transcription cocktail provided in the kit and incubated at 42 °C for exactly 
15 minutes. The reverse transcription reaction was quenched by heating the mixture at 
95°C for 5 minutes. The sample was diluted with RNAse free H2O and stored at −20°C 
overnight.  
2.2.9.  Quantitative Polymerase Chain Reaction with custom PCR arrays 
 Quantitative PCR was carried out on an ABI 7000 Sequence Detection System using 
2x SABiosciences RT2 qPCR Master Mix. The qPCR reaction mixture contained 2x 
SABiosciences RT2 qPCR Master Mix, and 250 ng of cDNA. 25 μl of the sample 
experimental cocktail was added to each well of 96-well Custom PCR arrays and placed 
in the real-time thermal cycler. The thermal cycler was run according to the real-time 
thermal cycler program recommended by the manufacturer (SABiosciences, Frederick, 
MD). The Custom PCR arrays contained primers for genes coding for DNA repair 
enzymes and housekeeping genes (ACTB & GAPDH) and positive and negative PCR 
controls (Table 2.4).  The absolute concentrations of intact DNA in the template were 
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calculated using the web-based PCR Array Data Analysis Software provided by the 
manufacturer (SABiosciences).  
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Table 2.4.  Custom PCR array layout 
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PPC: Positive PCR Control; HGDC: Human Genomic DNA Contamination 
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2.2.10. Protein Isolation and Quantification 
 Tissue samples were homogenized on ice with a Dounce homogenizer in a buffer 
containing 10 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]-ethanesulfonic acid (HEPES), 
137 mM NaCl, 4.6 mM KCl, 0.6 mM MgSO4, 0.7 µg/ml pepstatin A, 0.5 µg/ml 
leupeptin, 0.5 µg/ml aprotinin and 40 µg/ml PMSF). The resulting homogenate was 
centrifuged at 100,000 x g for 1 hour at 4 ◦C. Protein concentration of the supernatant was 
measured using the Pierce BCA protein assay (Sigma, St. Louis, MO). 
2.2.11.  Western Blot Analysis  
       20 µg of protein of each sample was separated on Criterion 4-15% Tris-HCL 
electrophoresis gradient gels followed by transfer to nitrocellulose transfer membranes.  
The membranes were then incubated in blocking buffer (5 % milk in 0.5% Tween-
20/Tris-buffered saline (TTBS)) for 1 hour.  Specific rabbit polyclonal anti-human 
primary antibodies against OGG1 (Novus Biologicals, Littleton, CO, USA), UNG, APE1, 
POLB, PARP1, XRCC1 & FEN1 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) 
(1:1000 dilution) were added and the membranes were placed on an orbital shaker 
overnight at 4°C. Subsequently, the membranes were washed with TTBS three times 
followed by incubation with 1:1000 dilution of horseradish peroxidase-labeled goat anti-
rabbit secondary antibody (Jackson Immunoreasearch Laboratories Inc., West Grove, PA, 
USA) for 2 hours. The membranes were again washed with TTBS three times and the 
bands developed using enhanced chemiluminescence according to the manufacturer’s 
instructions (Amersham Pharmacia Biotech, Piscataway, NJ, USA). Band intenisties 
were quantified using Scion Image Analysis (NIH). Results are expressed as mean ± 
SEM % control immunostaining. 
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2.2.12.  Enzyme Activity Assays  
2.2.12.1. Oligonucleotides 
 Oligonucleotides used in this study containing 8-oxodG, deoxy-uracil or 
tetrahydrofuran (THF) (Midland Certified Reagent Company, Midland, TX) and their 
complementary strand sequences are listed in Table 2.5. The lesion-containing 
oligonucleotides were 5′-32P-labeled by incubation with [γ-32P] ATP (PerkinElmer, 
Boston, MA, USA) and T4 polynucleotide kinase. G25 desalting columns (GE 
Healthcare Corp., Piscataway, NJ, USA) were used to remove the unincorporated free [γ-
32P] ATP from the reaction mixtures.  The 32P-labeled oligonucleotides were annealed to 
their complementary strands in annealing buffer (100 mM KCL, 10 mM Tris-HCl, pH 7.8 
and 1mM EDTA) by heating the samples at 90°C for 5 min. A double-stranded DNA 
substrate containing a double flap region used for the FEN1 activity assay was prepared 
by annealing three oligodeoxynucleotides (Table 2.5) (Biosearch Technologies Inc. 
Novato, CA, USA) in a reaction buffer containing 50 mM Tris (pH 8), 100 mM KCl and 
5mM MgCl2 by heating to 95 C for 5 minutes and subsequent cooling to room 
temperature.   
2.2.12.2.  OGG1 Activity Assay 
       OGG1 activity assays were carried out as previously described (Croteau and Bohr, 
1997; Shao et al., 2008). Briefly, 20 µg of protein were incubated at 37°C for 1 h in a 20 
μl reaction mixture containing 40 mM Hepes-KOH (pH 7.6), 5 mM EDTA, 2 mM DTT, 
75 mM KCl, 10% glycerol and 88.7 fmol 32P-labeled duplex oligonucleotide (Table 2.5). 
Reactions were subsequently quenched by addition of 20 μl of loading buffer containing 
90% formamide, 0.002% bromophenol blue, and 0.002% xylene green and heated at 
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95°C for 5 min. After cooling to room temperature, the reaction mixture was separated on 
a 20% denaturing polyacrylamide gel containing 7 M urea prerun at 18 W for 30 min. 
Samples were separated by electrophoresis for 90 min at 16 W using 1X Tris borate 
EDTA (TBE) (pH 8.0) as a running buffer. A reaction mixture consisting of 20 μg 
protein, heat-inactivated by boiling at 95°C for 5 min before initiating the activity assay 
was used as blank for the assay. 
       Samples were analyzed with NC, MCI, PCAD and LAD samples on the same gel to 
allow comparison. Radiolabeled bands were visualized as previously described (Croteau 
and Bohr, 1997; Souza-Pinto et al., 1999) and band intensities of the cleaved product and 
parent oligonucleotide bands were quantified using Scion Image Analysis (NIH).  
Activities were calculated as the amount of radioactivity in the incised product band 
relative to the total radioactivity in the lane (incised product + intact duplex 
oligonucleotide). Results are expressed as mean ± SEM % control protein activity. 
2.2.12.3.  UNG Activity Assay 
 UNG activity assays were as previously described (Maynard et al., 2010; Weissman 
et al., 2007). Briefly, 20 μl reaction mixtures containing 70 mM HEPES–KOH (pH 7.4), 
5 mM EDTA, 1 mM DTT, 75 mM NaCl, 10% glycerol, 50 fmol 32P-labeled duplex 
oligonucleotide (Table 2.5) and 10 μg of protein were incubated for 1 h at 37°C. 
Reactions were subsequently quenched by addition of formamide dye and converted to a 
single-strand break product by addition of 50 mM NaOH and incubation at 75°C for 15 
minutes. Samples were resolved and analyzed as described for the measurement of 
OGG1 activity. 
 
73 
 
2.2.12.4.  APE1 Activity Assay 
        APE1 activity assays were carried out as previously described (Maynard et al., 2010; 
Weissman et al., 2007).  Briefly, 5 µg of protein was incubated at 37°C for 1 h in a 10 μl 
reaction mixture containing 20 µg of protein was incubated at 37°C for 1 h in a 20 μl 
reaction mixture containing 25 mM HEPES–KOH (pH 7.4), 25 mM KCl, 0.1 mg/ml 
BSA, 5 mM MgCl2, 10% glycerol, 0.05% Triton X-100 and 1.0 pmol 32P-labeled duplex 
oligonucleotide (Table 2.5). Reactions were terminated and samples resolved and 
evaluated as described for the measurement of OGG1 activity. 
2.2.12.5.  POLB Activity Assay 
 POLB activity assays were as previously described (Maynard et al., 2010; Weissman 
et al., 2007). Samples were diluted in 10mM Tris-HCl (pH 7.4) containing 100 mM KCl. 
20 μl reaction mixtures containing 50 mM Tris-HCl (pH 7.4), 50 mM KCl, 1 mM DTT, 
75 mM MgCl2, 5% glycerol, 5 µM dCTP (Roche Applied Sciences, Indianapolis, IN, 
USA), 4 µCi α32P-dCTP (GE Healthcare Corp., Piscataway, NJ, USA), 1 pmol duplex 
gap oligonucleotide (Table 2.5) and 5 μg of protein were incubated for 1 h at 37°C. 
Reactions were terminated and samples resolved and evaluated as described for the 
measurement of OGG1 activity. 
2.2.12.6.  FEN1 Activity Assay 
 FEN1 activity assays were as previously described (Dorjsuren et al., 2011). Briefly, 
a 40 μl reaction mixture containing 50 mM Tris-HCl pH 8.0, 10 mM MgCl2, 1 mM DTT, 
0.01% Tween-20, 5 μg of protein and 1 pmol labeled oligonucleotide (Table 2.5) were 
pipetted into a 96-well plate and data collected using a FLx800 fluorescence microplate 
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reader (Biotek, Winooski, VT, USA) equipped with standard optics (excitation filter 525 
nm and emission filter 598 nm). 
2.2.12.7.  PARP1 Activity Assay 
 PARP1 activity assays were carried out as previously described (Adamczyk et al., 
2005; Strosznajder et al., 2000a, b). Briefly 100 μg of protein was incubated in 100 μl 
reaction mixture containing 200 uM [14C]NAD (2x105 d.p.m), 100 mM Tris-HCl (pH 
8.0), 10 mM MgCl2,1 mM DTT and 50 uM p-amidinophenylmethanesulfonyl fluoride 
(APMSF) for 5 minutes at 37°C. Reactions were terminated by addition of 800 μl of 25% 
ice-cold trichloroacetic acid (TCA). After collection of the precipitate on Whatman GF/B 
filters, it was washed five times with ice-cold 5% TCA, dried and 14C radioactivity was 
measured using a Packard 2500 TR scintillation counter (Thermo Fisher Scientific, 
Waltham, MA, USA). 
2.2.13.  Statistical Analysis  
  The % oxidative damage values from the fpg reaction and RT-PCR studies are 
reported as mean ± SD. Data obtained for gene expression fold change, protein levels and 
protein activities were tested for normality using the Wilks-Shapiro test. Statistical 
comparisons were carried out using the Mann-Whitney U-test for non-parametrically 
distributed data with values reported as the median [range]. For normally distributed data, 
statistical comparisons were carried out using ANOVA with Dunnett’s test for individual 
comparisons and the values reported as mean ± SEM. P < 0.05 was considered 
significant. 
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Table 2.5. Names and sequences of oligonucleotides used in protein activity assays 
Assay Sequence 
8-
Oxoguanine 
incison  
5′-GAA CGA CTG T(oxoG)A CTT GAC TGC TAC TGA T-3′ 
3′-CTT GCT GAC A C T GAA CTG ACG ATG ACT A-5′ 
Uracil 
incision 
5′-ATA TAC CGC GG(U) CGG CCG ATC AAG CTT ATT-3′ 
3′-TAT ATG GCG CC G GCC GGC TAG TTC GAA TAA-5′ 
AP-site 
incision 
5′-GAA CGA CTG T(abasic)A CTT GAC TGC TAC TGA T-3′ 
3′-CTT GCT GAC A C T GAA CTG ACG ATG ACT A-5′ 
POLB gap-
filling  
5′-CTGCAGCTGATGCGC(spacerC3)GTACGGATCCCCGGGTAC-
3′ 
3′-GAC GTC GAC TAC GCG GCA TGC CTA GGG GCC CAT G-5′ 
FEN1 
incision 
Quencher 
5′-CACGTTGACTACCGCTCAATCCTGACGAACACATC-BHQ-2 
Flap 
5′-TAMRA-
GATGTCAAGCAGTCCTAACTTTGAGGCAGAGTCCGC 
Template 
5′-GCGGACTCTGCCTCAAGACGGTAGTCAACGTG-3′ 
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CHAPTER THREE: RESULTS 
3.1. Oxidative DNA Damage in Genes of Proteins Modified during AD  
  Percent oxidative DNA damage was calculated in the SMTG (a vulnerable brain 
region) and cerebellum (a non-vulnerable brain region) of fourteen age-matched NC, five 
MCI, thirteen PCAD, thirteen LAD and nine DC subjects. The subject demographics are 
shown in Table 3.1. No significant differences were observed in PMI for any of the 
subjects studied. Although, there were no significant differences in ages of MCI (91.6 ± 
2.7 years), PCAD (85.7 ± 1.8 years) and LAD (81.2 ± 1.6 years) subjects compared to 
NC subjects (85.9 + 1.4 years), DC subjects which have an earlier disease age of onset 
(70.4 + 5.9 years) were significantly younger than NC subjects. Median Braak staging 
scores were significantly (P < 0.05) higher for PCAD (IV), MCI (III), LAD subjects (VI) 
and DC subjects (II) compared to NC subjects (I).  
     Two different DNA isolation methods, phenol-chloroform extraction and extraction 
using Qiagen DNeasy Tissue Kit, were compared to determine the method with minimal 
artifactual oxidation. Data obtained showed DNA isolated using the DNeasy kit 
demonstrated 10-20% more artifactual oxidation compared to phenol-chloroform 
extraction method. Based on these results, phenol extraction method was used for DNA 
isolation in this project.  Initially, samples were subjected to the Fpg reaction and 
oxidative damage as evidenced by fpg cleavage was analyzed using traditional PCR and a 
range of primers and visualized using agarose gel electrophoresis. The gels showed 
smaller molecular mass bands for fpg treated samples compared to the non-treated 
samples but did not provide quantitative data. Hence qPCR was used to quantitatively 
determine the % oxidative damage in this study. Primers were designed for PCR and 
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qPCR to encompass the coding sequence of each gene and are listed in Table 2.2 and 2.3 
respectively. The fluorescent dye SYBR Green was used for detection in the qPCR 
reactions. The absence/presence of non-specific amplification in a qPCR reaction was 
verified using melt curves. Amplicons highlighted in red in Tables 3.2-3.4 showed a 
significant increase (P < 0.05) or a trend towards a significant increase (0.05 < P < 0.1) in 
oxidative damage in MCI/PCAD/LAD/DC subjects compared to NC subjects. Results of 
this study were non-normally distributed (Wilks-Shapiro test) and are reported as Median 
[Range] % of NC values. Oxidative damage data for VADC1I in SMTG and VDAC2D in 
cerebellum displayed a normal distribution and are reported as mean (± SEM) % of NC. 
All comparisons are based on the average of triplicate experiments.  As the data are non-
normally distributed, box and whisker plots were used to describe the results. An 
example of a typical box and whisker plot is shown in Figure 3.1. The median value is 
represented by the line within the box. The boundaries of the box indicate the 25th (lower 
boundary, near zero) and 75th percentile (upper boundary) and the whiskers denote the 
10th (whisker below the box) and the 90th percentile (bar above the box). The dots (●) 
above and below the whiskers represent extreme data points or outliers. 
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Figure 3.1. Example of a box and whisker plot 
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3.1.1. VDAC1 
  Eight sets of VDAC1 primers (Table 2.3.1) were used to examine the % oxidative 
damage in the coding sequence of VDAC1 and significant differences in oxidative 
damage were observed for 5 amplicons. The results for quantification of oxidative 
damage for all 8 amplicons are described in the following section. For the VDAC1A 
amplicon (bp 438-613), no significant differences in % oxidative damage were observed 
in the SMTG of MCI (184.24 [6.78-244.05]), LAD (71.06 [0-320.84] %) or DC (8.87 [0-
304.49] %) subjects compared to NC subjects (19.14 [0-366.74] %). Median levels of % 
oxidative damage were significantly higher in the SMTG of PCAD subjects (288.36 [0-
355.38] %) compared to NC subjects for VDAC1A (Figure 3.2A). In the cerebellum, % 
oxidative damage was not significantly altered in MCI (0 [0-219.58] %), PCAD (0 [0-
301.71] %), LAD (72.49 [25.44-281.03] %) or DC (0 [0-298.98] %) subjects compared to 
NC subjects (102.83 [0-216.08] %) (Figure 3.2B) for VDAC1A. In the SMTG, there was 
a significant increase in median levels of % oxidative damage in LAD (231.53 [0-524.96] 
%) and DC (228.7 [62.32-371.39] %) subjects and a trend towards significant increase in 
PCAD subjects (217.49 [0-351.31] %) compared to NC subjects (0 [0-380.29] %) for the 
VDAC1B amplicon (bp 482-689). No significant changes in the median levels of % 
oxidative damage were observed in the SMTG of MCI subjects (214.86 [60.49-357.45] 
%) compared to NC subjects for VDAC1B (Figure 3.3A). In the cerebellum, median 
levels of % oxidative damage were significantly elevated in DC subjects (0 [0-298.98] %) 
compared to NC subjects (111.87 [0-223.75] %) for VDAC1B. In contrast, there were no 
significant differences in MCI (0 [0-219.58] %), PCAD (7.5 [0-286.51] %), LAD (126.63 
[0-337.72] %) for VDAC1B (Figure 3.3B).    
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  Analysis of the VDAC1C amplicon (bp 666-913) showed no significant differences 
in % oxidative damage in the SMTG of MCI (326.07 [0-439.58] %) but a significant 
increase in PCAD (276.22 [94.08-482.44] %), LAD (311.02 [0-494.12] %) and DC 
(263.46 [0-528.53] %) subjects compared to NC subjects (69.2 [0-467.70] %) (Figure 
3.4A). We observed no significant changes in median levels of % oxidative damage in 
the cerebellum of MCI (107.56 [0-283] %), PCAD (137.55 [0-369.19] %), LAD (70.04 
[0-362.01] %) or DC (13.83 [0-261.65 %) subjects compared to NC subjects (26.84 [0-
327.84] %) (Figure 3.4B). Median levels of % oxidative damage showed no significant 
differences in the SMTG of MCI (121.81 [0.01-186.61] %), PCAD (149.04 [0-185.66] 
%), LAD (53.43 [2.88-143.89] %) or DC (148.09 [0-187.9] %) subjects compared to NC 
subjects (126.55 [0-168.46] %) (Figure 3.5A) for the VDAC1D amplicon (bp 695-896). 
Similarly, there were no significant differences seen in % oxidative damage for 
VDAC1D in the cerebellum of MCI (0 [0-263.16] %), PCAD (0 [0-248.47] %), LAD 
(93.88 [0-229.52] %) or DC (48.55 [0-210.79 %) subjects compared NC subjects (104.87 
[0-240.47] %) (Figure 3.5B).  
    Median levels of % oxidative damage were significantly higher in the SMTG of 
PCAD (251.5 [0-294.42] %), LAD (192.57 [0-277.07] %) and DC (212.27 [0-301.77] %) 
subjects compared to NC subjects (148.07 [0-160.26] %) for the VDAC1E amplicon (bp 
722-913). There was a trend towards a significant increase in oxidative damage in SMTG 
of MCI (175.67 [123.8-269.36] %) compared to NC subjects (Figure 3.6A). No 
significant differences in % oxidative damage were observed for the VDAC1E amplicon 
in the cerebellum of MCI (223.13 [0-322.19] %), PCAD (78.16 [0-278.49] %), LAD 
(113.23 [0-309.12] %) or DC (143.9 [0-297.43] %) subjects compared to NC subjects 
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(69.59 [0-306.2] %) (Figure 3.6B). In the SMTG, there was a significant increase in 
median levels of % oxidative damage in LAD (157.87 [0-165.69] %) but no significant 
changes in MCI (121.37 [0-140] %), PCAD (139.66 [39.67-162.11] %) or DC (141.42 
[18.73-167.65] %) subjects compared to NC subjects (121.92 [0-160.26] %) for the 
VDAC1G amplicon (bp 914-1173) (Figure 3.7A). There were no significant differences 
observed in % oxidative damage for VDAC1G in the cerebellum of MCI (167.37 [0-
295.77] %), PCAD (54.69 [0-230.39] %), LAD (101.2 [0-284.02] %) or DC (159.48 [0-
266.9] %) subjects compared to NC subjects (25.78 [0-285.38] %) (Figure 3.7B). 
    Analysis of the VDAC1H amplicon (bp 1174-1411) showed no significant 
differences in % oxidative damage in the SMTG of MCI (85.34 [0-110.68] %), PCAD 
(87.82 [0-146.28] %), LAD (126.09 [0-153.39] %) or DC (122.2 [0-149.48] %) subjects 
compared to NC subjects (105.75 [10.83-141.4] %) (Figure 3.8A). Median levels of % 
oxidative damage were not significantly different in the cerebellum of MCI (171.58 
[69.69-429.3] %), PCAD (0 [0-292.21] %), LAD (106.23 [0-312.94] %) or DC (195.92 
[0-383.87] %) subjects compared to NC subjects (67.66 [0-335.75] %) (Figure 3.8B). In 
the SMTG, there were no significant differences in average % oxidative damage in MCI 
(80.27 ± 15.75 %), PCAD (78.22 ± 12.88 %), LAD (102.75 ± 14.74 %) and DC (113.17 
± 9.11 %) subjects compared to NC subjects (100 ± 8.05 %) for the VDAC1I amplicon 
(bp 1398-1594) (Figure 3.9A). No significant changes in median levels of % oxidative 
damage were observed for VDAC1I in the cerebellum of MCI (131.28 [0-190.85] %), 
PCAD (58.5 [0-337.85] %), LAD (45.85 [0-424.78] %) or DC (174.37 [0-350.29] %) 
subjects compared to NC subjects (75.46 [0-308.38] %) (Figure 3.9B). 
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Table 3.1. Subject demographics for the oxidative damage study 
 Age 
(Mean ± SEM) 
Braak Score 
(Median) 
PMI 
(Mean ± SEM) 
Sex 
NC (N = 14) 85.9 ± 1.4 I 2.8 ± 0.2 4M : 10W 
MCI (N = 5) 91.6 ± 2.7 III* 2.6 ± 0.2 2M : 3W 
PCAD (N = 13) 85.7 ± 1.8 IV* 2.8 ± 0.2 3M : 10W 
LAD (N = 13) 81.2 ± 1.6 VI* 3.6 ± 0.4 6M : 7W 
DC (N = 9) 70.4 ± 5.9 II* 3.2 ± 0.3 5M : 4W 
                                                                                                    * P < 0.05 
NC: Normal Control; MCI: Mild Cognitive Impairment; PCAD: Preclinical Alzheimer’s 
Disease; LAD: Late-stage Alzheimer’s Disease; SEM: Standard Error of Mean; PMI: 
Postmortem Interval; M: Men; W: Women 
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Table 3.2. Percent oxidative DNA damage for VDAC1 amplicons (Significant 
differences are shown in bold) 
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Figure 3.2. Oxidative damage in amplicons for VDAC1A in A) SMTG B) Cerebellum  
                  (* P < 0.05; ** 0.05 < P < 0.1) 
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Figure 3.3. Oxidative damage in amplicons for VDAC1B in A) SMTG B) Cerebellum 
                  (* P < 0.05; ** 0.05 < P < 0.1) 
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Figure 3.4. Oxidative damage in amplicons for VDAC1C in A) SMTG B) Cerebellum 
                  (* P < 0.05; ** 0.05 < P < 0.1) 
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 M
ed
ian
 [R
an
ge
]
%
 O
xi
da
tiv
e 
D
am
ag
e 
(%
 N
C
)
0
50
100
150
200
NC
MCI
PCAD
LAD
DC
% Oxidative Damage for VDAC1D
   
   
   
 M
ed
ian
 [R
an
ge
] 
%
 O
xi
da
tiv
e 
D
am
ag
e 
(%
 N
C
)
0
50
100
150
200
250
300
NC
MCI
PCAD
LAD
DC
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Oxidative damage in amplicons for VDAC1D in A) SMTG B) Cerebellum 
                  (* P < 0.05; ** 0.05 < P < 0.1) 
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Figure 3.6. Oxidative damage in amplicons for VDAC1E in A) SMTG B) Cerebellum 
                  (* P < 0.05; ** 0.05 < P < 0.1) 
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Figure 3.7. Oxidative damage in amplicons for VDAC1G in A) SMTG B) Cerebellum 
                   (* P < 0.05; ** 0.05 < P < 0.1) 
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Figure 3.8. Oxidative damage in amplicons for VDAC1H in A) SMTG B) Cerebellum 
                   (* P < 0.05; ** 0.05 < P < 0.1) 
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Figure 3.9. Oxidative damage in amplicons for VDAC1I in A) SMTG B) Cerebellum 
                   (* P < 0.05; ** 0.05 < P < 0.1) 
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3.1.2. VDAC2 
 Seven sets of VDAC2 primers (Table 2.3.2) were used to examine levels of 
oxidative damage in the coding sequence of VDAC2. The results of oxidative damage 
calculated for all the amplicons are discussed in detail in this section. All the amplicons 
had a GC content ratio of 44-50% except for the VDAC2A amplicon (bp 24-213) which 
had a > 50% GC content ratio. Melt curve analysis of qPCR reactions with primers for 
the VDAC2A amplicon showed multiple curves indicating high levels of non-specific 
binding. Therefore, the data obtained for VDAC2A could not be used to determine % 
oxidative damage.  For the VDAC2B amplicon (bp 167-354), no significant differences 
in % oxidative damage were observed in the SMTG of MCI (43.71 [0-195.88] %), PCAD 
(10.75 [0-457.89] %), LAD (0 [0-202.83] %) or DC (59.88 [0-378.58] %) subjects 
compared to NC subjects (21.45 [0-421.84] %) (Figure 3.10A). Similarly, median levels 
of % oxidative damage were not significantly different in the cerebellum of MCI (0 [0-
144.87] %), PCAD (14.42 [0-219.49 %), LAD (229.59 [0-378.58] %) or DC (0 [0-
224.49] %) subjects compared to NC subjects (31.77 [0-368.24] %) for VDAC2B (Figure 
3.10B). For VDAC2C (bp 331-538), % oxidative damage was not significantly altered in 
the SMTG of MCI (44.98 [1-251.56] %), PCAD (0 [0-250.21] %), LAD (0 [0-338.84] %) 
or DC (0 [0-216.49] %) subjects compared to NC subjects (62.79 [0-414.16] %) (Figure 
3.11A). In the cerebellum, analysis of VDAC2C showed no significant differences in 
median levels of % oxidative damage in MCI (0 [0-404.84] %), PCAD (0 [0-370.89] %), 
LAD (292.5 [0-625.31] %) or DC (3.04 [0-517.63] %) subjects compared to NC subjects 
(1.03 [0-484.2] %) (Figure 3.11B). 
93 
 
 No significant differences in median levels of % oxidative damage were observed in 
the SMTG of MCI (0 [0-872.98] %), PCAD (0 [0-1053.69] %), LAD (0 [0-667.96] %) or 
DC (82.35 [0-1249.86] %) subjects compared to NC subjects (0 [0-778.04] %) (Figure 
3.12A) for the VDAC2D amplicon (bp 522-738).  In the cerebellum, mean levels of % 
oxidative damage were not significantly altered in MCI (127.09 (±39.75) %), PCAD 
(114.82 (±22.44) %), LAD (84.44 (±19.12) %) or DC (88.73 (±25.56) %) subjects 
compared to NC subjects (100 (±21.2) %) for VDAC2D (Figure 3.12B). Analysis of the 
VDAC2E amplicon (bp 726-956), showed no significant differences in % oxidative 
damage in the SMTG of MCI (0 [0-573.73] %), PCAD (0 [0-1120.85] %), LAD (0 [0-
676.49] %) or DC (0 [0-830.88 %) subjects compared to NC subjects (0 [0-1176.67 %) 
(Figure 3.13A). In cerebellum, oxidative damage in VDAC2E was not significant 
different in MCI (39.67 [0-146.82] %), PCAD (97.59 [0-200.54] %), LAD (94.65 [0-
190.47] %) or DC (126.19 [0-181.23] %) subjects compared to NC subjects (116.4 [0-
182.12] %) (Figure 3.13B). 
 Median levels of % oxidative damage were not significantly different in the SMTG 
of MCI (0 [0-93.25] %), PCAD (182.34 [0-383.78] %) or LAD (19.98 [0-257.61] %) 
subjects compared to NC subjects (42.47 [0-313.84] %) (Figure 3.14A) for VDAC2G (bp 
948-1152). No significant differences in % oxidative damage were observed for 
VDAC2G in the cerebellum of MCI (0 [0-276.84] %), PCAD (1.61 [0-198.04] %), LAD 
(174.93 [0-351.57] %) or DC (140.05 [0-236.69] %) subjects compared to NC subjects 
(5.48 [0-312.73] %) (Figure 3.14B). Quantification of oxidative damage in VDAC2H 
amplicon (bp 1126-1310), showed no significant differences in the SMTG of MCI (0 [0-
5291.24] %), PCAD (0 [0-4418.17] %), LAD (0 [0-3746.8] %) or DC (0 [0-4425.36] %) 
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subjects compared to NC subjects (0 [0-1140.54] %) (Figure 3.15A). In the cerebellum, 
median levels of % oxidative damage were not significantly different in MCI (116.75 
[119.11-275.63] %), PCAD (167.86 [0-265.88] %), LAD (46.86 [0-267.57] %) or DC 
(131.67 [0-248.92] %) subjects compared to NC subjects (85.44 [0-278.89] %) for 
VDAC2H (Figure 3.15B). 
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Table 3.3. Percent oxidative DNA damage for VDAC2 amplicons (There were no 
significant differences observed for any of the subjects studied) 
 
 
                                                                                                              * P < 0.05 
                                                                                                                   ** 0.05 < P < 0.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amplicon NC MCI PCAD LAD DC SMTG CER SMTG CER SMTG CER SMTG CER SMTG CER 
VDAC2B 
21.45 
[0-
421.84 
31.77 
[0-
368.24] 
43.71 
[0-
195.88] 
0 [0-
144.87] 
10.75 
[0-
457.89] 
14.42 
[0-
219.49] 
0 [0-
202.83] 
229.59 
[0-
407.21] 
59.88 
[0-
378.58] 
0 [0-
224.49] 
VDAC2C 
62.79 
[0-
414.16] 
1.03 
[0-
484.2] 
44.98 
[1-
251.56] 
0 [0-
404.84] 
0[0-
250.21] 
0 [0-
370.89] 
0 [0-
338.84] 
292.5 
[0-
625.31] 
0 [0-
216.49] 
3.04 
[0-
517.63] 
VDAC2D 
0 [0-
778.04] 
100 (± 
21.2) 
0 [0-
872.98] 
127.09 
(± 
39.75) 
0 [0-
1053.69] 
114.82 
(± 
22.44) 
0 [0-
667.96] 
84.44 
(± 
19.12) 
82.35 
[0-
1249.86] 
88.73 
(± 
25.56) 
VDAC2E 
0 [0-
1176.67] 
116.4 
[0-
182.12] 
0 [0-
573.73] 
39.67 
[0-
146.82] 
0 [0-
1120.85] 
97.59 
[0-
200.54] 
0 [0-
676.49] 
94.65 
[0-
190.47] 
0 [0-
830.88] 
126.19 
[0-
181.23] 
VDAC2G 
42.47 
[0-
313.84] 
5.48 
[0-
312.73] 
0 [0-
93.25] 
0 [0-
276.84] 
182.34 
[0-
383.78] 
1.61 
[0-
198.04] 
19.98 
[0-
257.61] 
174.93 
[0-
351.57] 
 140.05 
[0-
236.69] 
VDAC2H 
0 [0-
1140.54] 
85.44 
[0-
278.89] 
0 [0-
5291.24] 
116.75 
[19.11-
275.63] 
0 [0-
4418.17] 
167.86 
[0-
265.88] 
0 [0-
3746.8] 
46.86 
[0-
267.57] 
0 [0-
4425.36] 
131.67 
[0-
248.92] 
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Figure 3.10. Oxidative damage in amplicons for VDAC2B in A) SMTG B) Cerebellum 
                   (* P < 0.05; ** 0.05 < P < 0.1) 
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Figure 3.11. Oxidative damage in amplicons for VDAC2C in A) SMTG B) Cerebellum 
                   (* P < 0.05; ** 0.05 < P < 0.1) 
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Figure 3.12. Oxidative damage in amplicons for VDAC2D in A) SMTG B) Cerebellum 
                   (* P < 0.05; ** 0.05 < P < 0.1) 
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Figure 3.13. Oxidative damage in amplicons for VDAC2E in A) SMTG B) Cerebellum 
                   (* P < 0.05; ** 0.05 < P < 0.1) 
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Figure 3.14. Oxidative damage in amplicons for VDAC2G in A) SMTG B) Cerebellum 
                   (* P < 0.05; ** 0.05 < P < 0.1) 
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Figure 3.15. Oxidative damage in amplicons for VDAC2H in A) SMTG B) Cerebellum 
                   (* P < 0.05; ** 0.05 < P < 0.1) 
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3.1.3. VDAC3 
 For quantification of oxidative damage to VDAC3, 5 primer sets encompassing the 
coding sequence were used in the study (Table 2.3.3). The results for oxidative damage 
observed for all the amplicons are described in detail in this section.  In case of the 
VDAC3A amplicon (bp 248-447) melt curve analysis of qPCR reactions showed multiple 
curves and hence the data obtained for VDAC3A could not be used to determine % 
oxidative damage. For the VDAC3B amplicon (bp 367-651), no significant differences in 
% oxidative damage were observed in the SMTG of MCI (0 [0-258.07] %), PCAD (36.49 
[0-301.24] %), LAD (9.7 [0-238.82] %) or DC (0 [0-291.6] %) subjects compared to NC 
subjects (59.85 [0-286.62] %) (Figure 3.16A). Similarly, median levels of % oxidative 
damage were not significantly altered in the cerebellum of MCI (0 [0-181.16] %), PCAD 
(71.48 [0-152.14] %), LAD (91.72 [0-209.81] %) or DC (49.33 [0-197.9] %) subjects 
compared to NC subjects (113.97 [0-201.24] %) in case of VDAC3B (Figure 3.16B). 
 In SMTG, there were no significant differences in median levels of % oxidative 
damage in MCI (84.24 [0-187.08] %), PCAD (20.59 [0-254.05] %), LAD (86.78 [0-
213.66] %) or DC (63.34 [0-182.46] %) subjects compared to NC subjects (72.99 [0-
308.28] %) (Figure 3.17A) for the VDAC3C amplicon (bp 540-735). In the cerebellum, 
median levels of % oxidative damage were not significantly changed in MCI (66.32 [0-
399.31] %), PCAD (30.49 [0-287.94] %), LAD (82.21 [0-378.46] %) or DC (182.86 [0-
327.51] %) subjects compared to NC subjects (34.43 [0-338.25] %) for VDAC3C (Figure 
3.17B). For the VDAC3D amplicon (bp 627-865), % oxidative damage was not 
significantly altered in the SMTG of MCI (15.4 [0-130.09] %), PCAD (8.18 [0-183.27] 
%), LAD (131.5 [0-253.12] %) or DC (48.35 [0-181.7] %) subjects compared to NC 
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subjects (56.27 [0-291.79] %) (Figure 3.18A). No significant changes in median levels of 
% oxidative damage were observed in the cerebellum of MCI (91.4 [0-304.81] %), 
PCAD (111.01 [0-305.05] %), LAD (89.29 [0-238.13] %) or DC (19.65 [0-294.59] %) 
subjects compared to NC subjects (60.96 [0-298.08] %) for VDAC3D (Figure 3.18B). In 
contrast, there was a significant increase in median levels of % oxidative damage in LAD 
subjects (249.8 [0-413.33] %) compared to NC subjects (49.04 [0-288.34] %) in the 
SMTG for the VDAC3E amplicon (bp 718-932).  There were no significant differences 
in % oxidative damage in the SMTG of MCI (121.48 [0-336.77] %), PCAD (228.88 [0-
447.4] %) or DC (220.95 [0-414.53] %) subjects compared to NC subjects for VDAC3E 
(Figure 3.19A). Median levels of % oxidative damage were not significantly changed in 
the cerebellum of MCI (70.27 [0-353.98] %), PCAD (29.4 [0-321.21] %), LAD (5.15 [0-
256.01] %) or DC (145.49 [31.65-288.02] %) subjects compared to NC subjects (83.92 
[0-290.73] %) for VDAC3E (Figure 3.19B). 
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Table 3.4. Percent oxidative DNA damage for VDAC3 amplicons (Significant 
differences are shown in bold) 
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Figure 3.16. Oxidative damage in amplicons for VDAC3B in A) SMTG B) Cerebellum 
                  (* P < 0.05; ** 0.05 < P < 0.1) 
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Figure 3.17. Oxidative damage in amplicons for VDAC3C in A) SMTG B) Cerebellum 
                   (* P < 0.05; ** 0.05 < P < 0.1) 
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Figure 3.18. Oxidative damage in amplicons for VDAC3D in A) SMTG B) Cerebellum 
                   (* P < 0.05; ** 0.05 < P < 0.1) 
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Figure 3.19. Oxidative damage in amplicons for VDAC3E in A) SMTG B) Cerebellum 
                   (* P < 0.05; ** 0.05 < P < 0.1) 
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3.1.4.  IGF2 
 A progressively increasing percentage of 8-oxoguanine was incorporated into IGF2 
gene sequence via PCR. DNA obtained was first transcribed to RNA in vitro and the 
RNA was translated to protein in vitro using cell free systems. No product was obtained 
for the sample incorporated with 100% 8-oxoguanine. Protein samples from the cell free 
expression system were subjected to Western blot analysis and probed for IGF2 using a 
specific antibody and  IGF2 enzyme activities were calculated to determine if the 
presence of oxidized guanines in DNA can lead to changes in protein levels or protein 
activity. The IGF2 enzyme activity was measured as the binding of radiolabeled IGF2 
with IGF2 receptors present in human plasma. Samples with 0% 8-oxoguanine (100% 
guanine) were used as positive control (PC) for the reaction. Mean ± SEM IGF2 protein 
levels (% PC) and protein activity levels (% PC) are shown in Table 3.5. IGF2 protein 
levels were significantly increased for 10% (161.47 ± 7.59), 25% (149.32 ± 10.63), 35% 
(149.46 ± 9.25) and 50% (146.27 ± 10.19) 8-oxoguanine incorporated samples compared 
to PC samples (100 ± 12.07). There was a trend towards significance for IGF2 protein 
levels in samples with 75% 8-xoguanine (139.27 ± 16.32) compared to PC samples. For 
protein activity levels, significant decreases were seen in samples with 10% (23.89 ± 
2.48), 35% (15.36 ± 4.54), 50% (56.95 ± 10.02) and 75% (35.6 ± 9.76) incorporation of 
8-oxoguanine compared to PC samples (100 ± 4.65). No significant differences were 
observed for samples with 25% 8-oxoguanine incorporated samples (40.78 ± 26.27) 
compared to PC samples. 
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Table 3.5. Protein levels and Enzyme activity levels of 8-oxoguanine incorporated IGF2 
[% PC] (Significant differences are shown in bold) 
PC = Positive Control 
* P < 0.05 
** 0.05 < P < 0.1 
 
# %   Oxo guanine 
IGF2 protein levels 
Mean ± SEM (% PC) 
IGF2 activity 
Mean ± SEM (% PC) 
1 0 (PC) 100 ± 12.07 100 ± 4.65 
2 10 161.47 ± 7.59* 23.89 ± 2.48* 
3 25 149.32 ± 10.63* 40.78 ± 26.27 
4 35 149.46 ± 9.25* 15.36 ± 4.54* 
5 50 146.27 ± 10.19* 56.95 ± 10.02* 
6 75 139.27 ± 16.32** 35.6 ± 9.76* 
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3.2. Changes in DNA Repair Enzymes of BER Pathway in AD Subjects 
 Changes in DNA repair enzymes involved in multiple pathways including OGG1, 
UNG, APE1, POLB, FEN1, PARP1, XRCC1, EXO1, RAD50, XPA, MRE11A and ATM 
were determined in the SMTG (a vulnerable brain region) and cerebellum (a non-
vulnerable brain region) of fifteen age-matched NC, six MCI, thirteen PCAD, fourteen 
LAD and twelve DC subjects. Subject demographic data are shown in Table 2.1. There 
were no significant differences in PMI between MCI/PCAD/LAD/DC subjects compared 
to age-matched NC subjects. No significant differences were observed in age of MCI 
(91.0 ± 2.2 years), PCAD (85.7 ± 1.8 years) or LAD (81.4 ± 1.4 years) subjects compared 
to age-matched NC subjects (86.3 ± 1.4 years) athough DC (68.9 ± 4.8 years) subjects 
were significantly younger than NC subjects. Braak staging scores are reported as median 
values and were significantly higher (P < 0.05) for MCI (III), PCAD (IV) LAD (VI) and 
DC subjects (II) compared to age-matched NC subjects (I).  The data for this study were 
tested for normality using the Wilks-Shapiro test. Non-normally distributed is reported as 
Median [Range] and normally distributed data is described as mean (± SEM). The results 
for this study are summarized in Table 3.9. 
3.2.1. Gene Expression 
 Gene expression of 12 genes involved in multiple DNA repair pathways including 
OGG1, UNG, APE1, POLB, FEN1, PARP1, XRCC1, EXO1, RAD50, XPA, MRE11A 
and ATM was analyzed using the DNA repair pathway RT2 custom PCR array 
(SABiosciences) (Table 2.4) and quantitative reverse transcription PCR in the SMTG and 
the cerebellum from PCAD, MCI, LAD, DC and age-matched NC subjects. The 
housekeeping genes, β-actin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
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were used for normalization. Results are expressed in terms of fold change in gene 
expression in MCI/PCAD/LAD/DC subjects compared to age-matched NC subjects. Fold 
change is defined as the ratio of 2−ΔCt values for samples from varied disease stages 
(MCI, PCAD, LAD) to the average 2−ΔCt value of NC samples. Positive and negative 
controls were run on each plate to verify genomic integrity and PCR efficiency. The data 
were found to be non-normally distributed as determined by the Wilks-Shapiro test for 
normality.  Table 3.6 shows the fold change values obtained for expression of specific 
genes in specimens of SMTG and cerebellum as median [range] for NC, MCI, PCAD, 
LAD and DC subjects.  
 A statistically significant increase (P < 0.05) was observed in fold change for OGG1 
in SMTG of PCAD (1.6 [1.34-4.14]) and LAD (2.06 [0.79-3.85]) subjects compared to 
NC subjects (1.21 [0.19-1.49]) whereas SMTG samples from MCI (1.33 [0.55-1.55]) and 
DC (1.14 [0.13-3.17]) subjects showed no significant changes in OGG1 gene expression 
compared to NC subjects. OGG1 gene expression levels in cerebellum showed no 
significant differences in MCI (1.11 [0.7-1.56]), PCAD (1.12 [0.75-1.96]), LAD (1.12 
[0.67-3.68]) or DC (1.28 [0.55-2.09]) subjects compared to NC subjects (0.98 [0.27-
2.15]). Levels of UNG expression were significantly increased in the SMTG of PCAD 
(1.72 [0.56-5.4]), LAD (1.59 [0.29-4.09]) and DC (2.48 [0.59-7.76]) subjects but showed 
no change in SMTG of MCI subjects (1.29 [0.85-4.65]) compared to NC subjects (0.89 
[0.45-1.79]). UNG gene expression levels in cerebellum were not significantly changed 
for any of the subject groups studied including MCI (0.96 [0.41-2.25]), PCAD (1.07 
[0.49-2.2]), LAD (0.99 [0.43-4.89]) and DC (1.05 [0.5-2.6]) subjects compared to NC 
subjects (0.99 [0.35-1.87]).  
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 No significant differences in the median levels of fold change in gene expression of 
APE1 were observed in the SMTG of MCI (0.91 [0.46-3.4]), PCAD (0.97 [0.4-1.63])), 
LAD (1.19 [0.66-2.71]) and DC (0.73 [0.02-1.7]) subjects compared to NC subjects (1.02 
[0.14-1.4]). In cerebellum, median fold change in APE1 expression levels were 
comparable for all the disease states studied including MCI (1.02 [0.47-1.12]), PCAD 
(0.85 [0.48-2.12]), LAD (1.07 [0.76-2.06]) and DC (1.14 [0.76-1.89]) subjects compared 
to NC subjects (0.95 [0.66-1.9]). Fold change in POLB expression levels were not 
significantly different in SMTG of MCI (1.23 [0.92-2.46]) and DC (1.02 [0.1-2.25]) 
subjects but showed a statistically significant increase in PCAD (1.35 [1.05-2.22]) and 
LAD (1.32 [0.84-3.27]) subjects compared to NC subjects (1.04 [0.38-1.34]). 
Comparison of fold change in POLB expression levels across the disease spectrum in the 
cerebellum showed no significant changes in MCI (1.3 [0.64-3.3]), PCAD (1.28 [0.24-
3.51]) and LAD (1.2 [0.4-4.81]) compared to NC subjects (1.15 [0.1-1.3]). In contrast, 
there was a significant increase in fold change of POLB expression in the cerebellum of 
DC (1.73 [0.47-3.14]) subjects compared to NC subjects. 
 In the SMTG, there were no significant changes in median levels of fold change in 
FEN1 expression levels in MCI (0.89 [0.38-1.39]), PCAD (1.05 [0.32-3.53]), LAD (1.1 
[0.21-2.51]) or DC (1.24 [0.11-2.18]) subjects compared to NC subjects (0.86 [0.41-
2.44]). Median levels of fold change in FEN1 expression levels were also significantly 
unchanged in the cerebellum of MCI (0.98 [0.75-1.45]), PCAD (1.17 [0.69-1.84]), LAD 
(1.29 [0.74-3.14]) and DC (1.33 [0.49-2.27]) subjects compared to NC subjects (1.04 
[0.49-1.32]). For PARP1 expression, there were no significant differences in the SMTG 
of MCI (0.94 [0.68-1.26]), PCAD (0.99 [0.29-2.01]) or DC (0.98 [0.02-2.82]) subjects 
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although there was a significant increase in fold change in LAD subjects (1.54 [0.67-
3.05]) compared to NC subjects (0.83 [0.41-2.44]). No significant differences in fold 
change in PARP1 expression levels were observed in the cerebellum of MCI (1.0 [0.64-
1.55]), PCAD (1.32 [0.35-5.11]), LAD (1.02 [0.53-4.15]) and DC (1.1 [0.5-2.86]) 
subjects compared to NC subjects (0.73 [0.47-3.27]). 
 In SMTG, median fold change in XRCC1 expression levels were comparable 
throughout the progression of AD including MCI (1.05 [0.75-2.09]), PCAD (1.12 [0.47-
7.08]) and LAD (1.41 [0.57-4.05]) subjects and also in DC (1.25 [0.61-6.19]) subjects 
compared to NC subjects (0.92 [0.35-1.59]). There was no significant difference 
observed in fold change in XRCC1 expression in the cerebellum of MCI (0.87 [0.51-
1.31]), PCAD (1.13 [0.53-1.76]), LAD (0.86 [0.7-8.39]) and DC (0.89 [0.51-2.0]) 
subjects compared to NC subjects (0.8 [0.32-3.15]). No significant changes in the median 
levels of fold change in EXO1 expression levels were observed in the SMTG of MCI 
(0.44 [0.11-2.19]), PCAD (0.33 [0.11-1.97]), LAD (0.55 [0.22-2.41]) and DC (0.66 
[0.22-12.69]) subjects compared to NC subjects (0.44 [0.11-7.0]). In the cerebellum, 
median levels of fold change in EXO1 expression levels were not significantly different 
in MCI (0.61 [0.4-1.13]), PCAD (0.48 [0.16-4.44]), LAD (0.36 [0.16-13.39]) and DC 
(0.48 [0.08-18.55]) subjects compared to NC subjects (0.32 [0.16-7.1]). 
 Fold change in RAD50 expression levels were not significantly different in SMTG 
of MCI (0.9 [0.41-1.69]), PCAD (0.9 [0.23-2.82]) or DC (0.79 [0.11-4.36]) subjects but 
showed a statistically significant increase in LAD subjects (1.35 [0.3-3.61]) compared to 
NC subjects (0.83 [0.08-3.68]). In contrast, no significant differences in fold change in 
RAD50 expression levels were observed in the cerebellum of MCI (1.0 [0.78-1.71]), 
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PCAD (0.78 [0.15-2.55]), LAD (1.08 [0.24-4.97]) or DC (0.93 [0.36-5.33]) subjects 
compared to NC subjects (0.82 [0.42-2.73]). In SMTG, median fold change in XPA 
expression levels were comparable throughout the progression of AD including MCI 
(0.99 [0.47-1.71]), PCAD (0.82 [0.6-9.6]) and LAD (1.04 [0.46-2.87]) and also in DC 
(1.06 [0.58-3.29]) subjects compared to NC subjects (0.82 [0.35-2.62]). Median levels of 
fold change in XPA expression levels were not significantly altered in the cerebellum of 
MCI (1.0 [0.15-1.92]), PCAD (1.15 [0.58-3.28]), LAD (1.07 [0.47-6.12]) and DC (0.9 
[0.48-1.96]) subjects compared to NC subjects (0.88 [0.35-2.33]). 
 No significant changes in median levels of fold change in MRE11A were observed 
in the SMTG of MCI (1.27 [0.32-2.81]), PCAD (0.77 [0.27-2.81]), LAD (0.93 [0.45-
5.12]) or DC (1.09 [0.13-5.25]) subjects compared to NC subjects (0.91 [0.27-2.94]). In 
the cerebellum, median levels of fold change in MRE11A expression levels were not 
significantly changed in MCI (1.36 [0.82-2.23]), PCAD (1.38 [0.5-2.3]), LAD (1.2 [0.11-
3.57]) or DC (1.59 [0.22-6.07]) subjects compared to NC subjects (0.88 [0.3-1.94]). In 
case of the fold change in ATM expression levels, there were no significant differences in 
the SMTG of MCI (0.71 [0.46-2.13]), PCAD (0.72 [0.16-2.64]), LAD (1.13 [0.44-4.81]) 
and DC (0.63 [0.09-3.77]) subjects compared to NC subjects (0.79 [0.14-2.61]). There 
were no significant differences observed in fold change in ATM expression levels in the 
cerebellum of MCI (1.08 [0.83-1.91]), PCAD (1.11 [0.53-5.27]), LAD (1.27 [0.52-
10.24]) or DC (1.12 [0.44-2.74]) subjects compared to NC subjects (1.0 [0.21-1.93]). 
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Table 3.6. Fold change in expression of DNA repair genes as determined by DNA 
Damage Repair PCR Custom PCR array (Bold numbers indicate significant difference) 
Gene NC 
Median (Range) 
MCI 
Median 
(Range) 
PCAD  
Median 
(Range) 
LAD 
Median 
(Range) 
DC 
Median 
(Range) 
SMTG Cer SMTG Cer SMTG Cer SMTG Cer SMTG Cer 
OGG1 1.21 
[0.19-
1.49] 
0.98 
[0.27-
2.15] 
1.33 
[.55-
1.55] 
1.11 
[0.7-
1.56] 
*1.6 
[1.34-
4.14] 
1.12 
[0.75-
1.96] 
*2.06 
[0.79-
3.85] 
1.12 
[0.67-
3.68] 
1.14 
[0.13-
3.17] 
1.28 
[0.55-
2.09] 
UNG  0.89 
[0.45-
1.79] 
0.99 
[0.35-
1.87] 
1.29 
[0.85-
4.65] 
0.96 
[0.41-
2.25] 
*1.72 
[0.56-
5.4] 
1.07 
[0.49-
2.2] 
*1.59 
[0.29-
4.09] 
0.99 
[0.43-
4.89] 
*2.48 
[0.59-
7.76] 
1.05 
[0.5-
2.6] 
APE1 1.02 
[0.14-
1.4] 
0.95 
[0.66-
1.9] 
0.91 
[0.46-
3.4] 
1.02 
[0.47-
1.12] 
0.97 
[0.4-
1.63] 
0.85 
[0.48-
2.12] 
1.19 
[0.66-
2.71] 
1.07 
[0.76-
2.06] 
0.73 
[0.02-
1.7] 
1.14 
[0.76-
1.89] 
POLB 1.04 
[0.38-
1.34] 
1.15 
[0.1-1.3] 
1.23 
[0.92-
2.46] 
1.3 
[0.64-
3.3] 
*1.35 
[1.05-
2.22] 
1.28 
[0.24-
3.51] 
*1.32 
[0.84-
3.27] 
1.2 
[0.4-
4.81] 
1.02 
[0.1-
2.25] 
*1.73 
[0.47-
3.14] 
FEN1 0.86 
[0.41-
2.44] 
1.04 
[0.49-
1.32] 
0.89 
[0.38-
1.39] 
0.98 
[0.75-
1.45] 
1.05 
[0.32-
3.53] 
1.17 
[0.69-
1.84] 
1.1 
[0.21-
2.51] 
1.29 
[0.74-
3.14] 
1.24 
[0.11-
2.18] 
1.33 
[0.49-
2.27] 
PARP1 0.83 
[0.17-
3.03] 
0.73 
[0.47-
3.27] 
0.94 
[0.68-
1.26] 
1.0 
[0.64-
1.55] 
0.99 
[0.29-
2.01] 
1.32 
[0.35-
5.11] 
*1.54 
[0.67-
3.05] 
1.02 
[0.53-
4.15] 
0.98 
[0.02-
2.82] 
1.1 
[0.5-
2.86] 
XRCC1 0.92 
[0.35-
1.59] 
0.8 
[0.32-
3.15] 
1.05 
[0.75-
2.09] 
0.87 
[0.51-
1.31] 
1.12 
[0.47-
7.08] 
1.13 
[0.53-
1.76] 
1.41 
[0.57-
4.05] 
0.86 
[0.7-
8.39] 
1.25 
[0.61-
6.19] 
0.89 
[0.51-
2.0] 
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Table 3.6. Contd. Fold change in expression of DNA repair genes as determined by DNA 
Damage Repair PCR Custom PCR array (Bold numbers indicate significant difference) 
Gene NC 
Median 
(Range) 
MCI 
Median 
(Range) 
PCAD  
Median 
(Range) 
LAD 
Median 
(Range) 
DC 
Median 
(Range) 
SMTG Cer SMTG Cer SMTG Cer SMTG Cer SMTG Cer 
EXO1 0.44 
[0.11-
7.0] 
0.32 
[0.16-
7.1] 
0.44 
[0.11-
2.19] 
0.61 
[0.4-
1.13] 
0.33 
[0.11-
1.97] 
0.48 
[0.16-
4.44] 
0.55 
[0.22-
2.41] 
0.36  
[0.16-
13.39] 
0.66 
[0.22-
12.69] 
0.48 
[0.08-
18.55] 
RAD50 0.83 
[0.08-
3.68] 
0.82 
[0.42-
2.73] 
0.9 
[0.41-
1.69]  
1.0 
[0.78-
1.71] 
0.9 
[0.23-
2.82]  
0.78 
[0.15-
2.55] 
*1.35 
[0.3-
3.61] 
1.08 
[0.24-
4.97] 
0.79 
[0.11-
4.36] 
0.93 
[0.36-
5.33] 
XPA 0.82 
[0.35-
2.62] 
0.88 
[0.35-
2.33] 
0.99 
[0.47-
1.71] 
1.0 
[0.15-
1.92] 
0.82 
[0.6-
9.6] 
1.15 
[0.58-
3.28] 
1.04 
[0.46-
2.87] 
1.07 
[0.47-
6.12] 
1.06 
[0.58-
3.29] 
0.9 
[0.48-
1.96] 
MRE11A 0.91 
[0.27-
2.94] 
0.88 
[0.3-
1.94] 
1.27 
[0.32-
2.81] 
1.36 
[0.82-
2.23] 
0.77 
[0.27-
2.81] 
1.38 
[0.5-
2.3] 
0.93 
[0.45-
5.12] 
1.2 
[0.11-
3.57] 
1.09 
[0.13-
5.25] 
1.59 
[0.22-
6.07] 
ATM 0.79 
[0.14-
2.61] 
1.0 
[0.21-
1.93] 
0.71 
[0.46-
2.13] 
1.08 
[0.83-
1.91] 
0.72 
[0.16-
2.64] 
1.11 
[0.53-
5.27] 
1.13 
[0.44-
4.81] 
1.27 
[0.52-
10.24] 
0.63 
[0.09-
3.77] 
1.12 
[0.44-
2.74] 
                                                                                                              * P < 0.05 
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Figure 3.20. Fold change in gene expression for OGG1 in A) SMTG B) Cerebellum 
                    (* P < 0.05) 
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Figure 3.21. Fold change in gene expression for UNG in A) SMTG B) Cerebellum 
                    (* P < 0.05) 
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Figure 3.22. Fold change in gene expression (SMTG) for APE1 in A) SMTG B) 
Cerebellum 
                    (* P < 0.05) 
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Figure 3.23. Fold change in gene expression for POLB in A) SMTG B) Cerebellum 
                    (* P < 0.05) 
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Figure 3.24. Fold change in gene expression for FEN1 in A) SMTG B) Cerebellum 
                    (* P < 0.05) 
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Figure 3.25. Fold change in gene expression for PARP1 in A) SMTG B) Cerebellum 
                    (* P < 0.05) 
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Figure 3.26. Fold change in gene expression for XRCC1 in A) SMTG B) Cerebellum 
                    (* P < 0.05) 
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Figure 3.27. Fold change in gene expression for EXO1 in A) SMTG B) Cerebellum 
                    (* P < 0.05) 
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Figure 3.28. Fold change in gene expression for RAD50 in A) SMTG B) Cerebellum 
                    (* P < 0.05) 
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Figure 3.29. Fold change in gene expression for XPA in A) SMTG B) Cerebellum 
                    (* P < 0.05)  
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Figure 3.30. Fold change in gene expression for MRE11A in A) SMTG B) Cerebellum 
                    (* P < 0.05) 
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Figure 3.31. Fold change in gene expression for ATM in A) SMTG B) Cerebellum 
                    (* P < 0.05) 
Fo
ld
 c
ha
ng
e 
no
rm
ali
ze
d 
to
 N
C
0
1
2
3
4
5
6
NC
MCI
PCAD
LAD
DC
A 
Fo
ld
 c
ha
ng
e 
no
rm
ali
ze
d 
to
 N
C
0
2
4
6
8
10
12
NC
MCI
PCAD
LAD
DC
B 
130 
 
3.2.2. Protein levels  
 To determine if changes in gene expression correspond to changes in protein level, 
20 µg protein specimens from samples used for the gene expression studies were 
subjected to Western blot analysis and separately probed for proteins involved in the BER 
pathway including OGG1, UNG, APE1, POLB, FEN1, PARP1 and XRCC1, using 
specific antibodies. A representative image of Western blots for the seven proteins in 
SMTG is shown in Figure 3.32. Median [Range] or Mean ± SEM OGG1, UNG APE1, 
POLB, FEN1, PARP1 and XRCC1 protein levels (% NC) are shown in Table 3.7. OGG1 
protein levels were not significantly different in SMTG of MCI (76.16 [33.31-108.11] % 
NC) or LAD (92.57 [52.26-164.13] % NC) subjects but showed a statistically significant 
increase in PCAD subjects (107.02 [75.96-178.47] % NC) and a significant decrease in 
DC subjects (50.98 [4.1-79.45] % NC) compared to NC subjects (99.24 [65.31-194.71] % 
NC) (Figure 3.33A). In contrast, no significant differences in OGG1 protein levels were 
observed in the cerebellum of MCI (106.18 (±13.33) % NC), PCAD (104.97 (±6.79) % 
NC), LAD (90.82 (±6.92) % NC) or DC (104.83 (±9.68) % NC) subjects compared to 
NC (100 (±6.61) % NC) subjects (Figure 3.33B). In SMTG, median UNG protein levels 
were comparable throughout the progression of AD including MCI (88.98 [67.89-215.66] 
% NC), PCAD (99.07 [63.93-148.97] % NC) and LAD (97.47 [57.39-153.74] % NC) 
subjects compared to age-matched NC (94.72 [79.76-142.91] % NC) subjects and DC 
(87.19 [67.26-174.25] % NC) subjects (Figure 3.34A).  UNG levels were significantly 
higher in the cerebellum of LAD subjects (124.3 [75.73-241.98] % NC) but showed no 
significant differences in MCI (113.27 [41.28-172.23] % NC), PCAD (110.52 [80.09-
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253.3] % NC) or DC (115.52 [75.38-214.37] % NC) subjects compared to NC subjects 
(97.37 [82.17-123.99] % NC) (Figure 3.34B).  
 A statistically significant decrease in APE1 protein was observed in SMTG of MCI 
(86.73 [78.63-98.61] % NC) and DC (71.17 [52.98-86.89] % NC) subjects. In contrast, 
no significant differences were observed in PCAD (110.02 [85.76-156.87] % NC) or 
LAD (96.14 [67.39-117.9] % NC) subjects compared to NC subjects (101.04 [87.4-
111.47] % NC) (Figure 3.35A). APE1 levels were not significantly different in the 
cerebellum for any of the subject groups studied including MCI (124.03 [80.21-160.84] 
% NC), PCAD (112.84 [62.81-263.69] % NC), LAD (109.53 [13.07-289.69] % NC) or 
DC (105.14 [21.29-139.31] % NC) subjects compared to NC subjects (93.69 [37.47-
156.38] % NC) (Figure 3.35B). In the SMTG, there was a significant decrease in mean 
levels of POLB protein in MCI subjects (76.09 (±5.39) % NC) compared to NC subjects 
(100 (±3.42) % NC). No significant changes in mean POLB protein levels were observed 
in the SMTG of PCAD (100.28 (±8.11) % NC), LAD (123.4 (±11.79) % NC) or DC 
(85.89 (±16.59) % NC) subjects compared to NC subjects (100 (±3.42) % NC) (Figure 
3.36A). In the cerebellum, median POLB protein levels were not significantly altered in 
MCI (101.33 [52.09-166.54] % NC), PCAD (109.93 [52.9-246.08] % NC), LAD (110.61 
[62.34-310.57] % NC) or DC (90.5 [37.25-196.69] % NC) subjects compared to NC 
subjects (99.14 [59.7-183.28] % NC) (Figure 3.36B). 
 Mean FEN1 protein levels were significantly higher in the SMTG of PCAD (146.42 
(±9.15) % NC) and LAD (132.21 (±10.24) % NC) subjects and showed no change in 
SMTG of MCI subjects (90.93 (±6.0) % NC) compared to NC subjects (98.59 (±4.3) % 
NC). In contrast, a significant decrease in FEN1 protein levels was observed in the 
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SMTG of DC subjects (63.98 (±5.63) % NC) compared to NC subjects (Figure 3.37A). 
Median FEN1 protein levels were not significantly altered in the cerebellum of MCI (98 
[39.09-161.83] % NC), PCAD (120.23 [54.86-141.24] % NC) or LAD (154.97 [23.18-
195.74] % NC) subjects but were significantly elevated in DC subjects (132.6 [116.37-
329.44] % NC) compared to NC subjects (99.14 [59.7-183.28] % NC) (Figure 3.37B). 
Median PARP1 protein levels were significantly decreased in SMTG of PCAD (33.1 
[17.53-121.42] % NC) and LAD (42.33 [13.66-193.82] % NC) subjects but was not 
altered in MCI (45.39 [22.59-135.98] % NC) or DC (61.14 [14.26-253.39] % NC) 
subjects compared to NC subjects (102.92 [23.32-238.01] % NC) (Figure 3.38A). In the 
cerebellum, mean PARP1 protein levels were significantly decreased in LAD (48.43 
(±6.35) % NC) and DC (43.85 (±7.73) % NC) subjects but showed no change in MCI 
(78.75 (±6.57) % NC) or PCAD (108.41 (±9.22) % NC) subjects compared to NC 
subjects (98.2 (±9.74) % NC) (Figure 3.38B). A statistically significant increase in 
XRCC1 protein levels was observed in SMTG of MCI (126.8 [117.33-146.41] % NC) 
and PCAD (126.64 [96.93-138.54] % NC) subjects but no significant changes were 
observed in SMTG of LAD (109.54 [77.87-135.92] % NC) or DC (99.6 [87.87-132.5] % 
NC) subjects compared to age-matched NC subjects (99.89 [85.7-113.16] % NC) (Figure 
3.39A). Median levels of XRCC1 protein throughout the progression of AD including 
MCI (101.54 (±7.29) % NC), PCAD (99.76 (±8.77) % NC) and LAD (102.22 (±11.41) % 
NC) subjects were comparable to those in age-matched NC subjects (100 (±3.42) % NC) 
in the cerebellum. However, XRCC1 protein levels in the cerebellum of DC subjects 
(144.73 (±24.55) % NC) were significantly increased compared to NC subjects (Figure 
3.39B).  
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Table 3.7: Protein levels of DNA repair genes [% NC] (Bold numbers indicate significant 
difference) 
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Figure 3.32A. Representative images of Western blots for OGG1, UNG, APE1 and POLB 
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Figure 3.32B. Representative images of Western blots for FEN1, PARP1 and XRCC1 
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Figure 3.33. Protein Levels of OGG1 (% NC) in A) SMTG and B) Cerebellum 
                    (* P < 0.05) 
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Figure 3.34. Protein Levels of UNG (% NC) in A) SMTG and B) Cerebellum 
                    (* P < 0.05) 
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Figure 3.35. Protein Levels of APE1 (% NC) in A) SMTG and B) Cerebellum 
                    (* P < 0.05) 
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Figure 3.36. Protein Levels of POLB (% NC) in A) SMTG and B) Cerebellum 
                    (* P < 0.05) 
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Figure 3.37. Protein Levels of FEN11 (% NC) in A) SMTG and B) Cerebellum 
                    (* P < 0.05) 
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Figure 3.38. Protein Levels of PARP1 (% NC) in A) SMTG and B) Cerebellum 
                    (* P < 0.05) 
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Figure 3.39. Protein Levels of XRCC1 (% NC) in A) SMTG and B) Cerebellum 
                    (* P < 0.05) 
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3.2.3 Enzyme activity levels 
 Enzyme activities for OGG1, UNG, APE1, POLB, FEN1 and PARP1 were 
calculated to determine if changes in protein levels led to a corresponding 
enhancement/loss in protein activity.  OGG1, UNG and APE1 activity was measured by 
examining their ability to cleave radiolabeled duplex DNA oligos (Table 2.5) containing 
a single 8-oxodG, deoxy-uracil or tetrahydrofuran lesion by electrophoresis on a 20% 
denaturing gel. The band intensities of the intact oligonucleotide and the incision product 
of each sample were quantified and incision activities of each assay were calculated as 
the percentage of the amount of radioactivity in the incised product band relative to the 
total radioactivity in the lane (incised product + intact duplex oligonucleotide). Activity 
of POLB was measured as the incorporation of a radiolabeled single nucleotide (α32P-
dCTP) into a 34-mer oligonucleotide containing a single gap followed by electrophoresis 
on a 20% denaturing gel. A dsDNA substrate containing flap strands prepared from three 
oligonucleotides (Table 2.5) labeled with a 6-TAMRA (fluorophore donor) at the 5’ end 
and BHQ-2 (fluorophore quencher) at the 3’ end was used in the FEN1 activity assay. 
Enzymatic cleavage of the flap strand by FEN1 leads to the release of a 6-TAMRA 
labeled short single stranded product and consequently an increase in fluorescence. 
[adenine-14C]NAD was used as the substrate to determine PARP1 activity by 
measurement of radioactive 14C incorporation into a TCA-insoluble material (protein-
bound [14C](ADP-ribose)n). Enzyme activity levels for OGG1, UNG, APE1, POLB, 
FEN1 and PARP1 are shown in Table 3.8 and are reported as median [range] or mean 
(±SEM) % NC activity.  Representative images for activity assays of OGG1, UNG, 
APE1 and POLB in SMTG are shown in Figure 3.40. No activity was observed in 
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representative protein samples heat-inactivated by boiling at 95°C before initiating the 
activity assays (blank).  
 OGG1 incision activity was not significantly different in the SMTG of MCI (123.89 
[95.89-144.47] % NC), PCAD (99.65 [91.62-106.35] % NC), LAD (99.81 [87.92-101.73] 
% NC) or DC (99.07 [94.81-103.05] % NC) subjects compared to NC subjects (100 
[87.15-111.92] % NC) (Figure 3.41A). Comparison of OGG1 activity across the disease 
spectrum in the cerebellum showed no significant changes in MCI (93.35 (±2.5) % NC), 
PCAD (97.81 (±2.51) % NC), LAD (101.56 (±2.1) % NC) or DC (96.99 (±1.7) % NC) 
subjects compared to NC subjects (99.19 (±1.48) % NC) (Figure 3.41B). UNG activity 
levels on the other hand were significantly higher in the SMTG of MCI (133.72 (±4.64) 
% NC), PCAD (149.67 (±4.42) % NC) and LAD (134.61 (±8.7) % NC) subjects 
compared to NC subjects (100 (±4.82) % NC). Mean levels of UNG activity were not 
significantly changed in SMTG of DC subjects (122.71 (±11.19) % NC) compared to NC 
subjects (Figure 3.42A). No significant differences were observed in UNG activity in 
CER of any of the diseased subjects studied including MCI (110.91 (±10.05) % NC), 
PCAD (120.94 (±7.44) % NC), LAD (106.81 (±6.5) % NC) and DC (91.58 (±11.7) % 
NC) subjects compared to NC subjects (100 (±6.05) % NC) (Figure 3.42B).  
 Levels of APE1 activity were not significantly changed in samples from SMTG of 
MCI (107.3 (±6.53) % NC), LAD (111.29 (±5.65) % NC) and DC (109.48 (±6.46) % 
NC) subjects but were significantly elevated in samples from PCAD subjects (116.42 
(±5.99) % NC) compared to those from NC subjects (100 (±3.64) % NC) (Figure 3.43A). 
In contrast, APE1 activity levels were significantly reduced in the cerebellum of PCAD 
(77.38 [12.12-98.74] % NC) and LAD (61.09 [20.75-125.45] % NC) subjects compared 
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to age-matched NC subjects (99.95 [61.3-145.03] % NC). Median APE1 activity levels 
showed no significant changes in cerebellum of MCI subjects (128.4 [88.87-139.37] % 
NC) or DC (47.01 [16.38-144.87] % NC) subjects compared to NC subjects (Figure 
3.43B). A statistically significant increase in POLB enzyme activity was observed in 
SMTG of MCI (113.25 [106.21-124.93] % NC) and PCAD (114.55 [86.81-146.31] % 
NC) subjects compared to NC subjects (101.82 [79.54-121.2] % NC). No significant 
changes in POLB enzyme activity levels were observed in SMTG of LAD (105.73 
[94.47-140.29] % NC) or DC (100.66 [91.22-116.09] % NC) subjects compared to NC 
subjects (Figure 3.44A). Mean POLB enzyme activity levels were not significantly 
altered in the cerebellum of MCI (106.85 (±3.98) % NC), LAD (105.03 (±3.2) % NC) or 
DC subjects (106.55 (±4.59) % NC) but were significantly elevated in PCAD (115.56 
(±3.48) % NC) subjects compared to NC subjects (98.69 (±2.66) % NC) (Figure 3.44B). 
 Mean levels of FEN1 activity were significantly decreased in SMTG of PCAD (88.5 
(±2.47) % NC), LAD (81.79 (±4.41) % NC) and DC (57.49 (±7.13) % NC) subjects but 
showed no change in MCI subjects (92.77 (±3.31) % NC) compared to NC subjects (100 
(±2.7) % NC) (Figure 3.45A). Comparison of FEN1 activity across the disease spectrum 
in the cerebellum showed no significant changes in MCI (108.64 (±13.39) % NC), PCAD 
(105.92 (±14.06) % NC) or LAD (71.96 (±9.4) % NC) subjects compared to NC subjects 
(100 (±7.86) % NC). A statistically significant decrease in FEN1 enzyme activity was 
observed in cerebellum of DC subjects (65.26 (±6.1) % NC) compared to NC subjects 
(Figure 3.45B). In SMTG, median PARP1 enzyme activity levels were not significantly 
different in MCI (65.84 [16.38-235.67] % NC), PCAD (100.82 [4.93-295.05] % NC) or 
DC (63.21 [36.74-502.77] % NC) subjects but were significantly elevated in LAD 
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subjects (229.08 [92.35-498.61] % NC) compared to NC subjects (56.19 [5.56-379.45] % 
NC) (Figure 3.46A). Median PARP1 activity levels were not significantly altered in the 
cerebellum of MCI subjects (147.89 [130.41-188.95] % NC) but were significantly 
higher in PCAD (213.1 [44.17-252.59] % NC), LAD (170.43 [63.84-338.08] % NC) and 
DC (295.34 [82.95-410.47] % NC) subjects compared to NC subjects (72.74 [19.26-
243.66] % NC) (Figure 3.46B). 
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Figure 3.40A. Representative images of activity assays for OGG1 and UNG  
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Figure 3.40B. Representative images of activity assays for APE1 and POLB 
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Table 3.8: Enzyme activity Levels of DNA repair genes [% NC] (Bold numbers indicate 
significant difference) 
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Figure 3.41. Protein Activity Levels of OGG1 (% NC) in A) SMTG and B) Cerebellum 
                    (* P < 0.05) 
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Figure 3.42. Protein Activity Levels of UNG (% NC) in A) SMTG and B) Cerebellum  
                    (* P < 0.05) 
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Figure 3.43. Protein Activity Levels of APE1 (% NC) in A) SMTG and B) Cerebellum  
                    (* P < 0.05) 
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Figure 3.44. Protein Activity Levels of POLB (% NC) in A) SMTG and B) Cerebellum  
                    (* P < 0.05) 
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Figure 3.45. Protein Activity Levels of FEN1 (% NC) in A) SMTG and B) Cerebellum 
                    (* P < 0.05) 
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Figure 3.46. Protein Activity Levels of PARP1 (% NC) in A) SMTG and B) Cerebellum 
                    (* P < 0.05) 
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Table 3.9. Summary of results for BER pathway 
 
 
 
 
 
 
 
Gene   OGG1 UNG APE1 POLB PARP
1 
FEN
1 
XRCC
1 
MCI SMTG Gene expression − − − − − − − 
Protein level − − ↓ ↓ − − ↑ 
Enzyme activity − ↑ − ↑ − −  
CER Gene expression − − − − − − − 
Protein level − − − − − − − 
Enzyme activity − − − − − −  
PCA
D 
SMTG Gene expression ↑ ↑ − ↑ − − − 
Protein level ↑ − − − ↓ ↑ ↑ 
Enzyme activity − ↑ ↑ ↑ − ↓ − 
CER Gene expression − − − − − − − 
Protein level − ↑ − − − − − 
Enzyme activity − − ↓ ↑ ↑ −  
LAD SMTG Gene expression ↑ ↑ − ↑ ↑ − − 
Protein level − − − ↑ ↓ ↑ − 
Enzyme activity − ↑ ↑ − ↑ ↓  
CER Gene expression − − − − − − − 
Protein level − − − − ↓ − − 
Enzyme activity − − ↓ − ↑ −  
DC SMTG Gene expression − ↑ − − − − − 
Protein level ↓ − ↓ − − ↓ − 
Enzyme activity − − − − − ↓  
CER Gene expression − − − ↑ − − − 
Protein level − − − − ↓ ↑ ↑ 
Enzyme activity − − − − ↑ ↓  
157 
 
Chapter 4: Discussion 
  Oxidative stress is considered one of the many contributing factors to the 
pathogenesis of AD. Reactive oxygen species (ROS), a major contributor to oxidative 
stress, are continuously produced in the human body by both endogenous (byproducts of 
cellular metabolism) and exogeneous (smoking, pollution, radiation) methods. ROS-
mediated oxidative damage is extremely critical in non-dividing postmitotic cells like 
neurons, as the damaged cells cannot be replaced by new ones.  Oxidative damage to the 
nucleic acid framework (nDNA, mtDNA and RNA) in such cells can lead to neuronal 
dysfunction and loss associated with aging and neurodegenerative processes like AD 
(Beal, 2005; Lu et al., 2004; Moreira et al., 2008; Nunomura et al., 1999). Multiple 
studies have shown an increase in biomarkers of oxidative DNA damage including 8-
hydroxyguanine (the predominant marker of oxidative DNA damage), 8-hydroxyadenine, 
8-hydroxycytosine, thymine glycol, fapy-adenine, fapy-guanine and 5-hydroxyuracil in 
brain tissues, leukocytes and ventricular CSF of AD subjects. Some of these changes 
were observed even in the earliest clinically detectable phase of AD (MCI) (Gabbita et 
al., 1998; Keller et al., 2005; Lovell and Markesbery, 2001; Lyras et al., 1997; 
Markesbery and Carney, 1999; Mecocci et al., 1994; Mecocci et al., 2002; Migliore et al., 
2005; Wang et al., 2005). The reason for increased oxidative damage in the progression 
of AD is at present unclear but could possibly be due to an increase in production of ROS 
and subsequent increased oxidative stress on DNA or decreased efficiency of DNA repair 
mechanisms or a combination of the two.  
  This dissertation is unique in that both DNA oxidative damage in specific genes 
affected during AD and changes in enzymes of the main DNA repair pathway that (BER) 
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were studied in a single well-characterized cohort of subjects throughout the progression 
of AD. This study utilized DNA, RNA and protein isolated from bulk tissue, so the 
results obtained reflect a comprehensive quantity of oxidative damage, gene expression, 
protein levels and enzyme activity from both neurons and glia. Previous studies 
(Nunomura et al., 1999; Smith et al., 2000a; Smith et al., 2000b) have indicated that 
although AD brains often display increased astrocytosis, 8-hydroxyguanine 
immunoreactivity was negligible in  glial cells but significantly increased in neuronal 
cytoplasm. This suggests that DNA oxidative damage and changes in the BER enzymes 
measured in this study are largely a neuronal manifestation rather than a glial one.  
4. 1. Oxidative DNA Damage in Genes of Proteins Modified during AD  
  DNA is vital to cellular function, therefore DNA oxidative damage could possibly be 
one of the most important factors in the neuronal degeneration observed in AD subjects. 
This study is the first to determine oxidative damage in the coding sequence of genes of 
proteins affected during AD in subjects throughout the progression of AD. Oxidative 
DNA damage was quantified using fpg mediated glycosylase activity and qPCR for the 
three isoforms of voltage-dependent anion channel protein (VDAC)- VDAC1, VDAC2 
and VDAC3. VDACs, also known as mitochondrial porins, are the most abundant 
proteins in the mitochondrial outer membrane and principally function as voltage-
dependent pores in the mitochondrial membrane for transfer of substrates (pyruvate, 
malate ATP, hemes, NADH, succinate and phosphate) used in oxidative phosphorylation 
and electron transport chain pathways. The three isoforms, VDAC1, VDAC2 and 
VDAC3, show an essentially conserved sequence but differ in abundance, size, function 
and activity. VDAC1 is the most abundant isoform of the VDAC family followed by 
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VDAC2 and then VDAC3. The VDAC isoforms were chosen for analysis because 
previous studies show differential expression of protein levels for the three proteins in 
AD. Yoo et al. (Yoo et al., 2001)  reported a significant decrease in VDAC1 levels in the 
frontal cortex and thalamus and a significant increase in VDAC2 protein levels in 
temporal cortex in AD subjects compared to age-matched control subjects. Yoo et al. did 
not report any changes in VDAC3 protein levels as it was not detected in the analyzed 
samples (Yoo et al., 2001). Lovell et al. showed a statistically significant elevation in 
VDAC1 protein levels, a trend towards significant increase in VDAC3 levels and no 
change in VDAC2 levels in primary neuron cultures treated with Aβ (Lovell et al., 2005). 
Based on these observations, we hypothesized there may be oxidative damage in the 
coding sequences of VDAC1 and VDAC3 but not in that of VDAC2. 
 Comparison of oxidative damage in DNA isolated using the phenol-chloroform 
extraction and extraction using a Qiagen DNeasy Tissue Kit showed 10-20% more 
artifactual oxidation in DNA from the Qiagen DNeasy Tissue Kit. Thus the phenol-
chloroform extraction method was used to extract all DNA samples used in this project. 
In the phenol-chloroform extraction method, 8-hydroxyquinoline was used as an 
antioxidant additive to phenol to prevent artifactual oxidation. Furthermore, oxidation by 
trace metals was prevented by chelation with EDTA during DNA isolation. The study 
utilized tissue samples from brain specimens with short PMI (Table 2.1) to further reduce 
the chances of artifactual oxidation. Levels of oxidative DNA damage were quantified 
using the fpg enzyme, primers designed to encompass each gene’s coding sequence and 
qPCR. The data obtained for this study were analyzed using the standard curve analysis 
method for qPCR derived from 5 to 7-fold serial dilutions of genomic DNA from NC 
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subjects. To prevent artifactual oxidation by freeze-thawing, new DNA samples were 
isolated from tissue for each qPCR reaction.  Primers for qPCR were designed to have 
~50% GC ratio, 24 bp length, Tm of ~60 (±2) °C and an amplicon size of 175-285 for 
maximum efficiency. The fluorescent dye SYBR Green which intercalates with dsDNA 
was used to measure amount of product in the qPCR reaction. 
  Among the 8 amplicons studied for VDAC1, 3 amplicons including VDAC1D, 
VDAC1H and VDAC1I showed no statistically significant changes in either the SMTG 
or cerebellum. In contrast, VDAC1B, VDAC1C, VDAC1E and VDAC1G showed 
statistically significant increases in % oxidative damage in SMTG of LAD subjects. 
Levels of % oxidative damage were also significantly elevated in the SMTG of PCAD 
subjects for VDAC1A, VDAC1C and VDAC1E. A trend towards a significant increase 
was observed for VDAC1B in SMTG of PCAD subjects and for VDAC1E in SMTG of 
MCI subjects. The cerebellum, where minimal AD pathology is observed, showed no 
significant changes at any stage of disease progression suggesting a brain region 
dependent differential distribution of oxidative DNA damage during the progression of 
AD.  There was significant oxidative damage in the VDAC1B, VDAC1C and VDAC1E 
amplicons in the SMTG of DC subjects and in cerebellum of DC subjects for the 
VDAC1B amplicon. This suggests oxidative damage in these two regions is probably not 
AD-specific but is a shared characteristic of multiple neurodegenerative diseases. The 
lack of detection of oxidative damage for any VDAC2 amplicon suggests VDAC2 is 
minimally affected during the progression of AD or other neurodegenerative diseases 
including FTD and DLB. VDAC3 is the smallest gene among the three and shows 
oxidative damage only in one amplicon, VDAC3E, in the SMTG of LAD subjects.  
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These data are supportive of our initial hypothesis. Lovell et al. showed a significant 
increase in VDAC1 protein levels  in Aβ-treated cultures and only a trend towards a 
significant increase in VDAC3 protein levels and we hypothesized that maximum 
oxidative damage would be seen in VDAC1 followed by some oxidation in VDAC3. 
Overall, our studies also suggest oxidative DNA damage in enzymes affected during AD 
occurs early in AD pathogenesis with more damage in areas with extensive AD 
pathology. A common characteristic of the regions with more oxidative damage is the 
presence of groups of multiple guanines. Prat et al. suggested that oxidation of one 
guanine reduces the ionization potential of sequential guanines present thus promoting 
increased oxidation (Prat et al., 1998).  
 At present, it is still unclear what effect genomic oxidation has on subsequent 
transcription and translation processes. Previous studies show oxidative DNA damage 
leads to mismatched base pairs (Cysewski and Olinski, 1999), strand breaks (Cullis et al., 
1996; Devasagayam et al., 1991) and protein crosslinking (Hickerson et al., 1999; 
Kurbanyan et al., 2003; Nguyen et al., 2000) in nuclear and mitochondrial DNA.  For 
VDACs, an increase in oxidative damage seems to correlate with increased translation 
and thus increased protein levels though the impact of this oxidative DNA damage on the 
functionality of VDAC proteins is as yet unknown. To begin to try and understand the 
effects of DNA oxidation on translated proteins, we chose to study IGF2, a small protein 
with a 202 bp coding sequence. Varying ratios of 8-oxoguanine/guanine (10/90, 25/75, 
35/65, 50/50, 75/25 and 0/100) were incorporated in the IGF2 coding sequence via PCR 
reactions and resulting DNA transcribed and translated using a cell-free system. Protein 
levels generated were quantified using Western blot analysis and showed a significant 
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increase in IGF2 in all the samples with 8-oxoguanine incorporation, although there was 
no clear concentration-based trend observed. This is similar to the data observed for 
VDAC oxidative damage and protein levels (Lovell et al., 2005). A previous study by 
Hailer-Morrison et al. showed an increase in binding affinity of the p50 subunit of the 
transcription factor NF-κB on substitution of guanine by 8-oxogunanine at sites critical 
for protein binding (Hailer-Morrison et al., 2003).  Protein activity of IGF2 on the other 
hand showed significant decreases in 8-oxoguanine incorporated samples compared to 
the positive control sample. Again there was no concentration based trend observed for 
enzyme activity with increasing amounts of 8-oxoguanine. A decrease in protein activity 
could be due to the production of non-functional protein due to presence of oxidation in 
the gene sequence and hence subsequent mistakes during transcription and translation. 
4.2. Changes in DNA Repair Enzymes of BER Pathway in AD Subjects 
   An increase in oxidative base lesions could be due to inactivity/alterations of the 
DNA repair enzymes or an increase in oxidative stress on DNA or a combination of both 
factors (Dianov et al., 2001; Lovell et al., 2000; Wang et al., 2005; Weissman et al., 
2007).  It is postulated that in age-related neurodegenerative diseases like AD, the DNA 
repair system loses its capacity for repair resulting in accumulated oxidative DNA 
damage (Lovell et al., 2000; Markesbery and Lovell, 2006; Moreira et al., 2008; 
Weissman et al., 2007).  In the brain, the BER pathway is the major pathway for repair of 
small base modifications in DNA caused by oxidation, alkylation or deamination. The 
BER pathway can primarily be broken down to five key steps: (1) recognition and 
elimination of damaged base (2) excision of abasic site (3) removal of 5´-abasic terminal 
fragment (4) gap filling with correct base and (5) ligation of the DNA strand. Based on 
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the size of the excised nucleotide, the BER pathway is further divided into two sub-
pathways: short-patch BER (single nucleotide excision) and long-patch BER (2-8 
nucleotides excision). Multiple enzymes including appropriate DNA glycosylases 
(OGG1, UNG etc.), endonucleases (APE1, FEN1), phosphatases, kinases, polymerases 
(POLB, POLδ, POLε), PARP1, XRCC1, ligases (LIG1, LIG3) and auxillary factors (e.g. 
p53, p21, PCNA, RPA) are required for the effective implementation of DNA repair via 
the BER pathway (Fan and Wilson, 2005; Izumi et al., 2003; Kim and Wilson, 2012; 
Parsons and Dianov, 2013). Multiple studies have reported alteration in enzymes of the 
BER pathway in AD subjects although research has been more focused on the enzymes in 
the early phase of BER specifically OGG1, UNG and APE1 (Coppede and Migliore, 
2009; Davydov et al., 2003; Iida et al., 2002; Love et al., 1999; Lovell et al., 2000; Tan et 
al., 1998; Weissman et al., 2007). This study is unique in the fact that changes in the 
seven major enzymes of the BER pathway were studied in a single well-characterized 
cohort of subjects throughout the progression of AD. In order to determine if the DNA 
repair enzymes of the BER pathway were inactive or altered, custom PCR arrays and 
quantitative reverse transcription polymerase chain reaction (qPCR), Western blot 
analysis and enzyme activity assays were used to quantify changes in BER enzymes 
(OGG1, UNG, APE1, POLB, FEN1, PARP1 and XRCC1).  
   Substrate-specific DNA glycosylases initiate the BER pathway by recognizing and 
subsequently removing the impaired base. One of the major lesions of DNA oxidative 
damage is the oxidation product of guanine, 8-hydroxyguanine which is primarily 
removed by OGG1 in both nDNA (α-OGG1) and mtDNA (β-OGG1). OGG1 is the one of 
the best characterized BER proteins but the regulation of OGG1 expression and function, 
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and consequently its role in multiple diseases including cancer and AD is still being 
investigated. Studies have suggested association of transcriptional regulation of the 
OGG1 gene with expression of p53 and Zn depletion (Habib et al., 2008; Sharif et al., 
2012; Song et al., 2009; Youn et al., 2007). Our data showed no significant changes in 
OGG1 gene expression, protein levels or nuclear OGG1 incision activity in the SMTG of 
MCI subjects compared to NC. In contrast, Shao et al. showed a significant increase in 
protein levels but a significant decrease in OGG1 activity in the SMTG of MCI subjects 
compared to NC subjects (Shao et al., 2008; Weissman et al., 2007). In the current study, 
we saw a statistically significant increase in fold change in gene expression of OGG1, a 
corresponding statistically significant increase in OGG1 protein levels but no significant 
changes in OGG1 incision activity in SMTG of PCAD subjects compared to NC subjects, 
suggesting regulation of OGG1 transcription and translation as a result of injury 
(oxidative damage) but functional inactivation of the protein. Shao et al. (Shao et al., 
2008) suggested that a decrease in OGG1 activity could be due to HNE (4-
hydroxynonenal, a by-product of lipid peroxidation) mediated aldehydic modification of 
OGG1. There was a significant increase in gene expression in SMTG of LAD subjects 
compared to NC subjects, but no corresponding change in protein level or incision 
activity of OGG1. The contrast in gene expression levels, protein and activity levels in 
the current study could be due to formation of modified protein more susceptible to 
proteolytic degradation after translation from oxidatively damaged genes in a ROS rich 
environment present in LAD subjects’ brain (Tanaka et al., 2007). In contrast, Lovell et 
al. and others showed decreased OGG1 activity and protein levels in SMTG of LAD 
subjects compared to NC subjects (Iida et al., 2002; Lovell et al., 2000; Weissman et al., 
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2007). No significant differences were observed in gene expression or protein activity in 
SMTG of DC subjects but there was a significant decrease observed in protein levels 
compared to NC subjects. Comparison of OGG1 gene expression, protein levels or 
enzyme activity levels in the cerebellum showed no significant differences for any of the 
subject groups studied which concurs with previous studies (Iida et al., 2002; Lovell et 
al., 2000; Weissman et al., 2007).  
   UNG, another DNA glycosylase highly specific for removal of uracil lesions in 
nuclear and mitochondrial DNA was also investigated in this study. Uracil can be 
introduced into genomic DNA by deamination of cytosine to 5’- hydroxyuracil by ROS. 
A significant decrease in UNG protein levels and activities in AD subjects compared to 
NC subjects in multiple brain regions was reported by Weissman et al. (Weissman et al., 
2007). Our results show a significant increase (P < 0.05) in gene expression but no 
corresponding change in protein levels of UNG in SMTG of MCI subjects compared to 
NC subjects. UNG activities were significantly higher in the SMTG of MCI subjects 
compared to NC subjects. There was a significant increase in gene expression but no 
corresponding change in protein levels of UNG in SMTG of PCAD and LAD subjects 
compared to NC subjects which could be attributed to modifications in the protein 
sequence leading to abnormal structure during the translation process due to the presence 
of oxidized bases in the protein coding sequence. Our study of UNG activity levels show 
a significant increase in SMTG of PCAD and LAD subjects compared to NC subjects.  
Previous studies show UNG activities can be enhanced by APE1 (Parikh et al., 1998) 
which was also elevated in SMTG of PCAD and LAD subjects. For DC subjects, levels 
of UNG gene expression were significantly elevated in SMTG although there were no 
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corresponding changes in protein levels or activities compared to NC subjects. This 
suggests alterations in UNG expression may not be AD-specific but may be a general 
event associated with neurodegeneration and can be seen in other forms of dementia 
including FTD and DLB. In the cerebellum, UNG gene expression levels and activity 
levels showed no significant difference for any of the subject groups studied. UNG 
protein levels on the other hand showed a significant increase in PCAD subjects in the 
cerebellum but no changes for the other subject groups.  
       DNA glycosylases remove damaged bases in a DNA strand generating an 
apurinic/apyrmidinic (AP) site also called a single strand break (SSB) site.  APE1 cleaves 
the AP site generated in the second step of the BER pathway creating a gap which is 
filled by DNA polymerases. It has been postulated that this excision of the AP site is the 
rate determining step of the pathway and that 95% of the excision can be attributed to 
APE1 (Chen et al., 1991). APE1 also plays a critical role in conservation of gene 
expression efficiency by regulating DNA binding capacity of multiple transcription 
factors including p53, NF-κB and AP1 and acting as a transcriptional repressor of its own 
gene and other genes including the PTH (parathyroid hormone) gene (Fritz, 2000; Izumi 
et al., 1996). Fritz et al. suggests regulation of APE1 activities by posttranslational 
modifications although further study is needed to elucidate the different physiological 
functions and functional regulation of this highly complex multifunctional enzyme (Fritz, 
2000; Fritz and Kaina, 1999). Protein-protein interactions with other enzymes in the BER 
pathway could also contribute to inhibition/enhancement of APE1 function. Studies have 
shown interactions between APE1 and multiple DNA glycosylases including OGG1 and 
UNG. A significant increase in activity of both OGG1 and UNG was observed in the 
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presence of APE1 (Aliyev et al., 2005a; Aliyev et al., 2005b; Aliyev and Aliyev, 2005; 
Hill et al., 2001; Parikh et al., 1998). Masuda et al. suggested that APE1 underwent 
product inhibition and showed an increase in APE1 activity in presence of POLB 
(Masuda et al., 1998). Similarly XRCC1, a scaffold protein involved in the BER 
pathway, has been shown to stimulate APE1 activity by protein-protein interactions (Sak 
et al., 2005; Vidal et al., 2001). Although multiple studies have shown physical 
interaction of APE1 with POLB, FEN1 and p53, the effect of these interactions on APE1 
functional regulation needs further investigation (Bennett et al., 1997; Dianova et al., 
2001; Gaiddon et al., 1999; Ranalli et al., 2002). It also remains unclear if the redox 
functions of APE1 affect its endonuclease activity.  
   Multiple studies have shown an increase in APE1 nuclear immunostaining in the 
cerebral cortex and hippocampus of AD subjects compared to NC subjects (Edwards et 
al., 1998a; Edwards et al., 1998b; Marcon et al., 2009). In this study, we found no 
significant changes in APE1 gene expression or protein levels in SMTG of PCAD or 
LAD subjects compared to NC subjects. APE1 enzyme activities interestingly were 
elevated in SMTG of both PCAD and LAD subjects compared to NC subjects. This 
increased APE1 activity could be due to posttranslational modifications, protein-protein 
interactions with other enzymes in the pathway or other as yet undiscovered regulatory 
mechanisms. Previous studies have also suggested interactions between APE1 and OGG1 
and UNG that affect enzymatic activity (Aliyev et al., 2005b; Aliyev and Aliyev, 2005; 
Tengiz et al., 2005). Surprisingly, our data also showed significant reduction in APE1 
activity levels in the cerebellum of PCAD and LAD subjects compared to those from NC 
subjects although no corresponding changes had been observed in gene expression or 
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APE1 protein levels indicating that changes in APE enzymatic activity could be brain 
region specific. The decrease in APE1 activity could be due to posttranslational 
modifications of APE1 such as phosphorylation, acetylation, ubiquitylation, poly(ADP-
ribosyl)ation or HNE mediated aldehydic modification as observed for OGG1 (Fritz and 
Kaina, 1999; Shao et al., 2008). This difference in activity levels in the SMTG (increase) 
and cerebellum (decrease) could also be due to differential protein-protein interactions 
with other BER proteins including glycosylases (OGG1, UNG), POLB, FEN1, PARP1 
and XRCC1. We found no significant changes in APE1 expression in MCI subjects but 
there was a statistically significant decrease in APE1 protein levels (but no corresponding 
change in APE1 activity) in SMTG of MCI and DC subjects compared to NC subjects. 
This increase in enzymatic activity could be due to the multifactorial reasons discussed 
previously. The changes seen in DC subjects suggest changes in APE1 are not AD 
specific but could possibly be present in other forms of dementia also.  
 The fourth enzyme investigated in this study was POLB. POLB is the primary 
polymerase for gap filling in both the short-patch and long-patch version of BER 
(Podlutsky et al., 2001a; Podlutsky et al., 2001b). The vital role played by POLB in fetal 
growth and development can be deduced by the fact that POLB deficient mice show 
embryonic lethality (Gu et al., 1994). Although multiple studies have suggested 
posttranslational modifications including acetylation, methylation, ubiquitylation and 
phosphorylation play a vital role in regulation of POLB activity and coordination of BER, 
the functional impact of most of these modifications still needs to be elucidated (El-
Andaloussi et al., 2007; El-Andaloussi et al., 2006; Hasan et al., 2002; Parsons et al., 
2011; Parsons et al., 2008). Parsons et al. suggested that availability of active BER 
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enzymes including POLB is directly dependent on the number of DNA lesions present in 
the cell. They suggested that excess POLB is sequentially ubiquitylated by the ubiquitin 
ligases Mule and CHIP and then degraded via the proteasome pathway. In case of an 
increase in amount of DNA lesions, higher amount of active POLB can be obtained by 
inhibition of Mule activity by the protein ARF (Alternative Reading Frame) and/or 
deubiquitylation of POLB by ubiquitin-specific proteases (USPs) (Chen et al., 2005; 
Gallagher et al., 2006; Lee et al., 2005; Parsons et al., 2011; Parsons et al., 2008; Parsons 
et al., 2009). Mule also regulates the activity of p53 which in turn interacts with multiple 
BER proteins.  
 Previous studies have also shown that protein-protein interactions between POLB 
and other proteins including APE1, PCNA, FEN1, PARP1, XRCC1, WRN, HMGB1, 
p53, LIG1, LIG3, RPA, Rad9/Rad1/Hus1 (9-1-1 complex) and APC could help in the 
regulation of POLB activity and selection between SP-BER and LP-BER (Goellner et al., 
2012; Yamtich and Sweasy, 2010). APE1 has been shown to stimulate POLB 5´-dRP 
lyase activity (Bennett et al., 1997) while APC (Adenomatous polyposis coli) inhibits 
POLB lyase activity (Balusu et al., 2007; Jaiswal et al., 2006; Narayan et al., 2005). 
Enhanced BER activity observed in the presence of p53 could be due to the interactions 
of POLB, p53 and APE1 as p53 seems to stabilize the POLB–AP–DNA complex in 
presence of APE1 (Zhou et al., 2001). XRCC1, LIG1 and APC inhibit POLB strand 
displacement synthesis thus promoting SP-BER (Balusu et al., 2007; Jaiswal et al., 2006; 
Kubota et al., 1996; Narayan et al., 2005; Prasad et al., 1996). Though it has been 
proposed that strand displacement synthesis by POLB is stimulated by FEN1, studies 
suggest that the impact of the interactions between the two enzymes is more intricate and 
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may depend on a number of factors including enzyme concentration and nature and 
amount of substrate. (Balakrishnan et al., 2009; Pascucci et al., 2002; Pascucci et al., 
1999; Prasad et al., 2000).  POLB strand displacement synthesis is also enhanced by 
PARP1, the 9-1-1 complex and WRN (Werner syndrome, RecQ helicase) (Harrigan et 
al., 2003; Prasad et al., 2001; Toueille et al., 2004).  POLB has also been shown to 
interact with multiple other proteins like HMGB1 (high mobility group box 1) and OGG1 
but the functional impact of these interactions is not yet fully understood (Braithwaite et 
al., 2010; Prasad et al., 2007).  
 Weissman et al. reported a decrease in POLB protein and activity levels in the 
inferior parietal lobule (IPL) and cerebellum of AD subjects (Weissman et al., 2007). 
Copani et al. showed a decrease in POLB expression in midtemporal cortex of AD 
subjects (Copani et al., 2006). Our data is in contrast to both these studies. There were no 
changes in POLB expression levels in SMTG of MCI subjects but there was a significant 
decrease in protein levels and surprisingly an increase in POLB enzymatic activity. In 
this study, we found that there was a statistically significant increase in gene expression 
in SMTG of PCAD subjects, no corresponding changes in POLB protein levels and 
interestingly a significant increase in POLB activity. POLB activity levels were also 
elevated in the cerebellum of PCAD subjects although POLB expression and protein 
levels were unchanged. It has been proposed that a fraction of POLB produced by the 
cells is stored in the cytoplasm in its mono-ubiquitylated form and is activated by 
deubiquitylation when required which in turn depends on the number of DNA lesions and 
the activity of the enzymes in the early phase of BER (Goellner et al., 2012; Parsons et 
al., 2011; Woodhouse et al., 2008). This storage mechanism, effects of post translational 
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modifications, and protein-protein interactions with other BER proteins could account for 
the discrepancy between gene expression, protein levels and levels of enzymatic activity 
that we observed. There were no changes in POLB gene expression, protein levels or 
enzyme activity in the cerebellum of MCI subjects. In the SMTG, there was a significant 
increase in POLB expression levels, a corresponding increase in protein levels but no 
analogous changes in enzyme activity in LAD subjects. No changes in POLB gene 
expression, protein levels or enzyme activity were observed in the cerebellum of LAD 
subjects. In case of DC subjects, gene expression, protein levels and POLB activity levels 
were unaltered in the SMTG. Although POLB expression levels were significantly higher 
in the cerebellum of DC subjects there were no corresponding changes in protein 
expression and enzymatic activity. In the SMTG, alterations in POLB enzyme levels 
seem to be an AD-specific event. The changes in POLB in the cerebellum seem to be a 
more generalized event in neurodegeneration rather than being specific to AD. These 
results again seem to point to a brain region-specific response to oxidative damage and 
alteration of BER enzymes. 
    FEN1 is the major endonuclease involved in LP-BER and cleaves the 5´-flap 
structure produced by strand-displacement synthesis. FEN1 activity on flap containing 
substrates has been shown to be stimulated by multiple proteins including POLB, 
PARP1, LIG1, PCNA, WRN, BLM,  HMGB1, Rad9/Rad1/Hus1 complex and even 
APE1. The interaction of APE1, PARP1 and POLB with FEN1 seems to be a vital factor 
in stimulation of LP-BER (Brosh et al., 2001; Dianova et al., 2001; Friedrich-Heineken et 
al., 2005; Prasad et al., 2000; Prasad et al., 2001; Prasad et al., 2007; Ranalli et al., 2002; 
Sharma et al., 2004; Tom et al., 2000; Wu et al., 1996). FEN1 is regulated not just by 
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protein-protein interactions but also by posttranslational modifications. Phosphorylation 
of FEN1 by cyclin-dependent kinase1 (Cdk-1)-Cyclin A decreases FEN1 activity and 
inhibits interaction of FEN1 with PCNA (Henneke et al., 2003). p300 acetylates FEN1 
which also leads to reduced FEN1 activity (Hasan et al., 2001). We saw no significant 
changes in FEN1 expression, protein levels or activity levels in SMTG or cerebellum of 
MCI subjects. Although there were no changes in gene expression, protein levels were 
significantly elevated and FEN1 activity levels were significantly decreased in SMTG of 
PCAD subjects. Surprisingly, the same trend of no change in gene expression, an increase 
in protein level and a decrease in enzyme activity was observed in the SMTG of LAD 
subjects and the cerebellum of DC subjects. Translational and posttranslational regulation 
by protein-protein interactions and posttranslational modifications could account for this 
trend in FEN1 protein and activity levels. In the cerebellum, no changes in gene 
expression, protein levels and FEN1 activity were seen in PCAD and LAD subjects. In 
SMTG of DC subjects, we saw no significant changes in gene expression but observed a 
decrease in protein level and a corresponding decrease in enzyme activity. Thus, changes 
in FEN1 seem to be a part of the neurodegenerative process rather than just being AD 
specific. Different brain regions also seem to have differential distribution of FEN1 
alterations. 
    Although the complete functionality of PARP1 still needs to be elucidated, it has 
been proposed that PARP1 plays an extremely critical role in BER as recruiter for other 
BER proteins to the damaged site and for recognition of the single stranded break (SSB) 
site. Besides BER, PARP1 is also involved in other cellular processes including 
transcriptional regulation, cell differentiation, chromatin modification, necrosis and 
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apoptosis. It has been proposed that PARP1 activity is also regulated by multiple 
posttranslational modifications including phosphorylation, poly(ADPribosylation), 
ubiquitylation, sumoylation and acetylation (Strosznajder et al., 2012). The idea that 
PARP1 is a recruiter protein for the latter half of BER is perpetuated by the interaction of 
PARP1 with multiple proteins of BER pathway including POLB, FEN1, XRCC1 and 
LIG3 probably by poly(ADP-ribosyl)ation of these proteins by PARP1. XRCC1 was 
reported to decrease PARP1 activity (El-Khamisy et al., 2003). Though it is known that 
PARP1 interacts with multiple other proteins, the functional impact of these interactions 
on PARP1 activity remains unclear. PARP1 activity has been reported to increase up to 
500 fold upon binding to damaged DNA (Adamczyk et al., 2005; Strosznajder et al., 
2012). Grube et al. and Muiras et al. found a positive correlation between PARP1 activity 
and longevity with maximum activity being observed in cells from centenarians though 
there was no change in PARP1 protein levels (Burkle et al., 1992; Grube and Burkle, 
1992; Muiras et al., 1998). Previous studies have reported an increase in PARP1 activity 
and accumulation of its reaction product, PAR (poly(ADP-ribose)) in frontal and 
temporal lobes, skin fibroblasts and lymphoblasts in AD patients (Cecchi et al., 2002; 
Love et al., 1999). PARP1 polymorphisms are also being associated as a risk factor for 
AD (Infante et al., 2007; Liu et al., 2010). 
    Our data showed no significant differences in PARP1 expression, protein levels or 
protein activity in the SMTG or cerebellum of MCI subjects. Although there were no 
significant changes in gene expression and enzymatic activity in SMTG of PCAD 
subjects, there was a significant decrease in protein levels. Surprisingly, in the cerebellum 
of PCAD subjects, there was an increase in protein activity but no analogous changes in 
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gene expression and protein levels. In the SMTG of LAD subjects, there was a significant 
increase in gene expression and a significant decrease in protein levels which could be in 
response to increased pathologic changes. There was a significant increase in enzyme 
activity in SMTG of LAD subjects which is consistent with the study by Adamczyk et al. 
that reported increased PARP1 activity on binding to damaged DNA (Adamczyk et al., 
2005; Strosznajder et al., 2012). No significant differences in fold change in PARP1 
expression levels were observed in the cerebellum of LAD subject but like in the SMTG, 
protein levels were significantly decreased and activity levels were significantly elevated. 
The same pattern of no change in gene expression, lower protein levels and higher 
enzymatic activity was seen in the cerebellum of DC subjects indicating that PARP1 
alterations are present in the seemingly non-vulnerable cerebellar region and that these 
changes are a part of neurodegenration rather than just AD. No changes in gene 
expression, protein levels and activity were observed in SMTG of DC subjects.  
 It is proposed that XRCC1 acts as a scaffold protein in the BER pathway as XRCC1 
reacts with multiple enzymes of BER but has no apparent enzyme activity. Protein-
protein interactions have been reported between XRCC1 and almost all the major 
enzymes involved in BER indicating the vital role this protein plays in genomic stability. 
XRCC1 interacts with and affects the activity of DNA glycosylases, APE1, POLB, 
PARP1, PCNA, LIG1 and LIG3 (El-Khamisy et al., 2003; Kubota et al., 1996; Sak et al., 
2005; Strom et al., 2011; Thompson and West, 2000; Vidal et al., 2001) though the effect 
of these proteins on XRCC1 activity is still not known. Fisher et al. reported down 
regulation of XRCC1 accumulation at site of DNA damage by the PAR degradation 
enzyme, poly(ADP-ribose) glycohydrolase (PARG) thus affecting the scaffold action of 
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XRCC1 (Fisher et al., 2007). We were unable to measure XRCC1 activity as XRCC1 has 
as yet no known enzymatic function. In SMTG of MCI subjects although no changes in 
gene expression were observed, there was a significant increase in protein levels. The 
same trend was observed in SMTG of PCAD subjects and cerebellum of DC subjects. 
There were no changes in gene expression and protein levels seen in the SMTG of LAD 
and DC subjects, cerebellum of MCI, PCAD and LAD subjects. Increases in XRCC1 
mRNA and protein levels after damage to DNA were reported by Yacoub et al. via 
activation of the XRCC1 promoter by the transcription factor EGF-2 (Yacoub et al., 
2003). It has been proposed that like the other enzymes in BER, XRCC1 is also regulated 
by posttranslational modifications including ubiquitylation, phosphorylation and PARP1-
mediated poly(ADP-ribosyl)ation (El-Khamisy et al., 2003; Parsons et al., 2008; Strom et 
al., 2011; Whitehouse et al., 2001). XRCC1 deficiency has been shown to decrease BER 
repair capacity indicating that overall BER functionality may depend to some extent on 
available active XRCC1 (Brem and Hall, 2005; Iftner et al., 2002; Vidal et al., 2001).  
       Overall, our findings suggest gene expression of DNA repair pathway enzymes is 
significantly affected in patients with AD and some of these changes can be seen even in 
the initial stages of AD (MCI and PCAD). Significant alterations in BER enzymes in the 
cerebellum, a brain region typically considered as an internal control in AD indicates that 
oxidative damage and consequently the repair response could be a global event in AD. A 
few previous studies have also shown disease related changes in the cerebellum. Braak et 
al. and Yamaguchi et al. showed diffuse amyloid plaques in the cerebellar cortex of AD 
subjects (Braak et al., 1989; Yamaguchi et al., 1989). A significant decrease in volume of 
the molecular and granular layers of AD subjects was observed by Wegiel et al. (Wegiel 
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et al., 1999). Thomann et al. (Thomann et al., 2008) showed a decrease in volume of the 
posterior cerebellar regions in AD subjects. This study also suggests that changes in BER 
enzymes could be an event common to neurodegeneration rather than an AD-associated 
event. The increase in gene expression seen with these proteins could be a compensatory 
response as the disease progresses. Protein-protein interactions between the various BER 
proteins and between BER proteins and other proteins like p300, p53 and HMGB1, and 
posttranslational modifications including ubiquitylation, phosphorylation and PARP1-
mediated poly(ADP-ribosyl)ation could account for the alterations in protein levels and 
enzymatic activity.  The changes observed in this study will hopefully provide a platform 
for further studies investigating the function, regulation and interactions of the enzymes 
of the complex BER pathway and thus offer further understanding of the ramifications of 
oxidative stress during the progression of Alzheimer’s disease. 
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Chapter 5: Conclusions 
 Demographics show that decreasing fertility rates and increased life expectancy have 
led to an aging world population. Approximately 800 million people were aged 65 and 
older in 2010 and this number is estimated to grow to 2 billion people by 2050 (22% of 
world’s population) (2010; Bloom et al., 2010; UNPD, 2011). Therefore there is an 
increasing need for awareness, diagnosis and treatment of age-related diseases including 
cardiovascular diseases, dementia and Alzheimer’s disease. Batsch et al. estimated that in 
2010, there were 36 million people suffering from dementia worldwide with a global cost 
of $604 billion  (Batsch, 2012).  Approximately 5 million of these AD patients live in the 
US with the number of AD patients expected to triple to 13.8 million by the year 2050 in 
the US alone (Thies and Bleiler, 2011, 2013). The cost of AD is an estimated $203 billion 
in 2013 projected to increase to $1.2 trillion in 2050. This number does not take into 
account the financial, emotional and physical toll the disease puts on the 15.4 million 
caregivers who provided an estimated 17.4 billion hours of unpaid care in 2012.  
 In spite of the increasing threat of financial and health crises that can be created by 
AD, early detection and treatment of the disease is still in its infancy. Most current drug 
therapeutics available to patients at present are symptomatic rather than 
curative/preventive. Although MCI patients are easily diagnosed by a skilled physician, 
detection of PCAD patients ante-mortem is still challenging. Early detection of AD 
would help patients be better prepared and possibly in the future have a better chance of 
treatment. As the exact etiology of AD is still unknown and seems to be multifactorial, it 
has been difficult for researchers to provide efficient stratagems for treatment. Studies 
have suggested oxidative stress plays a major role in AD pathogenesis and could thus be 
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a target for therapeutic strategies (Cooke et al., 2003; Lovell and Markesbery, 2007a; 
Markesbery, 1997b; Markesbery and Carney, 1999). Recent studies have shown an 
increase in markers of oxidative damage of biomolecules including proteins, lipids and 
nucleic acids in AD subjects (Gabbita et al., 1998; Keller et al., 2005; Milne et al., 2005; 
Williams et al., 2006). DNA oxidative damage is extremely critical in post-mitotic cells 
like neurons as it could lead to genomic instability, loss of fidelity during transcription 
and translation, and ultimately cell death. While previous studies have shown an increase 
in oxidative DNA damage in AD subjects (Gabbita et al., 1998; Lovell and Markesbery, 
2001; Wang et al., 2008), it is not yet clear if genomic oxidation is a global, random 
phenomenon or is it targeted to specific areas of the genome. Accumulation of oxidative 
DNA damage in AD brains could be due to two factors: an increase in ROS production or 
breakdown of the repair mechanisms especially the BER pathway (main repair pathway 
for oxidative damage in brain). The purpose of this study was twofold: (A) to determine 
if genomic oxidation was targeted to representative genes that show protein alterations 
during the progression of AD and (B) to determine if increased oxidative DNA damage 
was a result of a decrease in any of the seven major enzymes of the BER pathway during 
AD progression, in a single well-characterized cohort of samples. 
 We hypothesized that oxidative DNA damage is not a random global event but is 
targeted to specific areas of coding sequences of proteins that ultimately show alterations 
in AD. To study this, we focused our analyses on the three isoforms of the mitochondrial 
porin protein, VDAC. VDAC was the ideal candidate for this study as the three forms 
differ in abundance, size and activity, and are altered differentially in the AD brain. 
Lovell et al. (Lovell et al., 2005) reported a significant increase in levels of VDAC1, a 
179 
 
trend towards significant increase in VDAC3 and no changes in VDAC2 in Aβ-treated 
primary neuronal cultures. Based on our hypothesis, we should see the maximum 
increase/decrease in oxidative damage in VDAC1, some change in VDAC3 and no 
oxidative damage in VDAC2 coding sequences. Our results support the hypothesis. We 
saw an increase in oxidative damage in four areas of the VDAC1 coding sequence and 
one area of the VDAC3 coding sequence in the SMTG of subjects with AD. No oxidative 
damage was observed in the VDAC2 coding sequence in the SMTG of MCI, PCAD, 
LAD and DC subjects. Study of the oxidative damage in the 3 VDAC isoforms in tissue 
specimens from diseased control (FTD and DLB) subjects suggests that oxidative 
damage in VDAC is a global event associated with neurodegeneration rather than just 
being AD-specific. We did not see changes in the cerebellum for any of the three 
isoforms indicating a region-specific attack by ROS on VDAC. It would be interesting to 
see if this model is replicated for other proteins that show altered levels/activity during 
AD. As VDAC has no known enzymatic function, we could not measure its activity. It 
would have been instructive to see if increased genomic oxidation leads to changes in the 
functionality of the proteins. We observed that when we introduced 8-oxoguanine into a 
gene sequence (IGF2), there were significant changes in protein levels and activity which 
would indicate that genomic oxidation leads to changes in transcription and translation. 
This experiment was unique as the effect of oxidative stress on transcription and 
translation was studied for the first time using a cell free system. 
 This oxidative damage seen can be as a result of a breakdown in the DNA repair 
mechanisms in the brain. The second part of this study focused on investigating if 
alterations occur in gene expression, protein levels and protein activity levels in the 7 
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major enzymes involved in the BER pathway in an AD brain. The enzymes studied 
included OGG1 (major DNA glycosylase for removal of 8-oxoguanine), UNG (uracil 
DNA glycosylase), APE1 (accounts for 95% endonuclease activity), POLB (major DNA 
polymerase), FEN1 (major endonuclease in long patch BER), PARP1 
(poly(ADP)ribosylation and binding to SSbs) and XRCC1 (scaffold protein). Studies 
show that null mutation in APE1, POLB, FEN1, PARP1 and XRCC1 are embryonically 
lethal in mice indicating the vital role these enzymes play in cellular viability and 
development (Sobol et al., 1996; Tebbs et al., 1999; Woodhouse and Dianov, 2008; Wu 
et al., 1996; Xanthoudakis and Curran, 1992). The understanding of the BER pathway is 
further complicated by the fact that these enzymes are regulated by multiple protein-
protein interactions and posttranslational modifications. The functional impact of these 
interactions on some of the BER enzymes is still unknown. Some BER proteins like 
APE1 and PARP1 are also involved in other cellular pathways making it difficult to fully 
understand how they are regulated. The study of BER enzymes in AD has mainly focused 
on OGG1 with relatively few studies of APE1, UNG and POLB. Surprisingly all seven 
enzymes have not yet been studied in a well-characterized cohort in brain tissue 
specimens from the SMTG and cerebellum of MCI, PCAD, LAD and DC subjects. We 
did not see a direct correlation between gene expression, protein levels and protein 
activity for most of the enzymes which is understandable considering the complexity of 
the BER pathway and the multitude of interactions each protein undergoes. We saw no 
changes in gene expression for any of the proteins in SMTG of MCI subjects. Protein 
levels, on the other hand, were altered for APE1, POLB and XRCC1, and protein activity 
levels were significantly increased for UNG and POLB in SMTG of MCI subjects. A 
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significant increase in gene expression was observed for OGG1, UNG and POLB in 
SMTG of PCAD subjects. Change in protein levels was seen for OGG1, FEN1, PARP1 
and XRCC1 and change in protein activity levels were observed for UNG, APE1, POLB 
and FEN1 in SMTG of PCAD subjects. In SMTG of LAD subjects, changes were seen in 
OGG1, UNG, POLB and PARP1 expression. Protein levels were altered for POLB, 
FEN1 and PARP1 and protein activity levels for UNG, FEN1 and PARP1 in SMTG of 
LAD subjects. Changes were also observed in UNG gene expression; OGG1, APE1 and 
FEN1 protein levels; and FEN1 protein activity levels in SMTG of DC subjects 
indicating that alterations in BER enzyme especially the glycosylases and endonucleases 
could be an event associated with neurodegeneration. The results of the BER pathway 
analysis are discussed in more detail in Chapters 3 & 4. As some of these enzymes are 
also involved in other pathways, the alterations could also be due to interactions other 
than during BER. For example, we saw an increase in PARP1 activity in LAD subjects 
which implies an increase in BER activity but extensive PARP1 activation can also lead 
to neuronal death. Thus, the biological significance of all these changes in AD 
pathogenesis still needs to be elucidated. Some of the effects of protein-protein 
interactions and posttranslational modifications observed with BER enzymes might be 
better understood through gene expression, protein level and activity studies in 
appropriate mouse models. Because APE1, POLB, PARP1, XRCC1 and FEN1 deficient 
mice show embryonic lethality, the effect of the deficiency of these enzymes can be 
studied using lentivirus mediated knockdown in mice. We hope the current study will 
contribute to the understanding of BER enzymes in AD. Expectantly, understanding the 
changes in BER enzymes will open the platform for identification of novel therapeutic 
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strategies in AD. Inhibitors to some of the enzymes including APE1 and PARP1 are 
already either in use to treat cancer patients or are in clinical trials. Recently, PARP1 
inhibitors that assuage ischemic brain injury have also been introduced. Thus, as these 
enzymes are already therapeutic targets for other diseases, hopefully it would be less 
challenging to go from basic research to develop clinical trials as compared to completely 
unexplored targets. Most studies of the BER pathway in AD have focused on the 
glycolysases, especially OGG1. Very few studies are available that evaluate changes in 
XRCC1 which may be a critical lynchpin of BER. XRCC1 acts as a scaffold protein and 
also interacts with almost every protein in the BER pathway. Although the effect of 
interactions between XRCC1 and other BER proteins is unclear   there is a strong effect 
on enzymatic activity at least for some enzymes (APE1, PARP1). This study showed that 
XRCC1 protein levels were significantly lower in the disease groups, which could be one 
of the major reasons for decreased BER repair capacity in AD seen by multiple studies. 
Although more studies are needed to completely understand the role of XRCC1 in BER it 
is possible that activation of XRCC1 could possibly lead to an increase in repair of DNA 
oxidative damage making this an interesting novel target for therapeutic strategies. 
 The cerebellum is usually treated as an internal control in the AD brain as it has less 
AD-associated pathology. Although our studies didn’t show changes in oxidative damage 
in the VDAC isoforms, we saw significant changes in BER enzymes in the cerebellum. 
Some of the changes were in marked contrast to the changes observed in the SMTG 
indicating a region specific response. For example, while there was no difference in 
PARP1 activity in the SMTG of PCAD and DC subjects, there was a significant elevation 
observed in the cerebellum of these subjects. So the data from this study suggest that not 
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only is BER pathway affected during the process of neurodegeneration in general, the 
BER enzymes show a brain-region specific response even in the absence of substantial 
disease pathology.   
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